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Abstract 
Calcitonin gene-related peptide (CGRP), a potent vasodilator that mediates 
inflammatory pain, was found to co-occur in rat trigeminal ganglia neurons (TGNs) 
with 3 exocytotic soluble NSF (N-ethylmaleimide sensitive factor) attachment protein 
receptors (SNAREs) [synaptosomal-associated protein with Mr = 25 k (SNAP-25), 
syntaxin I, synaptobrevin (Sbr) isoforms] and synaptotagmin. Ca2+-dependent CGRP 
release evoked with K+-depolarisation was higher than that evoked by capsaicin or 
bradykinin from neurons containing the vanilloid receptor 1 and/or bradykinin receptor 
2. Botulinum neurotoxin (BoNT) type A cleaved SNAP-25 and inhibited release 
triggered by K+ >bradykinin >>capsaicin. Unlike BoNT/D, /B did not affect 
exocytosis although rat TGNs possess its receptor, synaptotagmin I/II, and Sbr II/III 
got proteolysed (I is resistant in rat) but, in mouse, /B additionally cleaved Sbr I and 
blocked release. Knock-down of Sbr I expression substantially reduced CGRP 
exocytosis. These novel findings implicate Sbr I in CGRP exocytosis together with 
SNAP-25. An in-depth study was performed on the feeble inhibition by /A of 
capsaicin-elicited CGRP release, as it stimulates C-fibres __ a prime target for 
attenuating nociception; their inactivation was sought using the superior membrane-
translocating properties of BoNT/E which cleaves 26 residues from SNAP-25 rather 
than the 9 by /A. Chimera EA was engineered to exploit the light chain and 
translocation domain from /E, together with the acceptor binding  from /A to overcome 
the inability of /E to interact with TGNs. Purified /EA bound synaptic vesicle protein 2 
type C  in vitro and entered the neurons because capsaicin-evoked exocytosis of CGRP 
was inhibited. Unlike /A, the longer truncation of SNAP-25 by /EA diminished its 
participation in stable SNARE complexes, unlike SNAP-25A. Prolonged elevation of 
[Ca2+]i by capsaicin, as revealed by 45Ca2+ uptake and Fluo 4-AM imaging, gives a 
persistent trigger for CGRP release from /A-treated cells. The successful targeted 
delivery of EA into nociceptive neurons and the consequential blockade of CGRP 
release, even when evoked by sustained elevation of [Ca2+]i, highlight the versatility of 
this novel chimera.  
 XIX
  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0 General introduction 
1.1 Botulinum neurotoxins  
 
1.1.1 Origin 
Clostridum botulinum is a gram-postive, anaerobic, spore-forming and rod-shaped 
bacterium which produces botulinum neurotoxin (BoNT). These are the most potent 
toxins known, causing flaccid neuromuscular paralysis. In 1817, the German physician 
Justinus Kerner described a paralytic condition caused by eating sausages, and such 
food-borne paralysis was named “botulism” (Latin for a ‘sausage-related condition’). 
The bacteria are commonly found in soil, and were first recognized and isolated in 
1895-1896 by Emile van Ermengem from home cured ham that had been implicated in 
a botulism outbreak (Ermengem, 1897). In 1944, Edward Schantz successfully cultured 
Clostridium botulinum and isolated botulinum toxin (Schantz, 1994), and, in 1949, 
Burgen's group discovered that the toxin blocks neuromuscular transmission (Burgen, 
1949). Since then, seven serologically distinct but structurally similar BoNTs serotypes 
have been idenfied (Dolly and Lawrence, 2007; Montecucco and Schiavo, 1994; 
Pellizzari et al., 1999; Popoff et al., 2001) and named A-G, according to the order of 
their discovery. Serotypes A, B, E and F are responsible for the majority of human 
botulism; BoNT/C and /D are causative agents for animal and avian botulism 
(Tsukamoto et al., 2005) and were discovered in birds and in cattle, respectively 
(Coffield et al., 1997; Davletov et al., 2005). Serotype G was isolated from soil. BoNTs 
usually occur in complexes with non-toxic proteins named haemagglutinins plus non-
toxic non-haemagglutinin (NTNH). These associated non-toxic proteins stablize the 
toxin at low pH and dissociate at neutral pH, protecting toxin moiety from proteolytic 
attack during exposure to the gastrointestinal environment [reviewed by (Humeau et al., 
2000)]. When BoNT-contaminated food reaches the small intestine, the toxin crosses 
the interstinal wall and enters the bloodstream (Simpson, 2004). Type A toxin has been 
the most widely studied and successfully used for therapeutic purposes to date. Type B 
is commercially available but higher doses are required (Davletov et al., 2005; Foran et 
al., 2003; Jankovic, 2004). 
 
1.1.2 Mechanism of action  
 These neurotoxins potently and preferentially inhibit the release of acetycholine from 
peripheral motor nerves causing flaccid neuromuscular paralysis typical of botulism 
(Dolly and Lawrence, 2007; Montecucco and Schiavo, 1994; Pellizzari et al., 1999; 
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Popoff et al., 2001). Intracellular administration of BoNTs blocks Ca+-regulated 
exocytosis of all transmitters, both from small clear synaptic vesicles (SCSVs) and 
large dense-core vesicles (LDCVs) (Bergquist et al., 2002; Foran et al., 1995; Foran et 
al., 2003; Keller and Neale, 2001; McInnes and Dolly, 1990). Each BoNT is 
synthesized as a relatively inactive single-chain protein with a molecular weight of 
~150 kDa and becomes activated upon proteolytic cleavage by bacterial endogeneous 
proteases or by trypsin in vitro to yield the binding/translocating heavy chain (HC) and 
enzymatic light chain (LC), linked through a disulphide bond and non-convalent 
interactions. The 3D crystal structures for BoNT/A and /B  have been determined 
(Lacy et al., 1998; Swaminathan and Eswaramoorthy, 2000) ( Fig. 1.1).  
BoNTs have 3 individual domains (each with a molecular mass of ~50 kDa): (1) a 
catalytic LC domain (a zinc-dependent endopeptidase); (2) a translocation domain (HN); 
(3) a binding domain (HC) composed of two subdomains: C terminal binding domain 
(HCC) and N terminal binding (HCN) (Fig. 1.1), which binding to gangliosides and high-
affinity protein acceptors (Chai et al., 2006; Jin et al., 2006). A multi-step mechanism 
of action for BoNT at the motor terminal was proposed (Black and Dolly, 1986; Dolly 
et al., 1984; Dolly et al., 1994; Humeau et al., 2000; Schiavo et al., 2000; Simpson, 
1979). These steps include: binding to ecto-acceptors on cholinergic nerve terminals; 
acceptor-mediated internalization and membrane translocation of LC; after gaining 
access into the neuronal cytosol, the metalloprotease activities of the LCs selectively 
proteolyse and disable soluble NSF (N-ethylmaleimide sensitive factor) attachment 
protein receptor (SNAREs) which mediate vesicular transmitter release. So far, 
synaptic vesicle protein 2 (SV2) has been identified as a high affinity binding 
component for BoNT/A. SV2 is an integral membrane glycoprotein, occuring in three 
well-characterized isoforms, SV2A, SV2B, and SV2C. SV2A is more widely 
distributed in the nervous system, whereas SV2C is only observed in a small number of 
neurons in a few brain areas  (Bajjalieh et al., 1994; Bajjalieh et al., 1993; Janz et al., 
1998; Janz and Sudhof, 1999). Isoforms of another synaptic protein, synaptotagmin I/II 
were found to be the putative protein acceptors for /B and /G (see later) (Dong et al., 
2003; Dong et al., 2006; Rummel et al., 2004). After binding, the toxins are 
internalized by acceptor-mediated endocytosis (Fig. 1.2 A). An intact di-chain (DC) is 
needed for translocation of LC to the cytosol where it cleaves one or two of three 
essential proteins involved in the Ca2+-regulated exocytosis machinery (Fig. 1.2 B). 
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SNAP-25 (synaptosomal associated protein with Mr = 25k) that predominantly resides 
on the plasma membrane is cleaved by BoNT/A, /C1 and /E, all at distinct sites; 
syntaxin IA/IB is also cleaved by BoNT/C1. BoNT/B,  /D, /F and /G act on 
synaptobrevin (Sbr) [also known as vesicle-associated membrane protein (VAMP)] 
isoforms I, II and III; Sbr I in rat is unusual in being resistant to type B cleavage due to 
a mutation at the fission site (Foran et al., 2003; Humeau et al., 2000; Yamasaki et al., 
1994) (Table 1.1). In neuronal exocytosis, syntaxin and sbr are anchored in plasma and 
synaptic vesicle membranes, respectively, by their C-terminal domains, whereas 
SNAP-25 is tethered to the plasma membrane via several cysteine-linked palmitoyl 
chains. The core SNARE complex is a four-α-helix bundle, where one α-helix is 
contributed each by syntaxin-1 and sbr and two α-helices by SNAP-25 (Sutton et al., 
1998). Synaptotagmin is a Ca2+ sensor and is involved in early synaptic vesicle docking 
to the presynaptic membrane via interaction with SNAP-25. Its N-terminal domain 
resides in the luman of synaptic vesicle and its C-terminal cytoplasmic region binds to 
Ca2+ (Fig. 1.3) (Littleton et al., 2001). Upon binding to Ca2+, it then facilates the late 
steps of  Ca2+-evoked synaptic vesicle fusion with the presynaptic membrane [reviewed 
by (Humeau et al., 2000)]. Truncation of the exocytotic machinery SNARE proteins by 
BoNTs pertubs the formation of SNARE complex and inhibits exocytosis (see Chapter 
5).   
 
Fig. 1.1 Structure of BoNT/A. Backbone trace of BoNT/A: LC in pink, the HN in blue, 
N-terminal (HCN, in brown) and C-terminal (HCC, in green) binding domains are shown. 
The picture was generated using Cn3D4.1 software from published structure database 
(GenBank accession No: 3BTA) (Lacy et al., 1998). 
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                                 Table 1.1 BoNTs and the substrates they cleave 
Serotype Intracellular target protein 
 
Cleavage sites in rat  
/A 
 
SNAP-25  EANQ197RATK 
/B 
 
Sbr I, II* GASQ76FETS 
(rat Sbr I is resistant:GASVFESS) 
/C1 
 
SNAP-25 
Syntaxin IA/ IB  
 
ANQR198ATKM 
DTKK254AVKY/ DTKK253AVKY 
/D 
 
Sbr I, II* 
 
RDQK61LSELD for I and II 
 
/E 
 
SNAP-25  
 
QIDR180IMEK 
/F 
 
Sbr I, II* 
 
ERDQ60KLSE for I 
ERDQ58KLSE for II 
 
/G 
 
Sbr I, II* 
 
ETSA83AKLK for I 
ETSA81AKLK for II 
*Rat and mouse Sbr III is also cleaved by BoNT/B, D, F, G 
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 A 
B 
Fig. 1.2 Inhibitory action of BoNTs on transmitter release. (A) Four steps are 
involved in the intoxication: (i) the toxin heavy chain (HC, black) mediates cell-
surface binding with ganglioside and glycoprotein receptors (orange); (ii) 
acceptors-mediated internalization; (iii) translocation of light chain LC (gray) to 
the cytosol and (iv) cleavage of their repective SNARE substrates; sbr (blue), 
syntaxin 1 (red) and SNAP-25 (green) (B) The relative cleavage sites of each BoNT 
on its substrate are shown [pictures are reproduced from (Brungerb, 2005)]. 
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Fig. 1.3 SNARE complex and synaptotagmin driven exocytosis. The core SNARE 
complex is formed by four α-helices constituted by each from sbr, syntaxin and two 
from SNAP-25; synaptotagmin is a Ca2+ sensor and regulates SNARE zipping and 
vesicle fusion. Synaptotagmin has an N-terminal transmembrane region and two C-
terminal C2 domains - C2A and C2B which bind to Ca2+. Picture is adapted from  
(Munson, 2007). 
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 1.2 Potential  anti-nociceptive uses of BoNTs  
 
1.2.1 Pain pathways and evidence for pain relief by BoNTs  
The symptoms of botulism suggest that BoNTs act preferentially on peripheral 
cholinergic motor nerve endings, a notion supported by many experimental findings; 
thus, the most common clinical application of these toxins is for the treatment of 
overactive muscles (voluntary and involuntary) or glands innervated by such neurons 
(Ward and Barnes, 2007). However, some patients treated for cholinergic over-activity 
disorders noted a concomitant relief of pain symptoms that was difficult to reconcile 
with a purely cholinergic block (Binder et al., 2000). Pain of various kinds (nociceptive, 
neuropathic, inflammatory) pose major medical challenges, with 21% of the worldwide 
adult population suffering from persistent pain (WHO report 2004). The experience of 
pain is due to the combined activity of distinct systems that transmit and modulate pain. 
The pain pathway is bi-directional and consists of ascending and descending pathways. 
The ascending pathways transmit information from peripheral nociceptors to higher 
levels of the central nervous system (Bloedel and McCreery, 1975). Transmission of 
pain signals from the periphery to the cortex involves signal processing within the 
spinal cord, brain stem, and forebrain (Levy et al., 2004). The descending pathway 
travel along the asending route and transfer information from central structures to 
neurons, including the dorsal horn of the spinal cord and sensory nuclei of the 
brainstem (i.e. trigeminal nuclei). The descending pathway allows the brain to 
modulate pain sensation so that the brain can either amplify or inhibit incoming pain 
signals through desending modulatory pathways (Bloedel and McCreery, 1975; Hole 
and Berge, 1981).  Recent clinical investigations have indicated that myofacial pain, 
migraine and certain types of headache seem to respond to local injection of botulinum 
toxin A-haemagglutinin complex (BoTOX) (Gupta, 2005). Additionally, the 
preparation can reduce capsaicin-induced pain [however this still remains controversial 
(see overview in Chapter 5)], and secondary hyperalgesia in a human experimental 
model of trigeminal sensitisation (Gazerani et al., 2006).  
Release of substance P (SP), a neuropeptide involved in neurogenic inflammation, is 
inhibited by various BoNT serotypes in cultured neurons from embryonic rat dorsal 
root ganglia (DRGs) (Welch et al., 2000). Exocytosis of glutamate, another 
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neurotransmitter involved in nociception in the periphery and in the dorsal horn of the 
spinal cord, was also shown be suppressed  in rat paw challenged with formalin (Cui et 
al., 2004). Some studies suggested that the mechanism of pain relief by BoNTs is due 
to peripheral desensitisation, which indirectly prevents central neuron sensitisation. 
Notablly, study examines the time course of muscle relaxation and pain relief in spastic 
and nonspastic muscle conditions, where the analgesic property has generally been 
attributed to muscular relaxation, the pain reduction by BoNT/A happens before 
muscle relaxation  and even last longer than the muscle relaxation (Aoki, 2005; Freund 
and Schwartz, 2003). 
1.2.2 Pathophysiology of migraine and evidence of involvement of neuropeptides 
The pathogenesis of migraine headache involves three major constituents: the cranial 
blood vessels, the trigeminal innervation of these vessels, and the reflex connection of 
the trigeminovascular system in the cranial parasympathetic outflow; so far, there is no 
in vivo model systems that mimic all aspects of the migraine attack (Goadsby et al., 
2002; Mehrotra et al., 2008). In support of particular roles for vasoactive neuropeptides 
such as calcitonin gene-related peptide (CGRP) and SP, antagonists for these peptides 
or their receptors were shown to reduce pain. CGRP antagonists, such as CGRP8-37, 
attenuated pain upon injection into the dorsal horn (Bird et al., 2006); another 
antagonist of the α type CGRP receptor (BIBN4096BS) reduces vasodilation (Salvatore 
et al., 2008). Infusion of CGRP produced a migraine-like headache (Olesen and Lipton, 
2004) and baseline CGRP levels were increased in migraineurs (Fusayasu et al., 2007). 
Inhibition of CGRP release or antagonism of CGRP receptors could be a viable 
therapeutic target for the pharmacological treatment of migraine (Edvinsson, 2004; 
Mehrotra et al., 2008). However, the short-lived effect of these antagonists is 
disadvantagous for use in therapy; the half-life for the two aforementioned antagonists 
is only hundreds of minutes (Edvinsson, 2007; Salvatore et al., 2008). With BOTOX® 
being found to be effective in the treatment of chronic pain, especially chronic 
headaches, it offers several advantages of being safe, tolerable and effective in 
prevention of migraines resistant to other drugs (Blumenfeld, 2003; Farinelli et al., 
2006; Menezes et al., 2007; Suzuki et al., 2007). One injection works for three months, 
rather than patients taking pills every day and frequently becoming intolerant or 
refractory. 
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To better understand release mechanisms of pain mediators and, thereby, exploit the 
advantages of using toxin therapy to attenuate pain symptoms (e.g. migraine), there is 
an urgent need for studies on the interaction between BoNTs and pain-sensing neurons.  
 
1.3 Peripheral sensory neurons: pain mediators and trigger factors 
A number of sensory nerve types are involved in propagating pain (Woolf, 2004; 
Woolf and Ma, 2007).  Activation of the trigeminal nerve is involved in migraine and 
cluster headache which are very prevalent (~16% of adults). 
 
1.3.1 Trigeminal ganglion neurons (TGNs) 
 Stimulation of the trigeminal nerve, the largest of the cranial nerves, triggers release of 
CGRP and SP from sensory neurons in trigeminal ganglia (TG), a migraine pain relay 
centre. Release of CGRP and SP induces vasodilation and mast cell degranulation; this 
further increases the levels of inflammatory agents which, in turn, enhance the 
synthesis and release of these peptides (Durham and Cady, 2004). Cell bodies of the 
trigeminal nerve reside in the trigeminal ganglion, which is located on the cerebral 
surface of the sphenoid bone in the middle cranial fossa. As its name suggests, it has 
three major branches: ophthalmic, maxillary and mandibular, and contains the cells of 
origin of most of the sensory fibers of the trigeminal nerve. The 3 branches provide 
most of nociceptive input from the cerebrovasculature and craniofacial region. 
Nociceptors are free nerve endings enriched with receptors sensitive to mechanical 
stress, extreme heat or cold, and noxious chemicals. Fig.1.4 shows the structure of 
trigeminal ganglion and surroundings. The central processes enter the brain at the level 
of the pons, conveying pain and temperature, descend into the brain stem and comprise 
the SPINAL TRACT V.  
According to the size of neurons and type of transmitters released, sensory neurons are 
divided into several groups: fast-conducting, myelinated A-β fibres mediate the 
synaptic release of transmitters such as excitatory amino acids from small clear 
synaptic vesicles (SCSVs) which cause cortical spreading depression, neuronal hyper-
excitability and central sensitization; on the other hand, the slow transfer of signals via 
the A-δ and unmyelinated C fibres elicit the secretion of CGRP, SP, neurokinin A 
(Silberstein and Aoki, 2003). Isolectin B4 (IB4), an alpha-D-galactose-binding lectin 
isolated from Griffonia (Bandeiraea) simplicifolia, has been used to label primary 
sensory afferent terminals of small-diameter TGNs in vivo. C-fibers can be divided into 
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two groups based on growth factor dependency and IB4 binding. IB4-negative 
nociceptors have been proposed to contribute to inflammatory pain, and IB4-positive 
neurons are sensitized to VR1 ligands during inflammation and, thus, IB4-positive C-
fiber neurons may contribute to inflammatory hyperalgesia (Breese et al., 2005). 
 
 
Fig. 1.4  Trigeminal ganglion dissection guidance 
Picture reproduced from http://medinfo.ufl.edu/year1/trigem/anatomy.html
 
1.3.2 CGRP, SP and their receptors 
CGRP is a 37-amino acid neuropeptide produced by tissue-specific alternative 
processing of the primary RNA transcripts of the calcitonin gene; it has two isoforms: α 
CGRP (or CGRP-I) and β CGRP (or CGRP-II). α and β differ by one amino acid in rats 
and three residues in humans (Poyner et al., 2002) (Table 1.2). α CGRP is present in 
sensory neurons whereas β CGRP mainly occurs in the enteric nervous system. The 
level of CGRP in the cerebrospinal fluid becomes elevated significantly during the 
painful phase of migraine (Goadsby and Edvinsson, 1993). Also, release of CGRP in 
the periphery is a reliable marker for neurogenic inflammation; the time course of 
CGRP plasma levels parallels headache intensity and successful treatment of such 
attacks abort both the associated pain and CGRP release (Goadsby and Edvinsson, 
1993). 
 
In the migraine pathophysiology, release of CGRP may be through several putative 
pathways of vascular hyper-reactivity: NO (nitric oxide) released from endothelial cells  
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not only has its own vascular effects but up-regulates CGRP gene expression in rat 
trigeminal ganglia (Fig. 1.5). While the primary dysfunction in brain causes CGRP-
dependent vasodilation; cortical spreading depression (CSD) could be the initial trigger 
for CGRP release due to activation of the trigeminovascular system (Doods et al., 
2007).    
There are two types of CGRP receptors identified so far: CGRP1 and CGRP2; isofrom 
1 shows preference for binding to the CGRP antagonist: CGRP8-37. CGRP receptors 
are hetero-dimers comprising GPCR (G-protein coupled receptor), CLR (calcitonin 
receptor-like receptor), an accessory protein, RAMP1 (receptor activity-modifying 
protein 1), and a receptor component protein (RCP) (Fig. 1.6); CGRP receptors are 
distributed on the postsynaptic and presynaptic membranes. CGRP initially released 
from trigeminal ganglion causes subsequent release of inflammatory cytokines from 
mast cells which, in turn, induce more CGRP release by activation of a positive feed 
back loop (Durham and Russo, 2003). Binding of CGRP to its receptor causes 
activation of multiple signalling pathways (Fig. 1.7).  
 
SP is a 11-amino acid peptide (H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-
NH )2 , and is a member the tachykinin family that also includes neurokinin A (NK-A), 
neurokinin B (NK-B), neuropeptide K (NP-K), and neuropeptide-  (NP- ). SP is 
derived from tissue-specific alternative splicing of the pre-protachykinin I gene and is 
produced almost exclusively in neuronal tissues. 
The SP receptor is a neurokinin A receptor which also belongs to the tachykinin 
receptor sub-family of GPCR; its activation leads to the mobilization of intracellular 
Ca2+ and elevation of cAMP levels (Mitsuhashi et al., 1992), and induces changes in 
the subsequent signalling as described for CGRP (Fig. 1.7). 
CGRP and SP are released from peripheral nerve terminals in response to an 
inflammatory stimulus, such as local application of capsaicin or bradykinin (see 1.3.3). 
In situ, nearly 80% of SP-positive trigeminal (and other sensory) ganglion neurons 
contain CGRP, which indicates both peptides are largely co-expressed; However, 
CGRP is also found in some C-fibers nociceptors that lack SP. Both peptides serve as 
the major mediators of inflammatory pain, and notably, they are released from LDCVs 
at sites away from the active zones where most SCSVs exocytosis occurs (Kummer, 
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1992). This more diffuse type of secretion affords communication with neighbouring 
cells over wide areas.  Accordingly, CGRP and SP cause dilation of intracranial blood 
vessels and transmit nociceptive signals from this vasculature to the central nervous 
system though CGRP was significantly more potent than SP as a cerebrovascular 
dilator (McCulloch et al., 1986).  
 
Table 1.2   Peptide sequences of α and β isoforms of CGRP in rat and human 
h  CGRP A C D T A T C V T H R L A G L L S R S G G V V K N N
  
F V P T N V G S K A F 
h  CGRP A C N T A T C V T H R L A G L L S R S G G M V K S N
  
F V P T N V G S K A F 
r  CGRP S C N T A T C V T H R L A G L L S R S G G V V K D N
  
F V P T N V G S E A F 
r  CGRP S C N T A T C V T H R L A G L L S R S G G V V K D N
  
F V P T N V G S K A F 
 
Non-conserved amino acids between the two isoforms of each species are underlied. h, 
human; r, rat. 
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Fig. 1.5 CGRP and SP are potent vasodilators in nociception of migraine and other 
inflammatory based pain. While triggers for migraine pathophysiology are currently 
unknown, endothelial NO (nitric oxide) is responsible for the initial vasodilation. NO 
production coincides with CGRP release from trigeminal ganglia implicating CGRP as 
a trigger of migraine through two possible mechanisms; one possibility is that released 
CGRP binds to mast cell via its receptor causing mast cell degranulation and 
subsequent release of other inflammatory agents. Alternatively, CGRP may bind the 
smooth muscle of cerebral artery causing its relaxation and increased blood flow. 
Additionally, CGRP binds the secondary hypothalamus neurons causing painful 
impulse transmission. Binding of CGRP to its receptor is blocked by an antagonist of 
the α type CGRP receptor (BIBN) Picture is reproduced from (Kapoor, 2004). 
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Fig. 1.6 The CGRP receptor. This is a complex proposed to comprise a ligand-binding 
protein (CRLR) which is an accessory protein for trafficking and pharmacology, a 
receptor activity-modifying protein 1 (RAMP1), and receptor component protein (RCP) 
which is a member of a multi-protein complex required for GPCR signal transduction. 
CGRP receptor is a G-protein coupled receptor, its subunit (GαS, G-protein α subunit) 
activates the adenylyl cyclase and then converts ATP to cyclic-AMP (cAMP), followed 
by activation of multiple signalling pathways, as shown in Fig. 1.7. Picture is 
reproduced from (Prado et al., 2002).  
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Fig. 1.7 Model for CGRP receptor function and its activation of signalling pathways.   
Left panel shows endothelium-independent vasodilatation in response to CGRP. 
Activation of CGRP receptors on smooth muscle cells is coupled to production of 
cAMP by adenylate cyclase. cAMP then binds to the regulatory subunits of PKA 
leading to dissociation of the associated catalytic subunits and phosphorylation of 
numerous substrates, opening K+ channels and activating Ca2+ sequestration 
mechanisms causing smooth muscle relaxation. Right panel shows endothelium-
dependent vasodilation response to CGRP. It interacts with receptors on endothelial 
cells and stimulates production of NO. This is mediated via cAMP accumulation, 
although a direct effect of PKA on endothelial NO synthase (eNOS) is yet to be fully 
characterized. Diffusion of NO into adjacent smooth muscle cells, activates guanylate 
cyclase, leading to muscle relaxation. [Picture is adapted from (Brain and Grant, 
2004)].  
 
 
 
. 
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1.3.3 Capsaicin and bradykinin  
There are subpopulations of nociceptive neurons in TG that are selectively stimulated 
by capsaicin and/or bradykinin. Capsaicin (chemical structure of carbon backbone and 
functional groups are shown in Fig. 1.8 A) from chilli peppers is well known as a C-
fibre specific activator that causes an inward currents and produces pain by acting on 
the vanilloid receptor type 1 (VR1, also known as TRPV1), a nonselective cation 
channel that prefers Ca2+ over Na+ and an integrator of inflammatory pain pathways,  
which is located mainly on the C-fibres (Caterina et al., 1997; Tominaga et al., 1998). 
VR1 positive neurons are recognised as nociceptive neurons because they are activated 
by three different stimuli — capsaicin, heat (>43°C) or protons (acidification) — that 
are known to cause pain in vivo (Caterina et al., 1997; Tominaga et al., 1998) (Fig. 1.8 
B). Recently, researchers proposed a VR1 pore dilation model. A time- and 
concentration-dependent change in ionic (i.e. Ca2+) permeability following prolonged 
exposure to capsaicin was found with VR1 channels. The prolonged exposure increases 
the permeability of the VR1 channel pore (Bautista and Julius, 2008; Chung, 2008). 
Capsaicin-responsive nerves may be stimulated to release pre-stored pro-inflammatory 
neuropeptides. The neuropeptides released from VR1-positive nerves such as CGRP 
and SP cause mast cells degranulation, thereby, liberating histamine which, in turn, 
stimulates VR1 positive nerves to release more CGRP and SP (Szallasi and Blumberg, 
1999) (Fig. 1.8 C). 
Bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), another nociceptive neuronal 
marker, activates sensory neurons by acting on the G-protein-coupled bradykinin type 
2 receptor (BR2), causing elevation of [Ca2+]i and inducing transmitter release (Chuang 
et al., 2001), which in turn, cause acute sensation of pain (Steranka et al., 1988).  
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A 
 
 
 
 
B 
 
 
 
C 
Fig. 1.8 Capsaicin chemical structure and its receptor VR1. (A) Capsaicin structure; 
(B) VR1 has six transmembrane (TM) domains and a short, pore-forming hydrophobic 
stretch between the fifth and sixth TM domains (Cortright and Szallasi, 2004; Ferrer-
Montiel et al., 2004); the channel pore has selectivity: Ca2+ >Mg2+>K+≈ Na+; initial 
open state of VR1 shows low permeability to large cations. Polonged exposure to 
agonists increases the pore size, leading to enhanced permeability of the channel to 
large cations [reviewed by (Bautista and Julius, 2008)].  (C) Schematic illustration of 
the role of peripheral vanilloid-sensitive nerve endings in evoking neurogenic 
inflammatory and allergic-hypersensitivity reactions (Szallasi and Blumberg, 1999). 
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1.4 Project aims and objectives 
For the purpose of deciphering a molecular basis for the anti-nociceptive effects of 
BoNTs, an in vitro model was needed. Two types of sensory neurons, TGNs and DRGs, 
were chosen because these can be easily dissected, cultured and both are important in 
pain-transduction; also, TGNs are especially well known as a migraine pain-relay 
centre (see section 1.3.1).  
The first objective, after successfully establishing these sensory neuronal systems in 
vitro, was to examine the location of their nociceptive neuronal markers (VR1, BR2 
and IB4 binding) in relation to pain-related peptides (i.e. CGRP or SP), by conventional 
or confocal microscopy in either phase-contrast or fluorescent mode. It was then 
necessary to demonstrate not only the presence of the core exocytotic machinery i.e. 
SNAREs (SNAP-25 and syntaxin or Sbr isoforms), and their associated proteins 
(synaptotagmin variants) but their co-occurence or co-localization with pain-related 
peptides. This should be achieved by separation of vesicles from these cultured sensory 
neurons allowing investigation of pain signalling pathways through immuno-analysis 
of their peptide content, SNAREs or related proteins. The presence of these BoNT 
substrates would imply the potential ability of various BoNTs in inhibiting the release 
of pain peptides.  
The application of robust enzyme immuno-assays would allow the quantification of 
Ca2+-dependent release of pain-peptides from these sensory neurons upon stimulation 
with various secretagogues (i.e. capsaicin or bradykinin with or without Ca2+) or by 
membrane depolarisation (via manipulation of the external [K+] in the presence or 
absence of Ca2+). Dependence of these exocytotic events on SNARE function should 
be ascertained by designing experiments utilising the 5 serotypes of natural BoNT (/A, 
/B, /C, /D, /E), all of which cleave their respective intracellular SNAREs at distinct 
sites. Blockade of the release of pain-mediators upon BoNT intoxication would not 
only demonstrate the role of SNAREs but allow the identification of particular SNARE 
isoforms. 
A major objective of this project was to address the potential role of Sbr I in CGRP 
release. As no toxin can cleave Sbr I selectively, it was necessary to employ gene 
knock-down experiments using shRNA expressed by lentiviral particles, previously 
demonstrated to easily infect non-dividing cells. Characterisation of the intact SNARE 
complexes and resolution of the activity of truncated-SNAREs in mediating exocytosis 
was a crucial objective of this work. Experiments employing immuno-precipitation, 
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vesicle immuno-isolation and 2-dimensional gel electrophorisis techniques allowed the 
characterisation of particular SNARE complexes. Because CGRP resides in LDCVs, 
the presence of isoforms of SNARE was largely unknown, the use of a particular 
variant by various neurons should raise functional implications for other cells 
previously unrecognised (i.e. Sbr II was shown to occur predominantly in SCSVs 
whereas Sbr I was found to be required for mediating CGRP release, see Chapter 4). 
Another experimental strategy of this work was to employ chimeric technology 
whereby various hybrid BoNTs were created by inter-changing binding domains 
between various serotypes. This approach would allow the introduction of different 
BoNT proteases into neurons previously insensitive to that particular serotype (i.e. 
chimeric EA toxin was engineered by substitution the binding domain of BoNT/E, 
which is unable to bind to neurons due to lack of its acceptor, by its counterpart from 
BoNT/A which can bind, see Chapter 5). Elucidation of the functionality of these 
chimeras and comparison with the parental toxins in different sensory models (each 
with dissimilar sensitivities to various BoNTs) should yield insights into, firstly, the 
functional domains of BoNT and, secondly, steps of transmitter release which 
previously could not be perturbed by their parental toxins in sensory systems (i.e. 
perticipation of SNAP-25 truncated by toxins in the formation of SDS-resistant 
SNARE complex). Only /A- but not chimera EA-truncated SNAP-25 was found to 
occur in the complex; and Ca2+-reversibility of inhibition of exocytosis was found to be 
much greater after treatment with BoNT/A than chimera EA, see Chapter 5).  
More in-depth studies were carried out in order to investigate the relationships between 
capsaicin-induced [Ca2+]i elevation and CGRP release rate; the observed prolonged 
elevation of [Ca2+]i elicited by capsaicin, revealed by 45Ca2+ uptake and confocal 
imaging using Fluo 4-AM, could overcome BoNT/A inhibition. Most importantly, 
these chimeric toxins could also have improved pharmacological outcomes over their 
parents.  
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2.0 Materials and Methods 
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2.1 Materials 
Suppliers’ addresses are listed in the Appendix. 
 
2.1.1 Cell culture and related reagents 
Leibowitz’s L15, Dulbecco’s modified Eagle’s Medium (DMEM) and Ham’s F12 
culture media, foetal bovine serum, Ca2+- and Mg2+-free Hanks’ balanced salt solution 
(CMF-HBSS), Dulbecco’s phosphate buffered saline (lacking Mg2+ and Ca2+), 
antibiotics and mouse nerve growth factor (NGF-2.5S or 7S) and GlutMax I were 
purchased from GibcoBRL. Dispase II, collagenase I and DNase I were supplied by 
Roche Inc. Basal Eagle’s Medium, Cytosine-β-D-arabinofuranoside (Ara-C), capsaicin, 
bradykinin, protease inhibitor cocktail, poly-L-lysine and laminin were bought from 
Sigma. 
 
2.1.2 Antibodies 
Table 2.1 List of antibodies 
Dilution 
 
Primary antibodies 
and catalogue 
numbers 
Monoclonal (Mab) or 
polyclonal, raised in 
species indicated and 
Immunogen epitope  
Vendor 
*IF *WB 
SNAP-25 
Cat. No. SMI81 
Mab, 
binding to the amino-
terminal of the C-terminal 
peptide 
Sternberger 
Monoclonal
s, Inc. 
1:500 1:1000 
SNAP-23 
Cat. No. 111 202 
Rabbit,  
synthetic peptide 
DRIDIANARAKKLIDS 
(aa 196-211 in human) 
Synaptic 
Systems 
1:1000 1:1000 
Syntaxin I 
Cat. No. S0664 
Mab Sigma 1:500 1:2000 
Syntaxin II 
Cat. No. 110 022 
Rabbit, cytoplasmic 
domain of rat syntaxin 2 
(aa 1 - 265). 
Synaptic 
Systems 
1:1000 1:1000 
Syntaxin III 
Cat. No. 110 032 
Rabbit, cytoplasmic 
domain of rat syntaxin 3 
(aa 1 - 260). 
Synaptic 
Systems 
1:1000 1:1000 
Sbr I 
Cat. No. 104 002 
Rabbit, synthetic peptide 
SAPAQPPAEGTEG (aa 2 
- 14 in rat synaptobrevin 1)
Synaptic 
Systems 
1:1000 1:1000 
Sbr II 
Cat. No. 104 202 
Rabbit, synthetic peptide 
SATAATVPPAAPAGEG 
(aa 2 - 17 in rat 
synaptobrevin 2) 
Synaptic 
Systems 
1:1000 1:1000 
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Sbr II (Cl69.1) 
Cat. No.104 211 
Mab, synthetic peptide 
SATAATVPPAAPAGEG 
(aa 2 - 17 in rat 
synaptobrevin 2) 
Synaptic 
Systems 
1:1000 1:1000 
Sbr I/II/III 
(anti-HV62) 
Guinea pig, a synthetic 
peptide corresponding to 
residues 33–94 of. human 
synaptobrevin-2 
Self-
generated  
(Foran et 
al., 2003) 
 1:400 
Synaptotag-min 
I/II 
Cat. No. SC-
12466 
Goat, an internal region of 
Synaptotagmin I 
Santa Cruz 
Biotechnolo
gy 
1:100  
Syt-Ecto (Cl604.2) 
Cat. No. 105 311C
3  
Mab, synthetic peptide (aa 
1 - 19 of rat synaptotagmin 
1)   
Synaptic 
Systems 
1:100  
SV2A 
Cat. No. 119 002 
Rabbit, synthetic peptide 
EEGFRDRAAFIRGAKD 
(aa 2 - 17 in human) 
Synaptic 
Systems 
1:1000 1:1000 
SV2B 
Cat. No. 119 102  
Rabbit, synthetic peptide 
DDYRYRDNYEGYAPN
D (aa 2 - 17 in rat) 
Synaptic 
Systems 
1:1000 1:1000 
SV2C 
Cat. No. SC-
11944
Goat, N-terminus of SV2C 
of rat origin 
Santa Cruz 
Biotechnolo
gy 
1:100 1:10000 
CGRP 
Cat. No. C8198 
Rabbit, synthetic CGRP 
(rat) 
Sigma 1:500  
CGRP (CD8) 
Cat. No. C9487 
Mab, synthetic peptide of 
C-terminal αCGRP (rat) 
Sigma 1:500  
SP 
Cat. No. AB14184 
 
Mab, Synthetic peptide: 
RPRPQQFFGLM, 
corresponding to amino 
acids 1-11 of Human 
Substance P. 
Abcam 1:1000  
VR1 
Cat. No. RA10110 
 
Rabbit, 
RASLDSEESESPPQENS
C 
Neuromics 1:1000  
VR1 
Cat. No. AB10295 
 
Guinea pig, synthetic 
peptide: 
YTGSLKPEDAEVFKDS
MVPGEK, corresponding 
to C terminal amino acids 
817-838 of Rat Vanilloid 
Receptor 1. 
Chemicon 1:1000  
BR2 
Cat. No. RDI-
BRDYKRabm  
    
Mab, peptide 350-364 C 
terminal of human B2 
Bradykinin Receptor 
RDI 
Division of 
Fitzgerald 
Industries 
Intl   
1:500  
NF-200 
Cat. No. N-0142   
Mab, the carboxyterminal 
tail segment of 
Sigma 1:500  
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enzymatically 
dephosphorylated pig 
neurofilament H-subunit  
BoNT/A Rabbit Allergan. 
Inc. 
 1:5000 
LC/E Rabbit Allergan. 
Inc. 
 1:15000 
*IF, immunofluorescence staining; WB, Western blotting  
Rabbit non-immune IgG was bought from Sigma; anti-species secondary antibodies 
fluorescently-labelled or conjugated to horseradish peroxidase were obtained from 
Invitrogen or Jackson Immuno-Research, respectively.   
 
2.1.3 Natural BoNTs 
Homogeneous, fully-active di-chain BoNT/A was obtained from Dr. B. DasGupta 
(Department of Food Microbiology and Toxicology, University of Wisconsin-Madison, 
53706, USA.).  Metabiologics Inc. supplied BoNT/B which contained some single 
chain; it was converted (> 95%) to the di-chain form by nicking with Trypzean (200 µg 
of toxin and 2 µg of enzyme in 0.2 ml 50 mM HEPES/50 mM NaCl, pH 7.4) at 27°C 
for 40 minutes, followed by addition of 20 µg of soyabean trypsin inhibitor.  BoNT/C1 
and /D were obtained from Metabiologics Inc. A highly purified single chain (SC) of 
natural BoNT/E from Metabiologics Inc was nicked to the DC form (>95%) with 
Trypzean (8µg/mg BoNT) for 40 minutes at 27ºC. 
 
2.1.4 Animals 
Wistar rats were bought from Bioresources Unit of Trinity College; Tyler’s Ordinary 
(TO) mice and Sprague Dawley rats were bred in an approved Bioresources Unit at 
Dublin City University (DCU).  
 
2.1.5 EIA assay reagents  
CGRP and SP enzyme immuno-assay (EIA) kit were bought from SPI-BIO. The EIA 
kit for rat vasoactive intestinal peptide (VIP) (EK-064-16) and neuropeptide Y (NPY) 
(EK-049-03) were purchased from PHOENIX PHARMACEUTICALS, INC. The 
serotonin EIA kit (17-EA602-96) was obtained from ALPCO DIAGNOSTICS.
 
2.1.6 ShRNA reagents for knock down of Sbr I gene expression 
ShRNA lentiviral transduction particles were bought from Sigma Aldrich. 
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 2.1.7 Other reagents 
Enhanced chemiluminescence (ECL) reagents were from Amersham or Millipore. 
Bicinchoninic acid (BCA) protein assay kit was bought from Pierce. Precast Bis-Tris 
gels, 20 x MOPs running buffer were purchased from Invitrogen. Trypzean, trypsin 
inhibitor, protein A agarose, 6'-diamidino-2-phenylindole (DAPI), isolectin B4-FITC 
and Coomassie Brilliant Blue G 250, trifloroacetic acid (TFA), and acetic acid were 
supplied by Sigma. Thrombin was bought from Novagen. Dolethal was prescribed by 
the Biosources Unit of Trinity College. Fluo 4-AM was purchased from Molecular 
Probes (Invitrogen).  Gangliosides mixture contained ~18% GM1, 55% GD1a, 15% 
GD1b, 10% GT1b and 2% other gangliosides extracted from bovine gray matter, and an 
aminopeptidase N inhibitor were supplied by Calbiochem.   
 
2.2 Procedures for isolation and culture of neurons 
 
2.2.1 Animals, anesthesia and dissection setup 
Postnatal day 5 (P5) Wistar or P3-5 Sprague Dawley rats or P5 TO mice were deeply-
anesthetized with intraperitoneal injection of Dolethal (50 mg/kg body wt). Heads were 
wiped with 70% ethanol, decapitated, and kept on ice until surgery. Dissection of TGs, 
DRGs and CGNs were performed inside an open-front laminar hood; working surface 
and all instruments including fine forceps, spring scissors, fine iris scissors were 
cleaned and sterilized by 70% ethanol to reduce the likehood of contamination. All 
dissection procedures were performed in the Bioresources Unit at Dublin City 
University (DCU).  
 
2.2.2 TGs dissection, dissociation and culture 
The procedures of (Eckert et al., 1997) were used with a number of modifications. The 
location of TGs is shown in Fig. 1.4 and 2.1.  After removal of skin from the skull, the 
brain and both optic nerves were removed to expose the TGs. The three main branches 
were cut and the connective tissue removed to release the TGs.  
The tissue was placed in ice-cold L15 medium, washed twice in ice-cold sterile Ca2+ 
and Ca2+- Mg2+- free Hanks’ balanced salt solution (CMF-HBSS) before centrifugation 
at 170 g for 1 minute. After chopping into small pieces and passing through L15 
medium precoated 10 ml Falcon pippetes, the tissue was incubated at 37°C for 30 
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minutes with shaking in 1:1 mixture of CMF-HBSS containing 2.4 U/ml dispase II and 
1 mg/ml collagenase I.  The suspension was then gently triturated through L15 medium 
precoated 10 ml serological pipetts until cloudy, before adding 1 mg/ml DNase I for 15 
minutes.  Following centrifugation at 170 g for 5 minutes, the pellet was resuspended 
and washed three times in culture medium [Ham’s F12 solution or DMEM containing 
10% (v/v) heat-inactivated foetal bovine serum, 100 U/ml penicillin, and 100 µg/ml 
streptomycin]. Cells were seeded at ~3x106 cells/well onto poly-L-lysine (0.1 mg/ml) 
and laminin (20 µg/ml) coated 24-well plates in F12 supplemented with 2.5 or 7s NGF 
(50 ng/ml) and maintained in a CO2 incubator at 37°C. After 24 hours and every other 
day thereafter, the culture supernatant was replaced with medium containing an anti-
mitotic agent, Ara-C (10µM).  
 
2.2.3 DRGs: dissection and culture of their neurons 
DRGs were dissected from P5 rats or mice. The locations of DRGs are shown in Fig. 
2.2. After opening the spine, the spinal cord was exposed and pushed back; ganglia 
were snipped, lifted and freed after cutting the connections. 
DRGs were washed, dissociated as for TGNs (above) and cultured at density 106/well 
in 24-well plate in DMEM containing 10% (v/v) foetal bovine serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 50 ng/ml 2.5s NGF. Ara-C (10 µM) was added 
from day 1 to 5 in culture; medium was exchanged every other day.  
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Fig. 2.1 Location of trigeminal ganglia (tg, double arrow) in rat cranial cavity: on, 
optic nerves; olf, olfactory bulb. The three trigeminal branches are labelled at the 
location to be severed for removal of the ganglia: 1, ophthalmic; 2, maxillary; 3, 
mandibular; 4, fifth cranial nerve. Picture adaped from (Malin et al., 2007).  
 
 
 
Fig. 2.2. Location of DRGs. The location of the ganglia are pointed with arrows. Pairs 
of DRGs reside at cervical, thoracic, lumbar and sacral vertebral levels. Picture 
adapted from (Malin et al., 2007). 
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2.2.4 Culturing of cerebellar granule neurons (CGNs)  
Procedures for isolation and culturing CGNs were adapted from (Foran et al., 2003). 
Briefly, cerebella were removed from 5-8 day-old rats and enzymetically digested 
using 1:1 mixture of trypsin-EDTA in Dulbecco’s phosphate buffered saline (lacking 
Mg2+ and Ca2+) (7.5 ml each) for 20 min at 37°C. Cells were collected by 
centrifugation at 170 g for 5 minutes and resuspended in culture medium at 1×106/ml in 
basal Eagle's medium containing 10 mM HEPES-NaOH, pH 7.3, 19.6 mM KCl, 9.4 mM 
D-glucose, 0.7 mM CaCl2, 0.4 mM MgSO4, and 0.25 mM NaH2PO4; 1x N2 supplement, 
1 mM GlutMax I (contains the dipeptide L-alanyl-L-glutamine which is only removed 
from the medium by cell metabolism; there is no build-up of toxic metabolites due to 
spontaneous breakdown); 60 U/ml penicillin, 60 µg/ml streptomycin, and 2% (v/v) 
horse dialyzed serum were subsequently added. Cells were seeded at density ~5x106 in 
24 well plates onto poly-L-lysine (0.1 mg/ml)-coated 24-well plates and Ara-C (40µM) 
was added after culturing for 20-24 hours. Neurons were maintained by replacement 
every 7-10 days with freshly-prepared medium.  
 
2.3 Cytochemical staining and microscopic recording of images 
TGNs cultured on poly-L-lysine and laminin coated coverslips were washed three 
times with Dulbecco’s phosphate buffer saline (lacking Mg2+and Ca2+) then fixed for 
20 minutes with 3.7% paraformaldehyde at room temperature in the latter buffer. The 
cells were then washed with PBS three times, followed by permeabilization for 5 
minutes with 0.2% Triton X-100 in PBS before blocking with 1% bovine serum 
albumin (BSA) in PBS for 1 hour.  Primary antibodies were applied in the same 
solution and left overnight at 4ºC; after extensive washing, fluorescently-conjugated 
secondary antibodies were added for 1 hour at room temperature. Fluorescent labelling 
of IB4–binding cells was performed as detailed by (Stucky et al., 2002). Briefly, rat 
cultured TGNs were fixed by 3.7% paraformaldehyde in CMF-PBS for 20 minutes, 
followed by rinsing 3 times with PBS. Staining was performed with 4 µg/ml FITC-IB4, 
in 0.1 M phosphate buffer (contains 84 ml 0.2 M Na2HPO4 mix with 216 ml 0.2 M 
NaH2PO4 and add H20 to 600 ml, pH 7.2), 0.1 mM CaCl2, 0.1 mM MgCl2, 0.1 mM 
MnCl2 for 1 hour at room temperature. In some cases, counter-staining of nuclei was 
carried out with DAPI (1 µg/ml in water) added before the final wash. 
Immuno-fluorescent pictures were taken with an inverted confocal (Leica Dmire 2) or 
an Olympus IX71 microscope equipped with a CCD camera. Images were analysed 
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using Leica confocal software and Image-Pro Plus 5.1, respectively. The omission of 
primary antibody from the fluorescence staining gave the background for secondary 
antibody; the signal intensity above this was taken as positive reactivity. 
 
2.4 Quantitation of neurotransmitters release and/or total cellular content 
 
2.4.1 Basal and stimulated release  
At 7 days in vitro (DIV), medium was gently aspirated from the TGNs or DRGs, 0.5 
ml of basal release buffer (BR-HBS, mM; 22.5 HEPES, 135 NaCl, 3.5 KCl, 1 MgCl2, 
2.5 CaCl2, 3.3 glucose, and 0.1% BSA, pH 7.4) was added into each well, followed by 
30 minutes incubation at 37°C. The solution bathing the cells was briefly centrifuged at 
4°C and the supernatants stored at -20°C until subjected to EIA. Ca2+-dependent 
release stimulated with 60 mM KCl in HBS (isotonically balanced with NaCl) or 
various concentrations of KCl (isotonically balanced with NaCl) as indicated in figure 
legends was performed in the same way. For stimulation with capsaicin or bradykinin, 
stocks (10 mM) were prepared in ethanol or dimethyl sulphoxide, respectively, and 
further diluted in BR-HBS to reach the required concentrations. In some cases, the final 
concentration of vehicle was kept at 0.1%; this was also included in BR-HBS when 
measuring basal efflux. Quantitation of Ca2+-independent basal release and that evoked 
by K+, capsaicin or bradykinin was carried out as above except for Ca2+ being replaced 
by 2 mM EGTA. The values obtained for each were subtracted from the requisite totals 
to yield the Ca2+-dependent components; the latter figure minus the basal value yielded 
the Ca2+-dependent evoked release; expression of the evoked release relative to that for 
basal efflux gave the increment for each stimulus. Intracellular total content per well 
was determined on randomly selected wells for each culture preparation. Briefly, 500 
µl of 2 M acetic acid/ 0.1% TFA were added into each well, cells are scraped off and 
lysed by freeze/thaw three times followed by high-speed vacuum evaporation. Before 
EIA assay, 500 µl of EIA buffer was added to resuspend the dried pellets; samples 
from each well were kept in -20°C prior to assay of neuropeptides. When EIA assay 
was performed (see below), no degradation of peptide was observed because addition 
of the aminopeptidase N inhibitor (1 mM final concentration) did not make any 
difference. 
 
2.4.2 Enzyme immuno-assay (EIA) of neuropeptides  
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 2.4.2.1 CGRP 
This EIA was based on a double-antibody sandwich technique that permits 
measurement of CGRP within the range of 1-500 pg/ml. The wells of the 96-well 
plates supplied with the kits were coated with a Mab specific for CGRP. This antibody 
binds any CGRP introduced in the wells (samples or standards supplied with the kits). 
An acetylcholinesterase (AChE)-Fab conjugate (anti-CGRP AChE tracer) which binds 
selectively to a different epitope on the CGRP molecule was also added to the wells. 
This allowed the two antibodies to form a sandwich by binding on different parts of the 
CGRP molecule, which remained immobilised on the plate; the excess reagents are 
washed away. The concentration of the CGRP was then determined by measuring the 
enzymatic acitivity of the AChE using Ellman's reagent, which contains 
acetylthiocholine as the substrate. The final product of the enzymatic reaction, 5-thio-2-
nitrobenzoic acid, is bright yellow and can be read at 405-420 nm. The intensity of the 
yellow colour, which was determined spectrophotometrically, is proportional to the 
amount of the CGRP present in the well.
For determining the amounts of CGRP released, 0.1 ml of sample or standard  was 
added to 96-well plates followed by 0.1 ml of CGRP tracer solution, and incubated at 
4ºC overnight. After plates were washed with buffer supplied in the kits for 5 times, 
Ellman's reagent was added and incubated in the dark at room temperature until the 
mixture turned yellow (at least 30 minutes). Plates were read photometrically at 405 
nm using a Techan microplate reader. For data analysis, a standard curve (linear curve 
fit) was generated for each assay (Fig. 2.3) and a best-fit line through the points drawn 
using Excel software; this was used to determine the concentration of CGRP in test 
samples. The accuracy of estimation of concentration for unknown samples depends on 
the absorbance falling within the desired range of standard curve. Samples with 
absorbance values beyond standard curve points need to be further diluted or 
concentrated before the assay is performed. 
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Fig. 2.3 A representative CGRP standard curve. This was generated by Excel software 
using linear regression. The blank reading was substracted from the sample or 
standard value and plotted in y-axis. Known concentrations of CGRP standards were 
plotted in x-axis. An equation was displayed above the chart and the peptide with 
unknown concentration in samples can be determined by extrapolation to it.  
 
2.4.2.2 SP 
SP EIA assay was based on the competition between SP and a SP-AChE tracer for a 
limited number of SP-specific binding sites in a rabbit antiserum. Because the 
concentration of the SP-tracer is held constant while the concentration of SP varies, the 
amount of SP-tracer that was able to bind to the rabbit antiserum would be inversely 
proportional to the concentration of SP in the well. This rabbit antiserum-SP (either 
free or tracer) complex was bound via a mouse monoclonal anti-rabbit IgG that had 
been previously attached to the well. The plate was washed to remove any unbound 
reagents, and then Ellman's reagent (which contains the substrate for AChE) was added 
to the well. The yellow product of this enzymatic reaction was read as for CGRP (see 
above). The intensity of this color was proportional to the amount of SP tracer bound to 
the well, which was inversely proportional to the quantity of free SP present during the 
incubation.  
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A sample or standard (0.05 ml) was added into each well followed by 0.1 ml SP-tracer, 
and plates were incubated at 4ºC overnight. After washing 5 times with washing buffer, 
Ellman's reagent was added into plates followed by incubation for 1~2 hours at room 
temperature. A representative SP standard curve is shown in Fig. 2.4, and the unknown 
concentration was determined from it by identifying the %B/B0, which is the (OD405 of 
sample or standard- OD405 of non-specific bound) / (OD405  of  maximum bound- OD405 
of non-specific bound); maximum bound is the reading value form assay when sample 
or standard was not added; non-specific binding (NSB) was obtained by omitting  
sample or standard and antibody from the assay (NSB also is called non-
immunological binding of the tracer to the well; even in the absence of specific 
antiserum, a very small amount of tracer still binds to the well). The sample 
concentrations were extrapolated from the known y-axis value using the standard 
curve.  A new standard curve was generated for every assay. 
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Fig. 2.4 A representative SP standard curve. This was generated by Prism software 
4.0 using nonlinear regression curve fit in two site binding (hyperbola) equation. 
%B/B0 is the % sample or standard bound/maximum bound. Known concentrations of 
SP standards were plotted in x-axis. Unknown concentrations of samples were 
extrapolated using the software based on standard curve created for each assay. 
 
2.4.2.3 NPY 
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Aliquots from the same samples assayed for CGRP or SP were also used to quantify 
the content of NPY present. The immuno-plate in this kit is pre-coated with secondary 
antibody and the non-specific binding sites are blocked. The secondary antibody binds 
to the Fc fragment of the primary antibody whose Fab fragment was competitively 
bound by both biotinylated peptide and peptide standard or samples. The biotinylated 
peptide interacted with streptavidin-horseradish peroxidase (SA-HRP) which catalyzes 
the 3,3',5,5'-tetramethylbenzidine (TMB) substrate solution composed of TMB and 
hydrogen peroxide producing a blue colored solution. The enzyme-substrate reaction is 
stopped by hydrogen chloride, turning the solution yellow which was read at 450 nm. 
The intensity of the yellow is directly proportional to the amount of biotinylated 
peptide-SA-HRP complex but inversely proportional to the quantity of the peptide in 
standard solutions or samples. A standard curve of a peptide with known concentration 
can be established accordingly. The peptide with unknown concentration in samples is 
determined by extrapolation from this standard curve. Very low cross-reactivity with 
SP or vasoactive intestinal peptide (VIP) is seen with this kit. 
 
2.4.2.4 VIP 
Aliquots of samples subjected to the above assays were also used to assess VIP present. 
Procedures were similar as that for NPY assay: 
Secondary
antibody
coated plate
Primary
antibody
Peptide
(in standard
solutions or 
samples)
Biotinylatedpeptide
SA-HRP Substrate
Read colour
at O.D405 nm
 
This kit showed very low cross-reactivity to NPY, SP, galanin, or secretin according to 
the information from the supplier. 
 
2.4.2.5 Serotonin 
Samples and standards were acylated and applied to a microtiter plate which was 
precoated with un-acylated serotonin. Serotonin antiserum was applied. Acylated 
serotonin and solid phase-bound serotonin compete for a fixed number of antiserum 
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binding sites. When the system reaches equilibrium, free antigen and free antigen-
antiserum complexes are removed by washing. The antibody bound to the solid phase 
serotonin is detected by anti-rabbit/peroxidase. The substrate TMB/peroxidase reaction 
product is read at 450 nm. The amount of antibody bound to the solid phase serotonin 
is inversely proportional to the serotonin concentration of the sample. The sensitivity 
for CSF and platelet-free plasma samples is 0.3 ng/ml, and the kit displays very low 
reactivity with tryptamine or melatonin.  
 
2.5 Crude fractionation of CGRP- and SP-containing large dense-core vesicles 
(LDCVs) from rat TGs 
TGs were dissected from around 35 5-day-old Wistar rats and homogenized using a 
motor-driven Teflon dounce homogenizer in 10 ml of homogenization buffer [0.32 M 
sucrose, 1 mM EDTA, 4 mM HEPES, pH 7.2, and a cocktail of protease inhibitors 
which is a mixture of protease inhibitors with broad specificity for the inhibition of 
serine, cysteine, aspartic proteases and aminopeptidases, and it contains 4-(2-
aminoethyl) benzenesulfonyl fluoride, pepstatinA, E-64, bestatin, leupeptin, and 
aprotinin without any metal chelators. Lysate was passaged through a 25G needle. 
Nuclei, unbroken cells, and large cell debris were removed by low speed centrifugation 
at 1,200 g for 15 minutes. Microsomes were pelleted by centrifuging the resultant 
supernatant at 100,000 g for 2 hours. Pellets were resuspended and hypo-osmoticly 
lysed for 45 minutes on ice in resuspension buffer (40 mM sucrose, 1 mM EDTA, 4 
mM HEPES, pH 7.2. and 1:100 (v:v) protease inhibitors from sigma). Continuous 
gradients were formed using 10% and 50% sucrose (w/v) in 1 mM EDTA, 4 mM 
HEPES, pH 7.2 with a gradient mixer. The resuspended pellet was then layered above 
this continuous gradient. After centrifugation at 95,000 g for 18 hours at 4°C, fractions 
(600 µl) were collected from the bottom working towards the top; protein 
concentrations were measured with a BCA kit (see 2.14). Aliquots of each fracion were 
solubilised in an equal volume of 4 M acetic acid/0.2% TFA followed by 3 cycles of 
freeze/thaw before the solvent was evaporated using speed-vacuum. The dried pellets 
were dissolved in EIA buffer before assay for CGRP or SP concentration by EIA.  
 
2.6 Immuno-absorption of vesicles from TGNs 
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Cultured TGNs from a pair of 24-well plates were washed and treated as above (in 2.5), 
modified from (Berg et al., 2000). After the resultant supernatant was subjected to 
centrifugation at 100,000 g for 2 hours, and the resultant pellets resuspended in ice-cold 
hypotonic lysis buffer (40 mM sucrose, 1 mM EDTA, 4 mM HEPES, pH 7.2 and 1:100 
(v:v) protease inhibitors from Sigma) for 45 minutes to osmoticly lyse microsomes and 
librate vesicles, then vesicles were sedimented (100,000 g for 2 hours) then 
resuspended in homogenisation buffer without applying to continuous gradient 
centrifugation.  Aliquots of the suspension (~144 µg protein determined by BCA assay) 
were incubated overnight at 4°C with rabbit antibodies (10 µg) specific for Sbr I or II 
(these antibodies recognise N-terminal cytoplasmic domain), or rabbit non-immune 
control IgG, all coupled to protein A agarose; the beads were washed 5 times with 
homogenisation buffer. Equal aliquots (0.5 ml) were sedimented and pellets dissolved 
in 2 x LDS sample buffer for SDS-PAGE, or in 2 M acetic acid/0.1%TFA for EIA; the 
solvents were removed from the latter by vacuum drying and the residues dissolved in 
EIA buffer for CGRP quantitation.  
 
2.7 Co-immunoprecipitation of SNAREs from detergent solubilised TGNs  
The pellets of PBS-washed TGNs were dissolved in 1 ml of extraction buffer [(mM): 
KCl, 140; EDTA, 2; HEPES-KOH pH 7.3, 20; and 1% (v/v) triton X-100].  After 
extraction for 1 hour at 4°C and centrifugation for 3 minutes at 700 g to remove 
unlysed cells and large debris, the supernatant was incubated overnight at 4°C with 10 
µg of rabbit IgG against Sbr I or II, or syntaxin II or III coupled to protein A agarose 
beads.  After sedimentation, the beads were washed 5 times in extraction buffer and 
proteins eluted using 2xLDS-PAGE sample buffer. A control sample was treated 
similarly except rabbit non-immune IgG was used.  SNAREs were detected by SDS-
PAGE and Western blotting, as described later.  
 
2.8 Treatment of neurons with BoNTs: monitoring of effects on CGRP release, 
SNARE cleavage, and exo-endocytotic activities 
 
2.8.1 Toxin incubation, release of neurotransmitters, cell lysis, SDS-PAGE and 
immunoblotting 
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After 7 DIV, fresh medium alone or that containing natural BoNT/A, /B, /C1, /D, /E or 
engineered chimeric toxin was added to the TGNs at 37°C for times indicated in figure 
legends, at the concentrations specified. After removal of the unbound toxin and 
subsequent washing with 2 x 1 ml of toxin-free BR-HBS buffer, Ca2+-dependent basal 
release of CGRP or SP and that evoked by 60 mM K+, 1 µM capsacin or 0.1 µM 
bradykinin were measured, as described previously. Non-toxin treated samples were 
processed similarly. In each case, stimulated release was calculated as in 2.4.1. 
Expression of the resultant values for BoNT-treated samples relative to those for the 
controls gave the % of CGRP or SP release remaining. After the release assay, the cells 
in each well were lysed in 0.2 ml of 2 x LDS sample buffer, heated for 5 minutes at 
95°C and separated by SDS-PAGE using 12% precast Bis-Tris gels (Foran et al., 2003). 
Specific antibodies were used for the Western blotting analysis. 
 
2.8.2 Quantitation of substrate cleavage  
After ECL development, digital images were obtained using the G BOX Chemi-16 gel 
documentation system; intensities of each lane were quantified with Image J software. 
For determination of the fraction of each SNARE cleaved, the ratios calculated for 
intact substrate and the requisite internal standard (i.e. a SNARE not susceptible to the 
toxin in use, to normalize any variation between wells) for BoNT-treated samples were 
expressed relative to those for non-toxin treated controls. Data were calculated and 
graphs generated by Excel and Prism 4.0 software; each point represents the mean ± 
s.e.m or mean ± s.d., as indicated in figure legends from several independent 
experiments.  
 
2.8.3 Ecto-Syt I binding and uptake into TGNs  
For assay of synaptic vesicle exocytosis and recycling, rat TGNs were cultured for 7 
DIV on poly-L-lysine and laminin coated coverslips, and incubated with 100 nM 
BoNT/A or chimera EA in culture medium for 24 hours. Toxins were washed away 
and cells exposed to Ecto-Syt Abs (1:100) for 15 minutes in the basal buffer, or 60 mM 
K+ or 1 µM capsaicin stimulation buffer (as described previously for CGRP release 
assays). After washing three times with basal buffer, cells on coverslips were fixed for 
20 minutes with 3.7% paraformaldehyde in Ca2+- and Mg2+-free PBS at room 
temperature and fluorescent  images were recorded using an Olympus IX71 inverted 
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microscope fitted with epifluorescence. Images were captured with a CCD camera and 
processed using Image Pro-Plus version 5.1 (Media Cybernetics). 
 
2.9 Measurement of intracellular [Ca2+] and Ca2+ uptake into TGNs 
Coverslips containing TGNs were loaded with 3 µM Fluo 4-AM in basal release buffer 
at room temperature for 20 minutes, mounted on a custom-built low-volume (350 µl) 
chamber attached to an Axioskop 2 FS MOT/LSM Pascal confocal microscope (Zeiss). 
An argon laser was used to excite Fluo 4-AM at 488 nm. Serial images were taken of 
Ca2+ fluorescent signals at 10 sec. intervals while the superfusate was switched after ~2 
minutes from BR-HBS to stimulation buffer: 60 mM K+ or 1 µM capsaicin. The 
intensity of fluorescence at 505~530 nm (f) was analysed off-line on a cell-by-cell 
basis, and expressed relative to the baseline fluorescence (f0) measured for each cell in 
BR-HBS. Mean f/f0 ratios ± SEM were plotted; n values are given in figure legends 
(Fig. 5.11).  
Cultured TGNs were incubated with 24 µCi/ml 45Ca2+ in BR-HBS containing 0.1% 
ethanol, l µM capsaicin or 60 mM K+ at room temperature for the times indicated in the 
figure. The incubation was stopped by 6 washes in 1 ml BR-HBS buffer, the samples 
solubilised in 200 µl of 0.1% SDS and counted in Beckman CP scintillation 
spectrometer. Ca2+ uptake was calculated from a standard curve of the amount of  
45Ca2+ against counts/minute. 
 
2.10 Knock-down of Sbr I gene expression in cultured TGNs using small hairpin 
RNA (shRNA)  
ShRNA (small hairpin RNA) lentiviral particles for knock down of Sbr I gene 
expression were used; these are transduction-ready viral particles with ~1.5×107 
transduction units (TU)/ml. The shRNA target set contains five clones specific for 
different regions of mouse Sbr I mRNA (Table 2.2). 20 µl (3×105 TU) of each clone of 
shRNA viral particles were added to 200 µl culture medium and applied to ~105 
cells/well of mouse cultured TGNs at 7 DIV; 200 µl fresh culture medium was added 
the next day and every other day thereafter. Neurons which were not treated by viral 
particles were used as negative controls. Infected cells were kept in culture for 8-10 
days before monitoring of basal and stimulated release of CGRP detailed in 2.4.1. 
Immediately thereafter, cells were solubilized in 2xLDS sample buffer prior to analysis 
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of level of each SNARE protein by SDS-PAGE and Western blotting, with specific 
antibodies for SNAP-25 (SMI-81), syntaxin I (HPC-1), Sbr I (rabbit IgG) or Sbr II 
(rabbit IgG). 
 
Table 2.2 ShRNA target set for knock-down of mouse Sbr I 
Clone 
no. 
ShRNA TRC No. Sequence 
5 TRCN0000110585 CCGGCGGGAATTATTTCCTGGGTTTCTCGAGAAACCCAGG
AAATAATTCCCGTTTTTG 
Region: 3’UTR  
4 TRCN0000110586 CCGGGCCATCATCGTGGTAGTGATTCTCGAGAATCACTAC
CACGATGATGGCTTTTTG 
Region: CDS  
3 TRCN0000110587 CCGGCGTGGTAGTGATTGTAATCTACTCGAGTAGATTACA
ATCACTACCACGTTTTTG 
Region: CDS  
2 TRCN0000110588 CCGGGCTGGGAGCTATCTGTGCCATCTCGAGATGGCACAG
ATAGCTCCCAGCTTTTTG 
Region: CDS  
1 TRCN0000110589 CCGGCATGACCAGTAACAGGCGGTTCTCGAGAACCGCCTG
TTACTGGTCATGTTTTTG 
Region: CDS  
3’UTR, 3’ untranslated region; CDS, coding sequence; TRC, the RNAi consortium 
 
2.11 Generation of a novel BoNT chimera EA which binds to the BoNT/A 
acceptor SV2C-L4 in vitro.  
 
2.11.1 Designing a construct for BoNT chimera EA by recombinant substitution of 
the HC domain of BoNT/E with its counterpart from BoNT/A 
In order to re-target BoNT/E proteolytic LC into TGNs insensitive to BoNT/E, I 
designed a new EA chimera.  The LC and HN gene fragments from BoNT/E (LC-HN/E) 
were fused to the HC of /A (HC/A) to generate chimera EA transgene (LC-HN/E-HC/A).  
 
2.11.2 Creation of chimera EA: construction, expression and purification followed 
by nicking with Trypzean 
 38
The chimera EA transgene was cloned into a prokaryotic expression vector and 
expressed in E. coli BL21 (DE3) strain. Its detailed construction, expression and 
purification were performed by Dr. Wang J and are described in (Wang et al., 2008). 
Nicking of this chimeric toxin between LC and HC was achieved by incubation with 
Trypzean (8 µg/mg BoNT) for 1 hour at 25°C and monitored by SDS-PAGE, followed 
by Coomassie protein staining and Western blotting, using rabbit antibodies against 
BoNT/A and LC/E.   
 
2.11.3 GST-SV2C-L4 pull-down assay for toxin-acceptor interaction 
A cDNA portion encoding the intra-luminal for toxin-acceptor interaction SV2C loop 4 
(SV2C-L4, amino acids 454-579) was PCR amplified from pCMV SV2C plasmid (a 
gift from T. Südhof, Houston, Texas), cloned into pGEX-2T and expressed in BL21 
(DE3) E. coli by Dr. Astrid Sasse. 
For pull down assay, GST-SV2C-L4 (~100µg) was immobilised onto 100 µl of 
glutathione–Sepharose-4B matrix and incubated with BoNT/A, /E, or EA chimera (100 
nM each) in a total volume of 100 µl of binding buffer (50 mM Tris, 150 mM NaCl, 
0.5% triton X-100, pH 7.6) in the presence of 0.6mg/ml gangliosides mixtures for 4 
hours at 4°C. Beads were collected by centrifugation and washed five times, each wash 
for 15 minutes at 4ºC with 1 ml of binding buffer. Bound proteins were eluted by 2x 
LDS-sample buffer, and less than 5% of bound protein was subjected to electrophoresis 
on 4-12% precast Bis-Tris gels. Toxins were detected by Western blotting with IgGs 
against LC/E or BoNT/A. Input GST-SV2C-L4 protein was detected with goat anti-
SV2C antibody. 
 
2.12 Production of BoNT chimeras AB (LC-HN/A-HC/B) and BA (LC-HN/B-HC/A)  
I designed BoNT chimeras AB and BA by recombinant substitution of the HC domain 
in /A and /B with their counterpart from the other serotype. The construction, 
expression and purification were performed by Dr Wang J (our unpublished data). 
Nicking of chimera AB toxin between LC and HC was achieved by incubation with 
Trypzean (3 µg/mg BoNT) for 1 hour at 25°C, followed by addition of soyabean 
trypsin inhibitor (30 µg/mg BoNT). Chimera BA which contains an engineered 
thrombin cleavage site in the loop region was efficiently and precisely nicked by 
thrombin (1 U/mg toxin) for 1 hour at 22°C, followed by addition of PMSF to a final 
concentration of 1 mM.  
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 2.13 SDS-PAGE, protein staining, Western blotting and 2-dimensional (2-D) gel 
electrophorisis 
 
2.13.1 SDS-PAGE 
Proteins were loaded onto 12% or 4-12% precast Bis-Tris gel and electrophoresis run at 
180 volts using MOPs running buffer (1 liter: 250 mM MOPS, 250 mM Tris, 5 mM 
EDTA, 0.1% SDS) until  proteins were separated according to their molecular weights, 
indicated by pre-stained protein markers. Proteins were then fixed and stained as 
detailed in 2.13.2 or 2.13.3, or electrophoretically transferred to a Immobilon™ PVDF 
membrane for immunoblot assay as described in 2.13.4.  
. 
2.13.2 Sypro-ruby staining of protein gels 
Gels were rinsed with distilled water and fixed in 10% methanol/7% acetic acid (v/v) 
for 30 minutes with shaking at room temperature. After rinsing the gels with distilled 
water, 10 ml of Sypro-ruby staining solution was added to the gel-trays which were 
covered by foil to protect from light. The staining was carried overnight with shaking 
at room temperature. After rinsing with distilled water and destaining with 10% 
methanol/7% acetic acid for 30 minutes, the gels were visualized under UV and stained 
bands were recorded using the gel-documentation system (described above). 
 
2.13.3 Coomassie Blue staining 
Protein gels prepared as in 2.13.1 were placed in 0.25 % (w/v) of  Coomassie brilliant 
blue G 250 in 10% acetic acid (v/v) and 45 % methanol for 2-4 hours with gentle 
rocking to distribute the dye evenly over the gel. Gels were destained using 30% 
methanol/10% acetic acid until protein bands became distinct. 
 
2.13.4 Western blotting  
A piece of PVDF membrane with a rated pore size of 0.45 µm (Millipore) was wet for 
about 30 second in methanol followed by rinsing with ddH2O twice, before soaking in 
transfer buffer (1L: 25 mM Tris-base, 190 mM glycine, 100 ml methanol and 900 ml 
H2O) for 15 mins; then, assemble "sandwich" for transblot:  (+) Sponge - filter paper -
membrane - protein gels (prepared as in 2.13.1) - filter paper - sponge (-). Then put 
assembled "sandwich" in a transfer tank (TE62, Hoefer. Inc.)  filled with transferring 
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buffer as above and transfer for 2~3 hours at 45 volts at 4°C; When finished, immerse 
membrane in blocking buffer (1L: 5 ml 2 M Tris-bis, 30 ml 5 M NaCl, 1 ml Tween 20, 
7.6, 5% skimmed milk w/v) and block for 1 hour at room temperature. Then incubate 
with primary antibody diluted in blocking buffer for 1 hour at room temperature. After 
washing 3 x 10 min with 0.1 % Tween 20 in PBS, anti-species secondary antibodies 
conjugated to horseradish peroxidase (diluted in blocking buffer) were incubated for 1 
hour; following washing 3 x 10 min with 0.1 % Tween 20 in PBS, proteins were 
detected by ECL reagent which contains a luminol substrate of horseradish peroxidase 
and can be converted to a light releasing substance.  Images were recorded using G 
BOX Chemi-16 gel documentation system and intensities quantified with Image J 
software. 
 
2.13.5 2-dimensional (2-D) gel electrophorisis  
An established 2D SDS-PAGE method (Lawrence and Dolly, 2002) was used to 
investigate whether cleaved SNAP-25 products form SDS-resistant SNARE complexes 
during Ca2+-triggered exocytosis in rat cultured TGNs treated with BoNT/A or chimera 
EA. After stimulating cells with 1 µM capsaicin for 30 minutes at 37°C, the buffer was 
removed and cells solubilised in LDS-sample buffer without boiling. Proteins were 
separated by SDS-PAGE on 4-12% precast Bis-Tris gel. Each sample lane was cut into 
strips reflecting different distances of migration through the gel, chopped into small 
pieces and boiled for 10 minutes in LDS-sample buffer; after being left overnight at 
room temperature, the samples were boiled again for 5 minutes before loading the 
extracted proteins onto a second 12% precast Bis-Tris gel. SNAREs released from 
complexes after boiling were detected in the second gel by Western blotting with 
specific antibodies, their position indicating the migration distance through the first gel 
(i.e. Mr of the SDS-resistant SNARE complex). 
 
2.14 Protein concentration assay by BCA protein assay kit  
The BCA protein assay combines the well-known reduction of Cu2+ to Cu+ by protein 
in an alkaline medium with the highly sensitive and selective colorimetric detection of 
the cuprous cation (Cu+) by bicinchoninic acid. The first step is the chelation of copper 
by protein in an alkaline solution to form a blue colored complex. In this step, known 
as the biuret reaction, peptides containing three or more amino acid residues form a 
light blue colored chelate complex with cupric ions in an alkaline environment (pH 8.0). 
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Proteins will react to produce a light blue to violet complex that absorbs light at 540 
nm. The intensity of the color produced is proportional to the number of peptide bonds 
participating in the reaction. In the second step of the color development reaction, BCA, 
a highly sensitive and selective colorimetric detection reagent reacts with the cuprous 
cation (Cu+) that was formed in step 1. The purple-colored reaction product is formed 
by the chelation of two molecules of BCA with one cuprous ion. The BCA/copper 
complex is water-soluble and exhibits a strong linear absorbance at 562 nm with 
increasing protein concentrations. Briefly, 25 µl of sample from each fraction or BSA 
standard were applied to a 96 microplate; 200 µl mixture of reagent A and B (50:1) 
supplied in the kit were added to each well. The plate was mixed thoroughly and 
incubated for 30 minutes at 37°C before absorbance at 562 nm was read. 
Concentrations were calculated from the linear range of the standard curve. 
 
2.15 Statistical analysis 
Data were calculated and graphs generated by GraphPad Prism 4.0; each point 
represents the means ± S.E.M. or ± S.D. as indicated in Figure legends; student’s 
unpaired t-test was used to evaluate significance of changes. 
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3.0 TGNs are a suitable model for investigating anti-nociceptive potential of 
BoNTs 
 43
3.1 Overview 
This chapter describes the culturing of TGNs and demonstrates their expression of 
sensory neuron markers and the release of pain-peptides in response to K+-
depolarisation or known pain stimuli. These cells were then used to establish a basis for 
the putative anti-nociceptive effects of BoNT/A and to evaluate the roles of particular 
SNARE isoforms in regulated CGRP exocytosis (Chapter 4). Based on insights gleaned 
with natural BoNTs, novel BoNT chimeras were generated recombinantly with the goal 
of eventually creating new variants with improved anti-nociceptive potential (Chapter 
5). 
 
3.2 Results 
 
3.2.1 Dissection of TGs and culture of their neurons  
Neonatal rats or mice were used as a source of TGs because sensory neurons usually 
appear at embryonic day E10-13 for mouse, and E9-14 for rat. At P3-5, mouse and rat 
TGs are bigger than in the embryonic stage, relatively ease to dissect and readily 
susceptible to enzymatic dissociation. The dissociated TGNs were seeded onto poly-L-
lysine and laminin precoated 24-well plates and cultured in F12 or DMEM medium 
supplemented with nerve growth factors (NGF 2.5s or 7s), as detailed in the Chapter 2. 
Sensory neurons obtained from neonatal rats require neuronal trophic factors, 
especially NGF to support differentiation, maintain phenotype and induce synthesis of 
transmitters (Malin et al., 2007). Immediately after plating cells, neuronal cell bodies 
were round, smooth, and phase-bright and usually less than 50% of total cell count. 
Within 2 hours of plating, most of neuronal cells attach to the coated surface. Neurites 
were discernable the next day. Non-neuronal cells attached more firmly to the culture 
surface, and divided quickly to occupy the growth area; thus, it was necessary to 
remove them as soon as possible. Therefore, Ara-C, a pyrimidine anti-metabolite that 
inhibits DNA synthesis, was added on day 2-5 to kill proliferating cells; 
fluorodeoxyuridine and uridine also proved effective.  By day 5, most of the non-
neuronal cells had died and cell debris could be removed by several changes of the 
culture medium. Morphological and histochemistrical experiments, neurotransmitters 
release assays, and treatment with toxins were performed at 5-7 DIV.   
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 3.2.2 Morphological and histochemical features of the cultured neurons  
 
3.2.2.1 Phase contrast microscopy of rat and mouse TGNs 
Phase contrast micrographs revealed that rat (Fig. 3.1 A, B) and mouse (Fig. 3.1 C) 
neuronal cells are easily distinguished by large, round, phase-bright cell bodies with 
extended fine fibres (Fig. 3.1). At 1 DIV, satellite cells show spindle-liked cell soma 
shape and relative broader fibres; Astrocytes usually have polygonal or star shape with 
short fibres (Fig. 3.1 A). TGNs possessed bipolar or multi-polar neurite extensions; 
some had a pseudo-unipolar shape. There was no distinct difference in the neuronal 
morphology between rat and mouse (Fig. 3.1 B, C). At 7 DIV neuronal cells are 
enriched comparing with 1 DIV (Fig. 3.1 B, C). Just like TGNs in vivo, the cultured 
neurons seemed to be roughly made up of two populations representing small and large 
neurons. 
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Fig. 3.1 Visualisation of the morphology of sensory neurons in cultured TGNs. Cell 
cultures from (A) rat (P5) at 1DIV, (B) rat (P5) and (C) mouse (P5) at 7 DIV were 
viewed in an inverted Olympus IX71 microscope in phase contrast mode. Compared 
with 1 DIV, TGNs were enriched at 7DIV. Neuronal cells are indicated by arrow heads, 
A respresentive astrocyte is indicated by arrows, and a satellite cell is circled. Scale 
bar, 30 µm.  
 
 
 
 
 
 
 
 
 
 
 
 47
3.2.2.2 Rat cultured TGNs display characteristics of sensory neurons: nociceptive 
markers and pain mediators 
 
3.2.2.2.1 A large proportion of DAPI-stained cells are immuno-stained for NF-200 
indicating enrichments for the neuron cells at DIV 5-7 
NF-200 is a phosphorylated heavy chain of neurofilament, a major marker for neuronal 
cells. Neurofilament expression is developmentally regulated and all cells containing 
neuron-specific enolase epitopes also are labelled with NF200 (Trojanowski et al., 
1986). A mAb against NF-200 stained both the cell soma and, strikingly, the processes 
of cultured TGNs (Fig. 3.2). After repetative treatment by Ara-C, there was only very 
limited contamination by non-neuronal cells, which cannot be totally removed by 
addition of anti-mototic regent because they proliferate slowly.  
 
3.2.2.2.2 CGRP  
The presence of a major pain-mediating peptide, CGRP, in most of the cells in TGN 
cultures was demonstrated by immuno-fluorescent microscopy and counter-staining 
with DAPI (Fig. 3.3). Striking punctate staining by a specific polyclonal antibody 
against CGRP was visualized on cell plasmalemma and along the fibres. 
 
3.2.2.2.3 SP co-occurs with CGRP 
Another pain peptide, SP, was found to co-occur with CGRP in cultured TGNs using a 
fluorescent inverted microscope (Fig. 3.4 A, B) and by confocal microscopy (Fig. 3.4 C, 
D, E). Both demonstrated predominant staining of the cell bodies with a mAb specific 
for SP and a polyclonal antibody against CGRP (as in Fig. 3.3) and less intense 
labelling of the extensive neurites. Confocal microscopy confirmed punctate staining 
for the two peptides throughout the cytoplasm and adjacent to the plasma membrane of 
the cell bodies and processes; the merged picture highlights the overlapping, but to 
some extent distinct, subcellular locations of CGRP and SP. 
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A, NF-200 B, DAPI
 
 Fig. 3.2 Representative micrographs demonstrating that most of the cultured cells 
were NF-200 positive, indicative enrichment of neurons at 5 DIV. Cells were grown 
on coverslips for 5 DIV, fixed and permeabilised prior to labelling overnight at 4 ºC 
with (A) mouse anti-NF-200 (1:500), followed by goat anti-mouse Alexa Fluor-488 
(1:200) for 1 hour at room temperature. (B) Samples were counter-stained by DAPI 
before being mounted onto slides and viewed in an inverted microscope under 
fluorescent mode. Scale bar, 30 µm. 
 
B, DAPI A, CGRP 
 
    
Fig. 3.3 Visualisation of CGRP immunoreactivity in cultured TGNs. Rat TGNs grown 
on coverslips for 7 DIV were fixed, permeabilised and stained by rabbit anti-CGRP 
antibody (1:500) (A) , followed by fluorescently-labelled secondary goat anti-rabbit 
Alexa Fluor-448 (1:200); the specimens were counter-stained with DAPI (B)  before 
samples were viewed in an inverted microscope in fluorescent mode. Scale bar, 20µm.  
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Fig. 3.4 Visualisation of CGRP and SP immunoreactivity in rat cul
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 3.2.2.2.4 Vanilloid receptor type 1(VR1) - capsaicin receptor   
The TGNs exihibited characteristics of differentiated pain sensory cells, as reflected by 
the staining patterns observed with antibodies to specific sensory markers. An antibody 
specific for VR1  a vanilloid receptor type 1 which is responsive to capsaicin and 
occurs in peptidergic C fibres (Caterina et al., 1997)  labelled a majority of the rat 
neurons (Fig. 3.5). VR1 immunoreactivity resided predominantly on the cell bodies and 
to a much lesser extent on fibres.  
 
3.2.2.2.5 VR1 and bradykinin receptor type 2 (BR2)  
Another sensory marker, BR2  a G protein-coupled receptor known to occur in 
nociceptive neurons (Steranka et al., 1988)  was detected in the VR1-positive cells, 
by labelling with a selective antibody (Fig. 3.6). Notably, the immunoreactivity 
appeared strongest in patches on the neurons (Fig. 3.6 B, C). Confocal microscopy 
clearly demonstrated BR2 protein located in a specific region (vascular-like 
distribution) and to a much lesser extent in the rest of cell membrane and cytoplasm 
(Fig. 3.6 E, G).  
 
     
 A, VR1 B, DAPI  
 
Fig 3.5 Visualisation of VR1 immunoreactivity in rat cultured TGNs. TGNs grown on 
coverslips at 7 DIV were fixed, permeabilised and stained with rabbit anti-VR1 
(1:1000) (A) followed by a fluorescently-labelled secondary goat anti-rabbit Alexa 
Fluor-546 (1:200); the specimens were counter-stained with DAPI (B) before viewing 
under low-magnification fluorescent microscopy. Scale bar, 30µm. 
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3.2.2.2.6 IB4 binding and DAPI staining 
Another nociceptive sensory neuron marker is revealed by a fluorescent conjugate of 
IB4, an isolectin that binds to small nociceptive neurons in C fibres (Guo et al., 1999). 
It stained most of the cells counterstained by DAPI (Fig. 3.7); these are irregular in 
shape and vary in size. It has been suggested that IB4-positive nociceptors mediate 
neuropathic pain, whereas IB4-negative nociceptors mediate inflammatory pain. More 
evidence is needed to support this theory (Stucky et al., 2002). 
 
  
A, IB4 B, DAPI 
 
Fig 3.7 Fluorescence staining of IB4 binding neurons. Rat cultured TGNs at 7 DIV 
were fixed by 3.7% paraformadelhyde in CMF-PBS for 20 minutes at room 
temperature, followed by rinsing for 3 times with PBS. Staining was performed by 4 
µg/ml FITC-IB4 (A) in 0.1 M phosphate buffer (see Chapter 2), 0.1 mM CaCl2, 0.1 mM 
MgCl2, 0.1 mM MnCl2 for 1 hour at room temperature. DAPI was applied for 5 
minutes to counter-stain the samples (B). Specimens were viewed in an inverted 
microscope in fluorescent mode. Scale bar, 20µm. 
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3.2.2.3 Sensory peptidergic TGNs contain all 3 SNAREs (SNAP-25, syntaxin, and 
Sbr) and synaptotagmin I/II which largely co-localise with CGRP  
 
3.2.2.3.1 SNAP-25, SNAP-25 and CGRP, SNAP-25 and VR1 
With regard to the molecular machinery underlying the regulated release of pain-
peptides, it was important to identify the key isoforms of SNAREs and SNARE- 
related proteins present in sensory neurons, especially because of these being related to 
the sensitivity to BoNTs. Lower magnification micrographs showed that the majority 
of neurons were stained with a specific antibody against SNAP-25 (Fig. 3.8 A), a target 
substrate of BoNT/A and /E. SNAP-25 co-staining with CGRP could be visualised by 
confocal immuno-microscopy (Fig. 3.8 B). Labelling of SNAP-25 appeared on the 
membrane of cell bodies, axons (broad) and dendrites (fine); also, punctate staining 
was visible in the cytoplasm. Dual-labelling of VR1 and SNAP-25 indicated nearly all 
the VR1-positive cells express SNAP-25 (Fig. 3.8 C). 
 
3.2.2.3.2 Syntaxin isoforms I, II, and III are expressed in TGNs 
In rat synaptosomes, syntaxin I, II and III are known to be cleaved by BoNT/C1 
(Schiavo et al., 1995). However, the presence of these proteins in nociceptive sensory 
neurons and their functions in pain-related peptides release are not clear. Herein, using 
immunofluorescence staining with isoform specific antibodies, it was demonstrated 
that these three isoforms are expressed in cultured TGNs.   
 
3.2.2.3.2.1 Syntaxin I and CGRP 
Labelling of the other t-SNARE, syntaxin I with a specific mAb gave a similar pattern 
of staining to that observed for SNAP-25. Lower magnification immunofluorescence 
micrographs demonstrated a majority of DAPI-stained cells expressing syntaxin I (Fig. 
3.9 A). However, immunoreactivity towards syntaxin I seemed stronger in certain cells 
and lower in others. Confocal microscope (Fig. 3.9 B) demonstrated that labelling of 
syntaxin I definitely appeared on the cell membrane as well as processess; also, 
punctate staining was visualised in the cytoplasm near the nucleus. Clearly, CGRP 
occurs together with syntaxin I as revealed by dual-labelling (Fig. 3.9 B). 
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3.2.2.3.2.2 Co-staining of syntaxin II or III with NF-200 
The presence of syntaxin II in cultured TGNs was confirmed by immuno-fluorescence 
microscopy, using a specific antibody against syntaxin II. Similar to syntaxin I, 
syntaxin II labelling appeared on the membrane of cell bodies, and to a much lesser 
extent on neurites, which were strongly labelled by NF-200 antibody (Fig. 3.10 A). 
Syntaxin isoform III was also expressed in TGNs and showed similar distributions as 
isoform II (Fig. 3.10 B). 
 
3.2.2.3.3 Sbr I and CGRP, Sbr II and CGRP 
Both of the v-SNARE isoforms, Sbr I and II, which are the substrates of Sbr-cleaving 
toxins as listed in the Chapter 1, were visualised by low magnification microscope (Fig. 
3.11 A), using antibodies selective for each. Focusing on the fine fibres at higher 
resolution revealed striking punctate labelling which co-localised well with CGRP (Fig. 
3.11 A). Confocal microscopy also confirmed Sbr II staining was located 
predominantly in the cell body with ‘vesicular-like’ staining visible in the perinuclear 
area and to a lesser extent along the fibres. Additionally, the extensive network of 
neurites was clearly labelled (Fig. 3.11 B). Next, it was warranted to define which 
isoform could be involved in the release of transmitters.   
 
3.2.2.3.4 Synaptotagmin I and CGRP  
Finally, using confocal microscope to visualise the vesicle protein synaptotagmin I, a 
Ca2+ sensor whose N-terminal is exposed to the lumen of the synaptic vesicle, binds to 
SNAP-25 and also serves as a putative high-affinity protein acceptor for BoNT/B and 
/G. The micrographs showed a striking punctate pattern of staining for synaptotagmin I, 
both in the cell body and along all the fine processes (Fig. 3.12 A, C). Importantly, dual 
labelling with antibody reactive towards CGRP (Fig. 3.12 B, C) demonstrated that this 
protein and CGRP are strongly co-localized (Fig. 3.12 D). This indicates that this Ca2+ 
sensor might be involved in CGRP release. 
 
In conclusion, CGRP occurs together with SNAP-25, syntaxin I, Sbr (I and II) and 
synaptotagmin I in the rat cultured TGNs. Although most of the cells became stained 
with all of these antibodies, some differences were apparent in the relative labelling 
intensity for CGRP and each of these proteins in individual neurons.  The striking 
similarities apparent in the distribution patterns for Sbr I, synaptotagmin I and CGRP 
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are suggestive of functional implications (see later). These collective findings highlight 
that all 3 SNAREs and the putative Ca2+ sensor, synaptotagmin I, occur in CGRP-
containing sensory neurons that, also, usually possess SP. 
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Fig. 3.9 Visualization of the presence of syntaxin I in rat TGNs together with CGRP. 
Normal (A) or confocal immuno-fluorescence miscroscopy (B) were used to capture 
the images. Cells grown on coverslipes at 7 DIV were fixed, permeabilised and 
labelled with specific antibodies against (A) syntaxin I (1:500) followed by goat anti-
mouse Alexa Fluor-488 (1:200) and counter-stained by DAPI, or (B) syntaxin I (1:500) 
(and goat anti-mouse Alexa Fluor-488 (1:200)) and CGRP (1:500) (and goat-anti 
rabbit Alexa Fluor-546 (1:200)). Scale bars, 15µm (A) and 5.88 µm (B).  
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Fig. 3.10 Microscopic demonstration of the presence of syntaxin II and III in rat 
cultured TGNs. The cells were grown on coverslips for 7 DIV, fixed and 
permeabalised prior to labelling with rabbit IgGs against (A) syntaxin II (1:1000) or 
(B) syntaxin III (1:1000) (and goat-anti rabbit Alexa Fluor-546 (1:200)) or mouse anti-
NF-200 (1:200) (and goat anti-mouse Alex Fluor-488 (1:200)). Samples were viewed 
in an inverted microscope in phase contrast and fluorescent mode, as indicated in 
pictures. Syntaixn II and III labelling appeared predominantly on the neuron cell 
bodies and to a much lesser extent in processes. Scale bar, 20µm. 
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Fig. 3.11 Representative fluorescence micrographs 
and II in CGRP-containing rat cultured TGNs. Cells
were fixed and permeabilised before staining with (A)
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Fig. 3.12 Visualization of the punctate co-staining of synaptotagmin I and CGRP in 
rat cultured TGNs. Cells grown on coverslips for 7 DIV were fixed and permeabilised 
before labelling with Mab against the lumenal domain of (A) synaptotagmin I (1:1000) 
followed by goat anti-mouse Alexa Fluor-488 (1:200), or (B) rabbit antibody against 
CGRP (1:500) followed by goat anti-rabbit Alexa Fluor-546 (1:200). (C) Merged 
picture showing overlapped signals. (D) The axes represent density of each fluorescent 
signal and the analysis graph shows the extent of co-localization of two fluorescence 
signals. Scale bar, 15µm. 
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3.2.3 Evoked-release of neurotransmitters from rat cultured TGNs  
 
3.2.3.1 K+ depolarisation-, capsaicin- or bradykinin-elicited release of CGRP and 
SP from cultured TGNs are Ca2+-dependent and show different levels 
After culturing TGNs for 7 days, the amounts of CGRP released under basal and 
stimulated conditions were quantified by EIA. The optimal stimulation time was 30 
minutes (Fig. 3.13 A). A minimal quantity of ‘resting’ release occurred in 3.5 mM 
K+/2.5 mM Ca2+ compared to the amounts evoked by elevated [K+], 60 mM K+ giving 
an optimal ~ 14-fold increase over the basal level (Fig. 3.13 B). Nearly all of this 
increment could be prevented by removal of Ca2+ from the external medium (Fig 3.13 
B), demonstrating a Ca2+-dependency. Likewise, K+ depolarisation-evoked SP release 
is also Ca2+-dependent but the extent of this increment (2.5-fold over basal) was much 
lower than that for CGRP (Fig. 3.13 C). Consistent with TGNs containing the VR1 
protein (demonstrated earlier), capsaicin-triggered CGRP release was Ca2+-dependent; 
1 µM gave a maximum of 3.3-times increment over basal (Fig. 3.14 A). Consistent 
with the occurrence of BR2 protein in the TGNs described earlier, bradykinin 
stimulated CGRP release is also Ca2+-dependent (Fig. 3.14 B). A maximum increment 
of 3.9-times over basal was achieved with 0.1 µM bradykinin. Collectively, the 
stimulation of Ca2+-dependent CGRP release from TGNs by K+, capsaicin and 
bradykinin accords with their efficacies in elevating the efflux of peptidergic 
transmitters in brain, as measured in perfusates (Gazerani et al., 2006).   
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Fig. 3.13 CGRP and SP release evoked by K+ from TGNs are K+-concentration and 
Ca2+-dependent: 30 minutes proved optimal. After 7 DIV, rat cultured TGNs were 
incubated in BR-HBS at 37 °C with varying times for basal release (hollow bars) 
followed by incubation in BR-HBS in the presence of 60 mM of K+,  for the same 
period as for basal, to stimulate CGRP release. Buffer bathing the cells were carefully 
removed and quantity of released CGRP was measured by EIA; 30 minutes incubation 
time proved to be optimal (A). In order to optimize the concentration of K+ used for 
stimulation of  CGRP (B) or  SP release (C), basal release over 30 minutes was 
measured in BR-HBS (hollow bars), then supplemented with various concentrations of 
K+ (isotonically-balanced Na+ concentration) for the same period as for stimulated 
release (filled bars). Release stimulated by 60 mM [K+] represented 30% (CGRP) or 
8% (SP) of the total content in cells. Ca2+-independent release was determined using 
Ca2+-free BR-HBS containing 2 mM EGTA. Data plotted are means ± S.D.; n = 4;  
student’s unpaired t-test: **, p<0.01.  
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Fig 3.14 CGRP release evoked by capsaicin or bradykinin from TGNs is 
concentration and Ca2+-dependent. After 7 DIV, the rat cultured TGNs were incubated 
in BR-HBS with the addition of vehicle (see Chapter 2) for measurement of basal 
release (hollow bars), and then incubated in BR-HBS in the presence of varying 
concentrations of capsaicin (A) or bradykinin (B) for the determination of stimulated 
release (hatched bars). 1 µM capsaicin- or 0.01 or 0.1 µM bradykinin- stimulated 
release represents 20 or 15% of the total content, respectively. Likewise, Ca2+-
independent release was determined in Ca2+-free BR-HBS containing 2 mM EGTA. 
Values are the means ± S.D.; n = 4; student’s unpaired t-test: **, p<0.01; ***, 
p<0.001.  
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3.2.3.2 Crudely fractionated SP- and CGRP-containing LDCVs showed similar 
sedimentation velocity and contain SNAREs plus associated proteins 
TGs were dissected from ~35 P3-5 neonatal rats and homogenized (see Chapter 2); 
Microsomes were collected by ultracentrifugation and lysed in resuspension buffer. 
Vesicles were seperated by continuous sucrose gradient centrifugation according to 
their density (see Chapter 2).  Fractions (600 µl) were collected from the bottom to top 
of the centrifuge tube using a peristaltic pump.  Amounts of SP and CGRP in each 
fraction were quantified by EIA assay. The neuropeptides-enriched fractions are those 
with high ratio of peptides concentration relative to total protein concentrations (Fig. 
3.15 B). Theortically, SCSVs should be collected in later fractions than LDCVs 
because they have slower sedimentation. Fractions from no. 5-13 seemed to be 
enriched in SP (Fig. 3.15 A). The occurrence of both CGRP and SP in fractions 7-10 
suggests that at least some of the vesicles containing peptides have similar 
sedimentation behaviour; possibly, to some extent, both peptides reside in the same 
vesicles (Fig. 3.15 A, B). Notably, fractionated CGRP level was lower than that of SP; 
whereas in culture, CGRP was released at higher level than SP (Fig. 3.13). This finding 
is consistent with that NGF supplementation in culture upregulates CGRP expression 
(Price et al., 2005). Neurotansmitters in SCSVs fractions could not be detected because 
of lower content (see Section 3.2.3.3). 
The presence of SNAREs and synaptophysin were detected in the collected fractions 
by SDS-PAGE and Western blotting, using specific antibodies. Note that the Sbr III 
antibody used was also able to detect isoforms I and II but signals were weaker. It is 
deduced that synaptophysin, syntaxin I, SNAP-25 and three isoforms of Sbr are all 
present in the LDCVs fractions (Fig. 3.15 C).  
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Fig. 3.15 Crude separation of CGRP- and SP-containng LDCVs by sucrose gradient 
sedimentation. Microsomes prepared from TGs were lysed in resuspension buffer and 
layered on a 10-50% continuous sucrose gradient for centrifugation (detailed in 
Chapter 2). Fractions were collected and analysed for CGRP (pink) and SP (blue) by 
EIA as shown in (A); the protein concentration of each collected fraction was 
measured by BCA kit (A, yellow), and ratios % of neuropeptide content relative to 
protein concentration (pg/µg) was calculated and plotted in  (B). Presence of SNAP-25, 
syntaxin I, Sbr (I, II and III) and synaptophysin in fractions were confirmed by 
immunoblot analysis in (C) using specific antibodies against synaptophysin, syntaxin I, 
SNAP-25, Sbr I, II except for a pan antibody used for Sbr III which recogises all three 
isoforms but with different affinities.  
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3.2.3.3 Release of other transmitters  from TGNs 
Attempts were made to measure additional LDCV-contained transmitters such as NPY, 
VIP and serotonin by EIA, but their levels of stimulated release from rat cultured 
TGNs were under the detection limit. Table 3.1 shows the total cellular content of these 
neurotransmitters in 106 cells/well (plating number). It proved difficult to detect 
stimulated release of classic transmitters (such as glutamate, aspartate, GABA and 
glycine) from SCSVs by a radioisotopic method, using the same stimulation protocol 
as for CGRP exocytosis. In conclusion, CGRP and SP are the main transmitters 
released from cultured TGNs. 
 
Table 3.1 NPY, VIP and serotonin are present at low levels in rat cultured TGNs 
Neurotransmitters Total content (pg) / 106 cells* 
NPY ~5  
VIP ~20 
Serotonin ~10 
 
* ~106cells/well of dissociated TGNs were cultured for 7 DIV, solubilised in 2 M acetic 
acid/ 0.1% TFA followed by freeze/thaw thrice and high speed-vaccum drying. Cell 
pellets were dissolved in EIA buffer and contents of NPY, VIP and serotonin were 
measured using EIA (see Chapter 2). 
 
3.3 Discussion 
Deciphering the molecular details of transmitter release from sensory neurons has been 
neglected, despite its great importance in understanding the propagation of painful 
stimuli. Also, there is an urgent need for drugs with capabilities to control chronic pain, 
in a variety of clinical conditions (e.g. migraine, low back pain, tension headache) 
where existing drugs are not effective in all patients. Lack of progress with 
investigations is in part due to difficulties in obtaining adequate quantities of pain-
propagating cells for biochemical work. This problem was overcome herein by using 
cultured TGNs which were chosen because they comprise a major pain-relay centre, 
and their release of CGRP and SP is elevated in migraine (Durham and Russo, 1999; 
Liu et al., 2003). The model was validated by showing that TGNs maintained in culture 
retain the morphological and histochemical properties reported for sensory neurons in 
situ (Baccaglini and Hogan, 1983; Guo et al., 1999; Price et al., 2005), as well as an 
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ability to release peptidergic transmitters in a Ca2+-dependent manner in response to 
different stimuli. However, the proportion of neurons in the cultures staining positive 
for VR1 and CGRP is higher than those observed in sections of TG (Durham and Cady, 
2004; Price et al., 2005); such a difference has been attributed to their upregulation by 
NGF added to the culture medium (Durham and Cady, 2004). In fact, this can be 
viewed as making the TGN model more similar to the situation in migraine in which 
there is also an increase in the level of NGF (Durham and Cady, 2004).  Such elevation 
is known to be involved in the development of nociceptive sensitization in a number of 
pathological states; NGF raises the sensitivity of sensory neurons to capsaicin and 
enhances its stimulation of CGRP release from TGNs in vitro (Price et al., 2005). 
Likewise, NGF raises the response to bradykinin of capsaicin-sensitive small neurons 
cultured from rat dorsal root ganglia (Kasai et al., 1998). Virtually all of the neurons 
identified by fluorescence microscopy to contain CGRP also possessed SP. The higher 
resolution offered by confocal microscopy revealed that the intracellular distribution of 
both peptidergic transmitters overlapped but were distinct in some respects. For 
example, an area resembling the endoplasmic reticulum/ Golgi network showed dual 
staining; on the other hand, SP occurred along the plasmalemma whereas CGRP 
seemed to have a more diffuse but ‘vesicle-like’ distribution. The latter indicates that 
these two peptides do not reside in the same vesicles at least to some extent, in 
accordance with the report that CGRP occurs only in LDCVs whilst SP can also exist 
in smaller vesicles from spinal cord sensory neurons (De Biasi and Rustioni, 1988; 
O'Connor and van der Kooy, 1988). Sucrose gradient centrifugation further suggested 
CGRP and SP had a similar sedimentation pattern but with some dissimilarity 
indicating not all of them reside in the same vesicles.  
A prime objective of our investigation was to find agents capable of blocking the 
evoked release of CGRP because of its pivotal role as a pain mediator. This required 
firstly establishing the complement of SNAREs in these sensory neurons, and then 
identifying which isoforms are involved in their release from LDCVs, compared to 
those known to mediate exocytosis from SCSVs.  
For the first time, all 3 SNAREs and synaptotagmin I were visualised in the sensory 
neurons by confocal microscopy. Each displayed some characteristic distribution 
features. For example, syntaxin I staining gave a ‘cloud-like’ appearance throughout 
the soma together with more defined labelling in the bigger neurites; syntaxin II, III 
also gave a similar pattern in neuronal cell bodies and comparably weaker signals in 
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neurites, as revealed by conventional fluorescent microscopy. SNAP-25 showed a 
similar pattern but with intracellular punctate staining and definite labelling of the 
membrane of the cell bodies and major processes. Finally, similar pictures were 
obtained for the vesicular proteins, Sbr II and synaptotagmin I, which included intense 
and fairly uniform staining of the cell bodies as well as punctate deposition of stain on 
even the smallest neurites. Isoform I of Sbr was visualized predominantly on the cell 
bodies together with a distinctive punctate pattern of staining on the fine neurites. Most 
importantly, conventional microscopy demonstrated co-occurrence of each of the 
exocytotic proteins with CGRP, and images with high resolution revealed some 
similarities and differences in their subcellular locations. Puncate staining of Sbr I co-
localised with CGRP on the fine fibres; in the case of Sbr II and synaptotagmin I, there 
is a striking degree of co-localisation whereas the granular band of CGRP staining of 
Sbr isoform II differs from the more widespread distribution of synaptotagmin I in the 
cytoplasm and on the plasmalemma.  Notably, there is a differential intensity of the 
relative staining for SNAP-25 and CGRP in adjacent neurons. In summary, these 
sensory neurons possess several components of the exocytotic machinery though the 
requirement for each, or a particular isoform, had to be established by other means.  
 
A large increment of  Ca2+-dependent CGRP release could be evoked by all three 
stimuli tested, with a rank order of K+> capsaicin > bradykinin; the respective values 
represents 30, 20, and 15 % of the total content. These figures suggest that some 
stimulants can only trigger the release of a limited pool of transmitter, in keeping with 
different signalling pathways being involved. In this regard, it is notable that the 
quantities of CGRP release elicited by capsaicin or bradykinin relative to that for K+ 
depolarisation approximate to the respective proportions of the cultured cells shown to 
contain VR1 and BR2, which overlapped as assessed by immunofluorescence staining. 
SP release was also detected from rat cultured TGNs but at a lower level.  
Clearly, sensory peptidergic neurons cultured from rat TGs contain the exocytotic 
machinery and release CGRP in response to depolarization or pain stimuli. However, 
involvement of SNARE proteins, and particular isoforms, in Ca+-regulated CGRP 
release needs to be established by using BoNTs, which are known to cleave distinct 
SNARE substrates and inhibit transmitters release in a number of neuron types. In vitro, 
cultured TGNs with their highly desirable properties used in combination with 
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recombinant BoNT make it feasible to examine the basic mechanisms of pain 
transmission. 
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4.0 CGRP exocytosis from sensory neurons is SNARE-dependent and unique in 
requiring Sbr I: inhibition by BoNTs reflects their anti-nociceptive potential 
 71
4.1 Overview 
Although BoNTs have proved instrumental in demonstrating that all three SNAREs are 
essential for Ca2+-regulated exocytosis in a number of neuron types, this remains to be 
established for cultured TGNs. As stimulation of neurotransmitter release by K+, 
capsaicin and bradykinin relies on somewhat different signalling mechanisms and in 
the two latter cases, occur in sub-populations possessing VR1 or BR2, determining 
their susceptibilities to BoNT serotypes is a prerequisite for the attractive prospect of 
engineering a variant that could be targeted and, thus, preferentially inhibit CGRP 
secretion in certain varieties of sensory neurons. 
 
4.2 Results 
 
4.2.1 Truncation of SNAP-25 by BoNT/A gives distinct inhibition of CGRP release 
evoked by 3 stimuli 
TGNs were incubated overnight at 37°C with BoNT/A and Ca2+-dependent CGRP 
secretion was measured in response to different stimuli, before the same cells were 
solubilised and subjected to SDS-PAGE and Western blotting of the SNAREs.  SNAP-
25 was detected with an antibody exhibiting equal reactivity with both the intact and 
the toxin-truncated SNARE (Fig. 4.1 A).  Increasing BoNT/A concentrations cleaved 
SNAP-25 as reflected by appearance of a faster-migrating product, giving an EC50 = 
0.3 nM derived from densitometric scanning of 5 replicate gels (Fig. 4.1 B). Only trace 
amounts of the BoNT/A-resistant homologue, SNAP-23, could be visualised (Fig. 4.1 
C). K+-evoked CGRP release was inhibited by BoNT/A with a concentration 
dependence identical to that for SNAP-25 cleavage (Fig. 4.1 B).  By contrast, it proved 
less potent in blocking exocytosis elicited by bradykinin (Fig. 4.1 B).  The CGRP 
release elicited by 1µM capsaicin was least susceptible to BoNT/A, with only ~ 15% 
reduction seen even at 100 nM toxin (Fig. 4.1 B); this minimal sensitivity is not 
attributable to lack of the receptors on these particular neurons because synaptic vesicle 
protein 2A, B and C were detected in VR1-positive cells (Fig. 4.1 D; see Discussion). 
Morever, K+-evoked SP release, assayed in an aliquot of the sample used for measuring 
CGRP release, was also blocked by BoNT/A (Fig. 4.1 B inset). Such disparate 
BoNT/A susceptibilities of neuro-exocytosis triggered by various stimuli differ from 
the rank order observed for type D (see later).  
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Fig. 4.1. BoNT/A cleaves SNAP-25 and differentially inhibits Ca2+-dependent CGRP 
release evoked from rat TGNs by three stimuli: the toxin’s acceptors occur on VR1-
positive cells. TGNs were exposed to BoNT/A, release of CGRP over 30 minutes 
assayed; then the cells were solubilized in LDS-sample buffer and equal volumes 
subjected to SDS-PAGE and Western blotting, using an antibody that recognises intact 
and truncated SNAP-25. The proportion of substrate remaining was calculated relative 
to an internal syntaxin control, using digital images of the gels.  (A) Immunoblot 
showing the cleavage by the neurotoxin of SNAP-25 but not syntaxin I. (B). Dose 
response curvse for BoNT/A-induced blockade of CGRP release evoked by 60 mM K+ 
(?) which correlates with the % of SNAP-25 remaining (▼). Lesser extents of 
inhibition by BoNT/A were observed for release evoked by 0.1 µM bradykinin (▲) and, 
especially, 1 µM capsaicin (?). Data plotted are means ± s.e.m.; n = 5. Inset shows 
inhibition of 60 mM K+-evoked SP release by 0.1 nM BoNT/A (data plotted are means 
± s.e.m.; n = 3). Note, there was no detectable SP release evoked by 60 mM K+ after 
treatment with 1 nM.  (C) A Western blot of TGNs visualised with antibodies specific 
for syntaxin I or SNAP-23 (*). (D) Representative micrographs demonstrating VR1 and 
SV2A, B and C in rat TGNs.  Fluorescent images were obtained after labelling the cells 
with antibodies raised in guinea pig specific for VR 1 (1:1000) and in rabbit for SV2A 
or SV2B (1:1000) or in goat for SV2C (1:100).  The controls were treated similarly 
except in the absence of primary antibodies but incubated with fluorescently-labelled 
secondary IgGs against rabbit (goat anti-rabbit Alexa Fluor-546, 1:200) and guinea 
pig (goat anti-guinea pig Alexa Fluor-488, 1:200) (1) or goat (donkey anti-goat Cy3, 
1:800) and guinea pig (donkey anti-guinea pig Cy2, 1:200) (2). Scale bars are 20 µm. 
It is noteworthy that all the SV2 isoforms are present in VR1-positive neurons. 
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4.2.2 Limited cleavage of syntaxin I and SNAP-25 by BoNT/C1 partially blocks 
exocytosis induced by all the stimuli  
 Incubation of TGNs with BoNT/C1 (under the conditions outlined above for BoNT/A) 
resulted in partial cleavage of syntaxins IA and/or IB as indicated by the decreased 
intensities on the Western blots, stained with a monoclonal antibody reactive with both 
isoforms of intact syntaxin I which were not resolved (Fig. 4.2 A).  Moreover, the toxin 
also truncated SNAP-25 (Fig. 4.2 A); the dose-response curves, derived from analysis 
of several blots, are similar for the toxin’s partial cleavage of both substrates (Fig. 4.2 
B). BoNT/C1 caused a minimal reduction in CGRP exocytosis and with little 
discrimination between the stimuli used (Fig. 4.2 C). Syntaxin II, III and IV (not shown) 
were also detected in TGNs by Western blotting but only isoforms II and III are 
BoNT/C1 sensitive (Schiavo et al., 1995); the limited cleavage  was accentuated by the 
toxin’s limited uptake, as reflected in the partial inhibition of CGRP release (Fig. 4.2). 
Although the function of these syntaxin isoforms in CGRP exocytosis is not clear, the 
presence of SNARE complexes containing either isoform II or III with SNAP-25, Sbr I 
or II were demonstrated by co-immunoprecipitation of detergent soluabilized lysate of 
rat TGNs (Fig. 4.3). Sbr isoforms could be detected after their release from the 
complexes by boiling; SNAP-25 signal was stronger than that for non-boiled samples. 
The simplest interpretations of these results are that the native BoNT/C1 has low 
potentcy or this toxin only enters a fraction of the responsive neurons or all the cells 
with poor efficiency; the contribution of its cleavage of syntaxin I to CGRP inhibition 
could not be determined because SNAP-25 also gets truncated. 
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Fig 4.2 BoNT/C1 incompletely cleaves SNAP-25 and syntaxin I, and partially 
inhibits Ca2+-dependent CGRP release evoked by three stimuli. TGNs at 7 DIV were 
treated with BoNT/C1, release of CGRP was assayed and Western blotting performed. 
Results were calculated as described in Fig. 4.1 A, B but relative to the Sbr I/II control. 
(A) Partial cleavage of SNAP-25 by BoNT/C1 shown with the IgG used in Fig. 4.1, and 
decrease in syntaxin I revealed with an antibody only reactive with this intact SNARE. 
Syntaxin II, and especially III, proved difficult to quantify and, thus, cleavage by toxin 
was not detectable. (B) Dose response curves for BoNT/C1-induced cleavage of SNAP-
25 (▼) and syntaxin I (▲).  (C) Inhibition by toxin of CGRP release evoked by 60 mM 
K+ (?), 0.1 µM bradykinin (?) or 1 µM capsaicin (?). Data plotted are means ± 
s.e.m.; n ≥ 3. 
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Fig. 4.3 Syntaxin II and III complexes with SNAP-25, Sbr I or II in TGNs. The 
pelleted cells were extracted in 1 ml of buffer containing 1% (v/v) triton X-100 (see 
Chapter 2) for 1 hour at 4°C, followed by a centrifugation. The supernatant was 
incubated at 4°C overnight with anti-syntaxin II or III IgG (as used in Fig. 4.2) 
coupled to protein A-agarose.  After sedimentation and extensive washing with the 
extraction buffer, the beads were suspended in 2xLDS sample buffer for SDS-PAGE (± 
boiling for 10 minutes) under non-reducing conditions, followed by Western blotting 
using antibodies specific for each SNARE. Note, excessive staining of the rabbit IgG 
overlapped with the SNARE complexes on the top halves of gels; however, multiple 
bands were shown in boiled samples in contrast to the one major broad band before 
boiling, indicating the the complex was dissociated; free Sbr isoforms were only 
detected in the boiled samples. Free SNARE proteins are indicated by arrow heads. 
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4.2.3 BoNT/D cleaves all Sbr isoforms and inhibits CGRP release: the importance 
of Sbr I is unveiled by BoNT/B-induced blockade of exocytosis from mouse but 
not rat TGNs even though they possess its acceptor  
TGNs were treated with BoNT/D as above, before visualising Sbr isoforms on Western 
blots with specific antibodies. Increasing concentrations of BoNT/D gave a progressive 
reduction in the staining for Sbr II or Sbr I and Sbr III bands (Fig. 4.4 A), indicative of 
their cleavage.  When Sbr II or Sbr I were individually labelled with isoform-specific 
antibodies, and the averaged intensities of each band normalised to an internal control 
(SNAP-25), the resultant plots (Fig. 4.4 B) demonstrated that BoNT/D cleaves Sbr I 
somewhat more effectively than Sbr II (EC50 = 3.6 and 14.6 nM, respectively). Such 
treatment of the cells with BoNT/D blocked K+- and capsaicin-evoked CGRP release 
(Fig. 4.4 B, C); the dose-dependence for K+-evoked CGRP release  is very close to that 
for Sbr I cleavage.  Likewise, CGRP exocytosis elicited by bradykinin was reduced by 
the toxin but with a lower potency (Fig. 4.4 C).  This differential inhibition of evoked 
release may relate to distinct BoNT/D susceptibilities of sensory neuron populations 
that respond to capsaicin or bradykinin. Basal efflux was also decreased (Fig. 4.4 C 
inset), as found with this toxin in other neurons (Hua et al., 1998).  Notably, BoNT/D 
also blocked K+-evoked SP release from rat cultured TGNs (Fig. 4.4 B inset).  
In order to exclude that BoNT/D-induced diminution of CGRP exocytosis is due to 
death of TGNs, a short time course study was performed. Rat cultured TGNs were 
incubated with or without 10 nM BoNT/D or /B for 24 hours. Toxins were washed 
away, and cells were tested immediately or fresh medium was replaced and cells were 
maintained for the time indicated. There was no observable difference in the levels of 
SNAP-25 and syntaxin I in control cells and these were not reduced by day 6, 
indicating no toxin-induced cell death (Fig. 4.5).  K+-evoked CGRP release was 
inhibited by BoNT/D at day 1, 3, and 6, but there was no drop in the total cellular 
content of CGRP over time (the increase in CGRP total content in BoNT/D treated 
cells may be caused by the accumulation of CGRP intracellularly due to the blockade 
of release), confirming BoNT/D-induced CGRP inhibition is directly caused by 
proteolysis of Sbr isoforms. In contrast, BoNT/B failed to give any inhibition even 
though it decreased the total immuno-signals for Sbr I and Sbr II.  
It was necessary to ascertain if cleavage of one or more isoforms of Sbr is required for 
the blockade of exocytosis.  Involvement of Sbr II was addressed using BoNT/B (Fig. 
4.6 A) because it does not cleave Sbr I in rat  (Schiavo et al., 1992).  Incubation of the 
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TGNs with BoNT/B decreased the intensity of Sbr II and III bands (Sbr I remained 
unchanged consistent with it being resistant) that were detected with the broad 
specificity HV-62 antibody (Fig. 4.6 A). Notably, the mAb specific for Sbr II showed a 
more complete cleavage of this isoform compared with HV-62 because the latter would 
have labelled the persisting BoNT/B–resistant Sbr I (Fig. 4.6 A). Despite this extensive 
cleavage of Sbr II and III, BoNT/B failed to inhibit K+-evoked CGRP release (Fig. 4.6 
B). Likewise, K+-evoked SP release from rat cultured TGNs was not affected by 
BoNT/B treatment (Data not shown). The possibility of BoNT/B-resistant release 
occurring from a sub-population of neurons that are unable to bind and internalize this 
toxin seems unlikely because of the complete cleavage of Sbr II observed (unless they 
lack Sbr II). Moreover – synaptotagmin I and II – the toxin’s acceptor, were detected in 
all TGNs containing CGRP (Fig. 4.6 E).  Thus, the lack of blockade of CGRP release 
by BoNT/B raised the question whether the insensitive Sbr isoform I is involved; this 
idea was reinforced by the co-occurrence of Sbr I and CGRP on the cell bodies and, 
particularly, their striking punctate location on the neurites (Fig. 3.11 A).  As murine 
Sbr I is susceptible to BoNT/B, experiments were repeated with TGNs prepared from 
P5 mice; the resultant cultured cells displayed similar morphology and purity (Fig 3.1 
B).  Importantly, type B toxin caused a pronounced inhibition of K+-elicited CGRP 
release from the mouse TGNs (Fig. 4.6 D) similar to seen with BoNT/D although 
higher doses were required (Fig. 4.6 D inset); moreover, capsaicin-evoked CGRP 
release was inhibited. Accordingly, BoNT/B cleaved Sbr I in mouse TGNs as revealed 
by the concentration-dependent reduction in labelling with an antibody exclusively 
reactive with this isoform (Fig. 4.6 C, D). Therefore, it is reasonable to deduce that 
CGRP release from LDCVs can utilise Sbr I.   
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Fig. 4.4 BoNT/D blocks evoked Ca2+-dependent CGRP release and cleaves 3 Sbr 
isoforms. The amounts of Ca2+-dependent basal and evoked release of CGRP for each 
stimulus were measured in cells treated with BoNT/D as in Fig. 4.1 (A). Three Sbr 
isoforms were detected using antibodies against Sbr I, or Sbr II, or Sbr I, II and III 
together (HV-62); isoform I and II co-migrate. (B) Dose response curves for the 
remaining intact Sbr II (▼) and Sbr I (∆), and for inhibition of release evoked by 60 
mM K+ (?). Inset shows dose-dependent inhibition of K+-evoked SP release by 
BoNT/D (?); (C) Dose response curves for inhibition of release evoked by 1 µM 
capsaicin (?) or 0.1 µM bradykinin (▲). Inset shows the reduction of basal release 
by BoNT/D (?). The values plotted are means ± s.e.m.; n = 8 except inset in B; n = 2 
performed in duplicates. 
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Fig. 4.5 The time course of BoNT/D-induced inhibition of K+-evoked Ca2+-dependent 
CGRP release implicates cleavage of its substrates rather than cell death. Rat 
cultured TGNs at 7 DIV were incubated in culture medium with 10 nM BoNT/D or /B 
for 24 hours. After removal of toxins by washing, the neurons were tested immediately 
(day 1) or the medium was replaced. Cells at day 3 and 6 were analyzed as described 
in Fig. 4.1. Released and cellular CGRP contents were assayed by EIA. (A) Sbr 
isoforms I and II were detected using HV-62 antibody (I and II co-migrated). BoNT/D 
cleaved both isoforms at all time points, whereas, BoNT/B only cleaved Sbr II (cf Fig. 
4.6); the latter caused lesser reduction in total signal for isoforms I and II. (B) BoNT/D 
blocked K+-evoked CGRP release, whereas, BoNT/B proved ineffective (cf.  Fig. 4.6). 
(C) Intracellular CGRP content relative to that of equivalent toxin-free control (filled 
bars) remained unchanged after expose to BoNT/B (hatched bars) but was increased 
by BoNT/D (open bars). Data plotted are average from n = 2 performed in duplicates.  
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Fig. 4.6 BoNT/B proteolyses Sbr II and III in rat TGNs but does not reduce K+- 
evoked CGRP release despite the presence of its receptor: in mouse TGNs, Sbr I is 
also cleaved and exocytosis blocked.  TGNs were cultured from rat (A, B, E) and 
mouse (C, D) for 7 DIV before exposure to BoNT/B; EIA of released CGRP and 
Western blotting were carried out as described in Fig. 4.1. Results presented are 
means ± s.e.m.; n = 8. (A, C) Immuno-blots showing the disappearance of 2 Sbr 
isoforms for rat (Sbr II and III) and 3 for mouse (Sbr I, II and III) relative to the 
internal standard (SNAP-25) that remained unchanged. (B, D) Dose response curves 
for inhibition of CGRP release evoked by 60 mM K+ (?), capsaicin (?) and remaining 
Sbr II (▼), Sbr I and II (▲), and Sbr I (?). Inset illustrates the inhibition by BoNT/D 
of K+-evoked CGRP release from mouse TGNs, for comparison.  (E) Representative 
fluorescent micrographs showing that the putative protein receptors of BoNT/B, 
synaptotagmin I and II, are present in CGRP positive neurons. Specimens were stained 
using rabbit anti-CGRP (1:500) (and donkey anti-rabbit IgG Cy2, 1:200) and goat 
anti-synaptotagmin I/II (1:100) (and donkey anti-goat IgG Cy3, 1:800). The control 
was treated in the absence of primary antibodies but incubated with secondary 
fluorescently-labelled IgGs against goat and rabbit. Scale bars are 20 µm.  
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4.2.4 Pre-incubation of rat cultured TGNs with BoNT/D but not BoNT/B inhibits 
BoNT/A binding/uptake  
Previous studies reported that incubation with BoNT/A in K+ depolarization buffer 
results in increased cleavage of SNAP-25 by /A in various cultured neuronal cells 
because this toxin’s acceptor, SV2 isoforms, are located on secretory vesicles and the 
luminal domains for BoNT/A binding are only exposed to the extracellular domain 
during exocytosis (Dong et al., 2006), indicating BoNT/A uptake occurs in an activity-
dependent manner. Consistent with this, K+ depolarization significantly increased 
uptake of BoNT/A into TGNs (Fig. 4.7 A). Because BoNT/D cleaved all three Sbr 
isoforms and inhibited CGRP exocytosis in rat cultured TGNs, the toxin might be 
expected to inhibit BoNT/A uptake; on the other hand, BoNT/B was unable to cleave 
rat Sbr I and failed to inhibit CGRP exocytosis from LDCVs and should, thus, allow 
BoNT/A binding to the luminal domain of SV2 proteins during exocytosis. Therefore, 
it was important to determine whether cleavage by BoNT/B of Sbr II and Sbr III, the 
SNARE which normally mediate classical transmitters release, will inhibit BoNT/A 
internalization. To address this question, rat cultured TGNs were pre-treated with 50 
nM BoNT/B or /D for 24 hours to allow cleavage of their substrates. After removal of 
the toxins by washing, the neurons were exposed to 50 nM BoNT/A in depolarization 
buffer for 5 mins. Unbound toxin was removed by washing with pre-warmed culture 
medium , and the cells were maintained in culture medium for 24 hours to allow 
internalized BoNT/A to cleave SNAP-25. The extent of BoNT/A binding/uptake was 
reflected by the observed cleavage of SNAP-25. Immunoblots demonstrated that both 
BoNT/B and BoNT/D cleaved Sbr II to similar extent (Fig. 4.7 B, C); however, pre-
treatment of BoNT/B only slightly reduced BoNT/A binding to rat TGNs because 60% 
of SNAP-25 became cleaved which is very similar to that for treatment with BoNT/A 
only. In constrast, pre-treatment with BoNT/D significantly inhibited BoNT/A uptake, 
as reflected by only ~15% SNAP-25 cleavage (Fig. 4.7 C). Negligible inhibition of 
BoNT/A binding by BoNT/B might implicate there are very small amounts of SCSVs 
in rat cultured TGNs or Sbr I is also presents in SCSVs and mediates SCSVs recycling. 
It can be deduced that binding of BoNT/A to the luminal domain of SV2 proteins must 
be significantly reduced due to the impaired exocytosis induced by /D; BoNT/A uptake 
remained almost unaltered after /B treatment because the latter failed to prevent vesicle 
recycling even though it cleaved Sbr II and Sbr III (Fig. 4.6). Our results suggest that 
Sbr II or III are somewhat redundant in CGRP release from rat TGNs. 
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Fig. 4.7 SNAP-25 cleavage by BoNT/A upon depolarization of rat cultured TGNs 
was significantly reduced by pre-treatment with BoNT/D but not /B. Rat cultured 
TGNs at 7 DIV were pretreated with 50 nM BoNT/B or /D for 24 hours. The washed 
cells were then exposed to 50 nM BoNT/A for 5 minutes in 60 mM K+ depolarization 
buffer. After removal of unbound toxin by pre-warmed culture medium, the latter was 
replaced and cells were further incubated for 24 hours at 37°C to allow internalized 
BoNT/A to cleave SNAP-25.  Cells were then solubilized in 2xLDS sample buffer and 
subject to SDS-PAGE and Western blotting. The proportion of remaining substrate was 
calculated relative to an internal uncleaved syntaxin I control. (A) SNAP-25 cleavage 
were demonstrated from samples that  treated by BoNT/A for 5 minutes in K+ 
depolarization buffer (HK) or basal buffer (LK) followed by 24 hours of incubation in 
toxin-free medium; (B) Representative immunoblot showing the similar extent of 
cleavage of Sbr II by BoNT/B and /D; SNAP-25 cleavage by BoNT/A after pre-
treatment with BoNT/B is only slightly less than that for BoNT/A alone, whereas pre-
exposure to BoNT/D significantly reduced SNAP-25 cleavage by BoNT/A. (C) 
Percentage of intact SNAP-25 (open bar) or Sbr II (filled bar) remaining, calculated 
relative to parallel toxin-free control after scanning of 3 blots from 3 independent 
experiments.  
 84
4.2.5 Novel BoNT chimeras AB and BA generated with ability to block pain-
peptide release reaffirm the involvement of Sbr I in CGRP exocytosis 
 
4.2.5.1 Designs of BoNT chimeras AB (LC-HN/A-HC/B) and BA (LC-HN/B-HC/A) 
To further confirm that the lack of inhibition by BoNT/B of CGRP release in rat is not 
due to its failure to bind TGNs but because of its inability to cleave Sbr I, I designed 
two novel chimeras AB and BA. Chimera AB comprises the LC-HN domains from 
BoNT/A (LC-HN/A) fused to the binding domain of BoNT/B (HC/B) to ascertain 
whether a /B-receptor exsists on rat TGNs by determining of SNAP-25 cleavage could 
be detected by its delivered /A protease activity. Likewise, the LC-HN domains from 
BoNT/B were fused to HC/A to address if Sbr I cleavage occurred when the protease of 
/B was delivered via the known /A-acceptor. A schematic of the toxin’s design strategy 
is shown in Fig. 4.8.   
 
4.2.5.2 Generation of chimera AB and BA 
Construction, expression and purification of chimera AB and BA were performed by 
Dr Wang J (our unpublished data). Briefly, chimera AB and BA were expressed in E. 
coli BL21 (DE3) and purified as SC polypeptides that upon SDS-PAGE migrated as 
Mr~150 k bands, in either the absence or presence of the reducing agent DTT (Fig. 4.9 
A). Controlled nicking of chimera AB with Trypzean gave near-complete conversion 
of the SC to disulphide-linked DC, as demonstrated by the appearance of HC and LC 
upon SDS-PAGE in the prescence of DTT; continued migration at ~150 k (Fig. 4.9 A) 
in the absence of DTT indicates that the inter-chain disulphide was formed in virtually 
all of the DC. Likewise, chimera BA was also successfully converted from SC to DC 
form by incubation with thrombin (Fig. 4.9 B). Western blotting with antibodies 
against LCA, BoNT/A or BoNT/B demonstrated the expected domains from each 
parental toxin were incorported into chimera AB and BA. 
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Trypzean
 
 
 
Fig. 4.8 Design strategy for chimera AB and BA. (A) Chimera AB SC gene comprises 
LC and HN gene fragments from BoNT/A fused to binding domain from BoNT/B. 
Likewise, LC-HN/B was fused to HC/A to generate chimera BA transgene (B). The 
nicking sites are indicated with (?). 
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Fig. 4.9 Expressed chimera AB and BA toxins. The purified chimera AB (A) and BA 
(B) SCs  which were subsequently converted to DC forms by controlled nicking (see 
Chapter 2; the gels were provideded by Dr Wang J) before SDS-PAGE in the absence 
or presence of DTT (as indicated), followed by Coomassie protein staining or Western 
blotting (WB) with the antibodies specified.  
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4.2.5.3 Chimera AB and BoNT/A equi-potently cleaved SNAP-25 whereas BA 
cleaved Sbr II to a similar extent as BoNT/B in cultured CGNs: chimeras exhibit 
protease activity of their parents 
CGNs are a useful model of central nerves for evaluating potency of BoNT due to their 
ease of preparation, with large yield and high sensitivity to the toxins. Cultured CGNs 
at 7 DIV were incubated with chimeric toxins AB and BA, as well as their parental 
toxins BoNT/A and /B for 24 hours (Fig. 4.10). Dose response curves for SNAP-25 
cleavage by BoNT/A and chimera AB overlapped, indicating both toxins have similar 
potency (Fig. 4.10 A). Moreover, Sbr II cleavage by chimera BA is similar to that by 
native BoNT/B (Fig. 4.10 B). Thus, changing the binding domains does not affect their 
potency for SNARE cleavage in rat cultured CGNs. 
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g. 4.10 The potencies in cultured CGNs of chimera AB and BA in cleaving their 
spective substrates are similar to that of their parental toxins containing the same 
otease. CGNs at 7 DIV were incubated with toxins for 24 hours in culture medium 
th the specified concentrations. After removal of toxins by washing, cells were then 
lubilized in 200 µl 2xLDS-sample buffer and equal volume of protein subjected to 
S-PAGE and Western blotting. The proportion of remaining substrate was 
lculated relative to an internal un-cleaved syntaxin control. (A, B) Dose response 
rves for remaining intact SNAP-25 (A) or Sbr II (B) after treatment with BoNT/A 
), chimera AB (?), BoNT/B (?) or chimera BA (?). Data plotted are means ± 
.m.; n=3. 
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4.2.5.4 Inhibition of CGRP release by chimera AB demonstrated the presence of 
acceptors for BoNT/B in rat cultured TGNs: lack of inhibition of CGRP 
exocytosis by chimera BA accords with BoNT/B-resistant Sbr being required 
Rat cultured TGNs were incubated with chimera AB, BA, BoNT/A or BoNT/B in 
culture medium for 24 hours at 37°C and K+-evoked Ca2+-dependent. CGRP release 
was measured, before the same cells were subjected to SDS-PAGE and Western 
blotting. Chimera AB gave dose-dependent cleavage of SNAP-25 and inhibition of K+-
evoked CGRP release (Fig. 4.11 A, B). Notablly, 100 nM of chimera AB gave the 
same inhibition of CGRP release as BoNT/A (Fig. 4.11 B). Due to chimera AB having 
the binding domain from BoNT/B, it seemed rat TGNs contains a functional BoNT/B 
receptor which led to intracellular delivery of the /A protease giving the cleavage of 
SNAP-25 (Fig. 4.11 A). In contrast, 100 nM chimera BA nearly cleaved all of Sbr II 
whereas Sbr I is resistant (Fig. 4.11 C);  however, chimera BA did not inhibit K+-
evoked CGRP release from rat TGNs just like BoNT/B (Fig. 4.11 D). This further 
demonstrated the inability of BoNT/B to inhibit CGRP release is not due to BoNT/B 
being unable to enter the cells becase chimera BA also failed to give any inhibtion even 
though it was targeted to BoNT/A-susceptible neurons. Clearly, lack of inhibition of 
CGRP release is due to a lack of cleavage of rat Sbr I by type B toxins (chimera BA 
and BoNT/B).  
 
4.2.5.5 Chimera AB- and BA-induced inhibition of CGRP exocytosis from mouse 
TGNs correlates with the cleavage of their respective substrates: SNAP-25 and 
Sbr I  
Mouse cultured TGNs at 7 DIV were incubated overnight at 37°C with various 
concentrations of chimera AB and BA and Ca2+-dependent CGRP release was 
measured. K+-evoked CGRP release was inhibited by chimera AB with a concentration 
dependence identical to that for SNAP-25 cleavage. In comparison with its parental 
toxin BoNT/B, inhibition by chimera AB is much more effective even though they 
share same binding domain (Fig. 4.12 A, B; cf. Fig. 4.6). Increasing concentration of 
chimera BA gave a progressive cleavage of Sbr I (Fig. 4.12 C, D), as revealed by 
Western blotting with isoform-specific antibodies. The dose-response curves derived 
from analysis of several blots demonstrated that chimera BA dose-dependently cleaved 
Sbr I and induced inhibition of K+-evoked CGRP release (Fig. 4.12 C, D).  
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Fig. 4.11 Chimera AB cleaves SNAP-25 and inhibits K+-evoked CGRP release from 
rat TGNs to a similar extent as BoNT/A; in contrast, BA gives no inhibition, just like 
BoNT/B, though both cleave Sbr II. Rat cultured TGNs at 7 DIV were exposed to 
chimera AB or BoNT/A (A, B), or chimera BA or BoNT/B (C, D) at 37°C for 24 hours.  
CGRP release was assayed and the cells were solubilised in 2xLDS sample buffer for 
SDS-PAGE and Western blotting. Immunoblots illustrate the cleavage of SNAP-25 (A) 
or Sbr II (C) by the toxins treatment and the effects on (B, D) K+-evoked CGRP release. 
Data plotted are means±s.e.m.; n=3. 
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Fig. 4.12 Chimera AB potently cleaves SNAP-25 and inhibits K+-evoked CGRP 
release from mouse cultured TGNs whereas BA incompletely cleaves Sbr I and 
partially blocks CGRP release. Mouse cultured TGNs at 7 DIV were exposed to 
various concentrations of chimera AB or BA at 37°C in culture medium for 24 hours. 
K+-evoked CGRP release was assayed, Western blotting performed and results 
calculated (see Fig. 4.1). (A, C) Immunoblots illustrate the cleavage of SNAP-25 by 
chimera AB, or Sbr I by chimera BA. (B, D) Dose response curves for chimera AB- or 
BA-induced inhibition of K+-evoked CGRP release (?) correlate with remaining intact 
(B) SNAP-25 (?), or (D) Sbr I (?), respectively. Data plotted are means±s.e.m.; n=3. 
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4.2.6 CGRP–containing vesicles possess Sbr I and II: each can form a separate 
SNARE complex 
 
4.2.6.1 Immuno-isolation of CGRP containing vesicles  
BoNT/B- or chimera BA-induced cleavage of Sbr II (and III) in rat TGNs failed to 
reduce K+-evoked CGRP exocytosis, whereas the additional cleavage of Sbr I in the 
mouse neurons resulted in blockade. This indicates that isoform I can mediate 
exocytosis from these peptidergic LDCVs.  Evidence to support this hypothesis was 
obtained by precipitating vesicles including CGRP- containing LDCVs from a TGN 
lysate with IgG that is known to be exclusively reactive with Sbr I (Fig. 4.4 A). The 
resultant vesicles were found to be enriched in CGRP (Fig. 4.13 A) relative to the level 
observed in the control (prepared with non-immune IgG beads).  Moreover, analysis of 
these isolated vesicles by SDS-PAGE and Western blotting revealed the expected 
presence of Sbr I which was absent from the control (Fig. 4.13 B). Notably, the 
immuno-isolated vesicles also contained isoform II (Fig. 4.13 B). Clearly, Sbr II co-
exists with isoform I on CGRP-containing vesicles because both were found in the 
immuno-isolates irrespective of whether IgGs specific for Sbr II (Fig. 4.13) or I  were 
used.  This is in agreement with our eailer findings that Sbr I and II are present in the 
fractionated SP- or CGRP- containing vesicles (cf. Fig. 3.15). 
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Fig. 4.13 Immuno-absorption of vesicles from TGNs by antibodies against Sbr I and 
II. Equal amounts of the total membrane fraction from lysed TGNs were incubated 
overnight at 4°C with protein A-agarose coupled to IgGs specific for Sbr I or II, or 
rabbit non-immune IgG (control).  After extensive washing, equivalent aliquots of the 
beads were sedimented and pellets dissolved in LDS sample buffer for SDS-PAGE and 
Western blotting, as in Fig. 4.3. Alternatively, 2M acetic acid with 0.1% TFA was 
added to replicate samples for CGRP determination. (A) CGRP contents (± s.e.m.) 
measured in two separate preparations show the large enrichment in vesicles obtained 
using beads containing Sbr I or Sbr II relative to the control.  (B) Western blots of the 
two vesicle preparations and the control, using antibodies specific for Sbr I or II. 
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4.2.6.2 Immuno-precipitation of SNARE complexes  
The functionality of Sbr I in these vesicles was confirmed by its demonstrated presence 
in characteristic SDS-resistant SNARE complexes separated from an extract of TGNs, 
in non-denaturing detergent with IgG specific for Sbr I, coupled to protein A beads.  
The sedimented proteins were solubilized in LDS sample buffer, subjected to SDS-
PAGE and Western blotting. One aliquot of each sample was boiled before the analysis. 
A sensitive protein reagent (Sypro-ruby) stained a major broad band of complexes 
(Mr>100 k) before boiling. Boiling reduced the amount of apparent intact complexes 
and resulted in additional lower molecular weight bands (Fig. 4.14 A). Immunblots of 
the samples before boiling, with antibodies specific for SNAP-25 or syntaxin I, 
visualised a broad band corresponding to the main SNARE complexes (Mr  > 100 k); 
much lower levels of these free constituents were present (Fig. 4.14 B).  Boiling raised 
the proportions of dissociated SNAP-25 and syntaxin I whilst decreasing the relative 
amounts of the complex, although substantial protein remained (Fig. 4.14 B). As 
expected, some free Sbr I was found in the unheated sample but its level increased after 
boiling (Fig. 4.14 B); this accords with the corresponding decreased intensity of the 
major immuno-reactive protein complexes (Mr > 100 k) upon boiling (cf. Fig. 4.14 A). 
Notably, Sbr II could not be detected in the non-boiled or boiled samples (Fig. 4.14 B). 
In conclusion, the collective evidence presented here suggests, for the first time, that 
Sbr I can mediate regulated CGRP exocytosis from TGNs. 
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Fig. 4.14 Sbr I complexes with SNAP-25 and syntaxin I in TGNs. The pelleted cells 
were extracted in 1 ml of buffer containing 1% (v/v) Triton X-100 (see Chapter 2) for 1 
hour at 4°C, followed by centrifugation. The supernatant was incubated at 4°C 
overnight with anti-Sbr I IgG coupled to protein A-agarose.  After sedimentation and 
extensive washing with the extraction buffer, beads were suspended in LDS sample 
buffer for SDS-PAGE (with and without boiling for 10 minutes) under non-reducing 
conditions, followed by Sypro-ruby staining  (A) or  Western blotting using antibodies 
specific for each SNARE (B). Only the lower halves of the gels blotted for Sbr I or II 
are shown because of excessive staining of the rabbit IgG that overlapped the SNARE 
complex. Note that boiling raised the proportion of dissociated SNAP-25, syntaxin I 
and Sbr I; this corresponds to the decrease in the complex. 
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4.2.7 Sbr I requirement in CGRP release also applies to other types of sensory 
neurons, such as DRGs 
Various BoNTs are known to be effective in cleaving their substrates and inhibiting SP 
release from cultured rat embryonic DRGs (Welch et al., 2000), whereas BoNT/B did 
not give significant inhibition though it cleaved its substrate Sbr II.  
Considering the dramatic co-localization of CGRP and SP in sensory neurons and 
reported co-release of both peptides from LDCVs [our results described earlier and 
(Skofitsch and Jacobowitz, 1985)], it was necessary to establish whether the CGRP 
released from DRGs is also mediated by Sbr I.  
 
4.2.7.1 Phase contrast microscopy of DRGs showing their similar morphology to 
TGNs 
DRG neurons were successfully maintained in culture using the methods described 
(Chapter 2). Similar to cultured TGNs, 24 hours after plating cells start to develop 
neurites, and after 7 days in medium supplemented with Ara-C and NGF DRG 
neuronal cells became enriched and formed an extensive neurite network (Fig. 4.15).  
 
4.2.7.2 BoNT/B inhibited K+-evoked CGRP exocytosis from mouse but not rat 
cultured DRG neurons whereas BoNT/D blocked release from both implicating 
Sbr I in CGRP release  
K+-evoked CGRP release was monitored from rat cultured DRG neurons at 7DIV, and 
its release was found to be significantly inhibited by 100 nM BoNT/D but not by /B 
(Fig. 4.16 A); in constrast, both of these toxins could inhibit CGRP release from mouse 
DRG neurons (Fig. 4.16 B). This is consistent with what we found in TGNs, which 
indicated that Sbr I may be essential for other CGRP releasing sensory neurons.  
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Fig. 4.15 Representative phase contrast micrograph of rat cultured DRGs at 7 DIV. 
Rat DRGs were dissected from P5 rats, dissociated and cultured following the 
procedures as described in Chapter 2. Image was taken at 7 DIV with an inverted 
microscopy in phase contrast mode. At 7 DIV neurites were well developed and 
neuronal cells enriched. Scale bar = 20µm. 
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Fig. 4.16 BoNT/D but not /B inhibited K+-evoked CGRP release from rat cultured 
DRG cells, whereas both blocked release from mouse DRG neurons. DRGs were 
dissected from P5 Wistar rats (A) and TO mice (B), dissociated and cultured 
(described in Matherials and Methods). DRG neurons at 7 DIV were exposed to 100 
nM BoNT/D or /B in culture medium for 24 hours at 37°C; 60mM K+-evoked Ca2+-
dependent CGRP release was assayed using EIA. Results are means ± s.e.m.; n = 3.  
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4.2.8 Knock down of Sbr I gene expression by shRNA resulted in a substantial 
reduction of CGRP exocytosis directly pinpointing Sbr I as being required 
ShRNA is a short sequence of RNA which makes a tight hairpin turn and can be used 
for stable and long-term gene silencing. Sbr I shRNA lentiviral transduction particles 
supplied by Sigma contains 5 clones for knock down of mouse Sbr I gene expression. 
Each clone targets a specific sequence, as indicated in Fig. 4.17A. 
Mouse cultured TGNs at 7 DIV were infected with individual clones of Sbr I shRNA 
lentiviral particles for 8 days before basal and K+-evoked CGRP release were 
monitored (see Chapter 2). After release, cells were then solubilised in LDS-sample 
buffer and subject to SDS-PAGE and Western blotting. Sbr I and Sbr II were 
visualized using isoform-specific antibodies. Other SNARE proteins, SNAP-25 and 
syntaxin I were also detected using their specific antibodies. All 5 individual clones 
knocked down expression of Sbr I as shown in Fig. 4.18 A. In contrast, Sbr II and 
internal control proteins (syntaxin I, SNAP-25) remained unaltered (Fig. 4.18 A).  
Knock down of expression of Sbr I did not significantly affect basal release (data not 
shown) but caused nearly 45% reduction of CGRP release evoked by 60 mM [K+] from 
mouse TGNs (Fig. 4.18 B), which directly pinpoint a pivotal role of Sbr I in mediating 
exocytosis of this transmitter. The same procedures were performed in rat TGNs 
though all these 5 clones of shRNA were originally designed for knock-down of mouse 
Sbr I gene. According to gene sequence alignment, clone #2 perfectly matches the rat 
gene sequence and clone #4 has only 1 nucleotide mismatch (Fig. 4.17 B). 
Subsequently, both of them significantly reduced rat Sbr I expression (Fig. 4.18 C); the 
control proteins, SNAP-25, syntaxin I and Sbr II remained unchanged. For the reduced 
expression level of Sbr I, K+-evoked Ca2+-dependent CGRP release was decreased 
~55% by clone #2 (Fig. 4.18 D).  
From Western blotting, Sbr I protein was hardly detected from shRNA lentiviral 
particles infected cells. However, immunocytochemical staining using the same 
antibodies against Sbr I with different dilution indicated there was residual Sbr I after 
shRNA treatment (Fig. 4.19). Mouse cultured TGNs grown on coverslips were treated 
with clone #3, followed by fixation, permeabilisation and staining with antibodies 
specific for Sbr I or II. Notably, Sbr I signal is significantly reduced on the neurites and 
cell bodies relative to the untreated samples; in contrast, Sbr II signal remained same as 
control. Such differences were more apparent in the merged images (Fig. 4.19).  
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Fig. 4.17A.
shRNA targ
  
  Mouse  Sbr I cDNA sequence (GenBank accession No. NM_009496). 5 
eting regions are indicated. 
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1    CCGCAGTTAG AGTTCCGGGT GGCTCGCGTG AGGCGGAGCT CGGCAGTTCC GTCTACTTCA
61   GCCGCAGCGT CTCCCTGCCT GTCTCATTGC ATTCTCTAGA GAGGGGACGG ACCTCCACTT
121  CCTCTTTCAG AAAAATGTCT GCTCCAGCTC AGCCACCTGC TGAAGGGACA GAAGGGGCTG
 
 
181  CCCCAGGTGG GGGTCCTCCT GGTCCTCCTC CCAATACGAC CAGTAACAGA CGATTACAGC
                                          *   *                  *       * 
241  AAACCCAGGC ACAAGTGGAG GAGGTGGTGG ACATCATGCG CGTGAATGTG GACAAGGTCT
301  TGGAGAGGGA CCAGAAGTTG TCAGAGTTGG ATGACCGAGC TGACGCCTTG CAGGCAGGAG
361  CGTCAGTGTT TGAGAGCAGT GCTGCCAAGC TAAAAAGGAA GTATTGGTGG AAAAACTGCA
 
 
 
 
 
421  AGATGATGAT CATGCTGGGA GCTATCTGTG CCATCATCGT GGTAGTAATT GTAATCTACA
                                                       * 
481  TTTTTACTTG AGAATGTGCC ATCCCTTCCC TGTTCTCCAT TGCCATCCAA GCTCATGTTT
541  CCCCTCTGTT TGCTCTCTCA ACAAAGTCCT CCATCTTCCG TTCTCCATCC TGGCCCAGGC
601  TTCTCTGTGA TCCGACCTTC CCTTTTTGTT GCATTCATTC GCACTCTTCC TCAAAACTAG
661  AAATGCTGCT CGTGGCACAG TCCTGAAAGT CACTGCCCGA AGAGAACACC CAGCACCTCC
721  TCTTTACCCA TTTATCATGT GCCCTGGAGC TTAAAAGAGT TGTGGCCAAT GGCAGAGGTG
781  AAGTGTCTGA GAAGTTAGCA TGGCTGAGGG GAAGAGAAAG GCATTTGTGT CCAAGAAAGG
841  CTGGCCTTTG GCAGGAGGGA AGCAAGAATA GTTGGGAAGT AGTAGCTTGC TGCCAGTGTA
901  TATGTATATG TATATGTATA TGTATATGTA TATGTATATG TATATGTATA TGTATATGTA
961  TATGTATATG TATATGTATA TGTATATGTA TATGTATATG TATATGTATA TATTAGTTGG
1021 GAACTATGAC CTGCTGTCCT CATTTGGAAC TTTCCTCCCA TACCAGGCCT GTCTTGGGTC
1081 CCAGAGGTCT GTTTAAAGAC CAACTTCAAA TCCCTTTTAG AAAAACATCA AACTTGCATT
1141 TTGTAGCTAC TGTTATCTGT CAGTACAAGA TTTTCTGTGT CTTTGGGGGA ACTTTACAAC
1201 TTTTCGCTTT GTCTCTATAG CCCCAGGAGA GAAGTACCTT CTGATTTTAA AAACAGCAGG
1261 ACACTCTTAC CTTCTTCTAG AAGGCGTCCC ACATGCTTCT GACTAGAAGG AGCTACCACC
1321 TCTTCATGTC ATCTGAAGCA TTTGATGTTG TTCATGAAGG CACCAAATAA TTTCAGGGAA
1381 TGAGGGGCTT TGAGGATAAC AGGCTCTCAG GAACACGCTC CATGCCATCC CACTCTCCAA
1441 TGAAAGCCCT GTACCTCCCT TGTTGATTAA GAGAAATGAG AGTTATATGG TGAGACTCCC
1501 AGGGTCCCAC AGAACACTTC CCCCTGCACT ACCCACTTAC TGTGTGTAAG ACAAGGATGA
1561 GGCAGGAGGG CCTTTCCAGA TTCAGCTCAG ACTTGGATAG CGGGGTCTAG GCTGTGTCAG
1621 GTGTACCGTG CACTGCTGTG TGGCATGGGC CTCGCATCCG CAGCTGCCTG CCGTGCTTCC
1681 TTCAGTTCTT TCTCTGCAGC TGCCGTGTCC ATCCATCCTG CATCACCTCC TTCCTTTCCC
1741 TCCCTTTGCA TGCTCTGTGC GCAGACTCTG GAACCGAGGA CAGGAGCTGC TCAGTCTGTT
1801 TTGGGAGCTT CTGCTGAGCC TCAGATAGGA TGCTGCATGG GGTAAAGCCA GGTGCTGGGG
1861 TGGGAGCAGG GTGGGAGCAG GAGGGGTGTT CTCAGACCTC TATTCCTGCT GTCCTCTGGT
1921 GCACAAGCAG GAGAGGTGGC CATGCTAGGC TGGGTGCCCA CTTCCCGTGA AGCAGCATTT
1981 CATTCTGCAG AACCATCCTT CCTTTCCCTT GCCCATTTCC CACGTTTCCT TCGTGCTGCC
2041 TCAGGGCAGG ACTGAAGAGC TGGAAGGAAG CAGTCAGTGT ACCCTCCCAA CGTTCCCTGA
2101 AGGTCTCCAC TAGACTCTGG GCTTCCCTTT GCCTAGTGCA GGGGTCACCG CTGGAGAAGA
2161 ACCAACACTG TCCTTGGTGT GCTCCAAGCC TGGAGCCAAT TTACCCTGTT GGCCCACCCA
 
 
2221 GCCCCAGCGG GGGATTATTT CCTGGGTTTC TGTCCCTCCA AGGCTTACCA GGTGTAGTTG
             *         * 
2281 GCTTTGTTCT TCTGGGGCTG TTAGTCCTTC TACTTTCTTT CTCACTTCAC CCTGGACCCC
2341 CTTCTGTGTC TCTGCAGTCT TCTGTCCCTC CCACCCATGT GCATGAGCAA ATATGCAACT
2401 TACCTTGGGA TCTGCAGTCA GTTGAAGCCA AGCTTCCCAC ATCCTCTTTG TTTGCCATGA
2461 GGTGATGTGG GGTTTCCATT GTGTCTGTCA TTACCACCGT GTCTTTCCTA ACCCAGTCTC
2521 ACAGTTTATG TATAGTAGTA AGAGTTGTCC TTCCACCAAA GGCATGTGAC AGATTTACCA
2581 ATCTCATGTA TTCTCAACAA AGGCGAAAAA TACAAATTCC TACCACAACA TGGAAAAAAA
#1
#2 #3 
#4
#5
 
Fig. 4.17B. Rat  Sbr I cDNA sequence (GenBank accession No. NM_013090). 5 
shRNA targeting regions are indicated and the nucleotides differing from mouse gene 
are pointed by * and highlighted in yellow. 
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Fig. 4.18 Knock down of Sbr I by shRNA caused significant reduction of K+-evoked 
CGRP release. TGNs at 7 DIV were separately infected by 5 different Sbr I shRNA 
lentiviral particles (3x 105 each). At 8-10 days post-infection, release of CGRP from 
infected- and non-infected control cells under basal and 60 mM [K+] stimulation 
conditions were assayed. Released cells were then solubilised in 2xLDS sample buffer 
and equal volumes (1/10) of samples were subjected to SDS-PAGE and Western 
blotting. The same samples were loaded onto two different gels seperately blotted with 
antibodies against SNAP-25, syntaxin I and Sbr I or Sbr II. Representative 
immunoblots showing Sbr I protein level in all 5 clones infected mouse TGNs (A) or 
clone #2- and #4-infected rat TGNs (C) was significantly decreased compared to non-
infected control cells, whereas shRNA did not affect Sbr II expression. Other SNARE 
proteins, SNAP-25 and syntaxin I also maintained unchanged in treated cells and non-
treated cells. The antibodies used for Sbr I and II are isoform-specific with no cross-
reactivity with each other. Knock down of Sbr I expression caused substantial 
reduction of K+-evoked CGRP release in mouse (B) and in rat (D) compared to non-
infected control. Data plotted are means ± s.e.m.; n = 4 (mouse) or 2 (rat). 
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Fig. 4.19 Immuno-fluorescence staining demonstrated reduction of Sbr I expression 
in the shRNA-treated samples compared to control cells. Mouse TGNs grown on 
coverslips at 7 DIV were infected by clone #3 shRNA lentiviral particles. At 8 days post 
infection, cells were fixed, permeabilised  and stained with rabbit anti-Sbr I (1:1000) 
followed by donkey anti-rabbit Alexa Fluor 546 (1:200) or mouse anti-Sbr II (1:1000) 
followed by donkey anti-mouse Alexa Fluor 488 (1:200). Representative micrographs 
show the reduced Sbr I expression and unchanged Sbr II level in the (A) shRNA treated 
relative to the (B) un-treated control specimens, by indirect immuno-cytochemistry 
staining. ShRNA clone #3 treated cells were chosen as a representative example. Scale 
bar=20µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sbr II Sbr I Merged A
 
Sbr II Sbr I Merged B
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4.3 Discussion  
The evidence obtained for SNAP-25 being essential for K+-evoked CGRP release is 
clear-cut because BoNT/A caused near-complete inhibition (~ 90%) and an equivalent 
extent of cleavage. This accords with its putative acceptor __ synaptic vesicle protein 
2A, B and C (Dong et al., 2006; Mahrhold et al., 2006) __ being found in the TGNs.  In 
contrast, capsaicin-elicited exocytosis of CGRP from TGNs proved largely non-
susceptible to BoNT/A; this corresponds to the a minimal inhibition of SP release by 
this toxin from rat dorsal root ganglionic neurons (Purkiss et al., 2000).  As VR1-
positive TGNs express SV2, BoNT/A should be able to enter the capsaicin-responsive 
neurons. Although SNAP-23 is non-susceptible to BoNT/A, only a low level was 
detected in TGNs; therefore, this seems inadequate to explain the lack of inhibition of 
CGRP exocytosis from capsaicin-sensitive neurons. Thus, the observed lower 
efficiency of BoNT/A in blocking capsaicin–evoked release of CGRP may be due to 
the known ability of elevated intra-neuronal Ca2+ concentration to partially reverse 
BoNT/A-induced inhibition [(Sakaba et al., 2005; Verderio et al., 2004), see Chapter 5]; 
this could result from a large, capsaicin-triggered Ca2+ influx through the non-selective 
cation channel of the VR1 receptor (Caterina et al., 2000) and, also, causes Ca2+-
induced Ca2+ release form the internal Ca2+ store (Karai et al., 2004).  Contrary to the 
consistent outcome of this study and that of (Purkiss et al., 2000), there is a single 
report that a haemagglutinin–toxin complex of type A blocks capsaicin-evoked CGRP 
release from TGNs (Durham and Cady, 2004); however, the latter result could not be 
reproduced and a more indepth mechanism study was conducted to investigate the 
inability of BoNT/A inhibitions CGRP release elicited by capsaicin (see Chapter 5).  
Unlike SNAP-25, determination of the contribution of syntaxin I to exocytosis from 
TGNs was not possible because a near-equal cleavage of syntaxin I and SNAP-25 by 
BoNT/C1 precluded assessment of their individual contributions to its partial inhibition 
of CGRP release.   
Evidence for Sbr being essential for CGRP release evoked by K+, capsaicin or 
bradykinin was provided by the inhibition of each with BoNT/D associated with 
cleavage of Sbr I, II and III; moreover, basal efflux seemed to be reduced which 
accords with its ability to reduce spontaneous release at crayfish motor synapses (Hua 
et al., 1998). As this neurotoxin cleaved all 3 isoforms of Sbr, assessment of their 
relative contributions to exocytosis necessitated carrying out additional experiments 
with type B which is unable to cleave Sbr I in rat (Fig. 4.6 A). Despite near-complete 
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cleavage of Sbr II (and III) by 100 nM BoNT/B, its observed inability to cause any 
detectable inhibition of K+-evoked CGRP release indicated that these two isoforms are 
not essential as their roles can be taken by Sbr I. The possibility of BoNT/B-resistant 
CGRP release occurring from a sub-population of neurons unable to internalize this 
toxin was excluded by the complete cleavage of Sbr II and, especially, the 
demonstrated presence of synaptotagmin I/II in all of the CGRP-positive neurons 
because these proteins act as acceptors for the /B toxin (Chai et al., 2006; Dong et al., 
2003; Jin et al., 2006). Participation of Sbr I in CGRP exocytosis is an interesting and 
novel feature of TGNs, also seen with K+-evoked Ca2+-dependent release of SP from 
rat TGNs which proved non-susceptible to BoNT/B but was inhibited by serotypes /D 
or /A. Importantly, BoNT/B did cleave Sbr I and blocked exocytosis of CGRP from 
mouse TGNs. Use of newly-generated chimera AB and BA have shed significant light 
on the functionality of Sbr I. Chimera AB with its HC/B domain was found to enter rat 
TGNs, cleave SNAP-25 and cause inhibition of CGRP release to the same extent as 
BoNT/A. This demonstrated the presence of functional receptors for BoNT/B on all rat 
TGNs, consistent with immuno-fluorescence staining results showing synaptotagmin 
I/II present on CGRP positive rat TGNs. Chimera BA, harnessing the HC/A domain 
was found to readily enter TGNs (rat and mouse) cleaving almost all Sbr II at a 
concentration of 100 nM; this blocked CGRP release from mouse but not rat, further 
confirming Sbr I involvement in CGRP release from TGNs.  Knock down of Sbr I gene 
by shRNA resulted in a substantial reduction in CGRP release. Thus, it is reasonable to 
conclude that isoform I can mediate CGRP release from LDCVs, at least in sensory 
neurons. This is supported by co-immunoprecipitation experiments on TGNs showing 
that Sbr I occurs in SNARE complexes that contain SNAP-25 and syntaxin I.  A large 
proportion of these complexes proved resistant to SDS-denaturation and showed Mr > 
100 k on SDS-PAGE unless the samples were boiled, in which case the signals for the 
individual SNARE components were increased due to complex disassembly. These 
features are characteristic of neuronal SNARE complexes (Hayashi et al., 1994; Otto et 
al., 1997). Moreover, CGRP-containing vesicles immuno-isolated by Sbr I-specific 
IgGs possessed Sbr I and II; accordingly, LDCVs isolated by density gradient 
centrifugation were shown to contain CGRP as well as the SNAREs (Sbr I, II and III 
together with SNAP-25 and syntaxin I).  In rat where Sbr I is non-susceptible to 
BoNT/B, this toxin can nevertheless block exocytosis from central neurons of several 
transmitters (e.g. glutamate, γ-amino-butyrate) (Foran et al., 2003; Schoch et al., 2001; 
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Verderio et al., 2004). These published data indicate that the majority of Ca2+-
dependent exocytosis from SCSVs in these neurons (at least 80% of glutamate release 
from rat cerebellar neurons) requires Sbr II and/or III; thus, it seems Sbr I is not 
essential for the latter. Likewise, a major role for Sbr II in exocytosis from SCSVs 
(Takamori et al., 2006) accords with its predominance therein and correlates with a 
100-fold reduction in Ca2+-triggered fast transmitter release in knock-out mice lacking 
this isoform (Schoch et al., 2001).  Hence, the ability of Sbr I to support exocytosis in 
TGNs is not replicated in all neuron types, possibly due to the reported differential 
expression of Sbr I and II  (Aguado et al., 1999; Trimble et al., 1990).  Unfortunately, 
the release of detectable levels of classical SCSV transmitters could not be elicited 
from the TGNs with the stimulation methods used for CGRP and, thus, it was not 
possible to investigate the responsible Sbr isoform. Utilisation of Sbr I may be a 
characteristic of sensory neurons because studies on rat derived preparations, in which 
this isoform is BoNT/B-resistant, have shown that cleavage of Sbr II/III blocks 
exocytosis of noradrenaline release from ‘large dense-core like’ vesicles in 
cerebrocortical synaptosomes and PC-12 cells (Ashton and Dolly, 1997; Lomneth et al., 
1991). Although this is the first demonstration that Sbr I can mediate regulated 
exocytosis in TGNs, it is noteworthy that dopamine release from LDCVs in rat brain 
nerve terminals can be reduced by BoNT/B but not its somato-dendritic release 
(Bergquist et al., 2002).  Therefore, considering this together with our direct evidence 
leads to the deduction that Sbr I participates in toxin B-resistant release from rat TGNs 
at sites remote from the active zones in the presynaptic membrane  where CGRP 
exocytosis has been shown to occur (Bernardini et al., 2004).  Indeed, as BoNT/B was 
completely ineffective in reducing CGRP release (despite cleaving all the Sbr II and III 
in rat TGNs), it must largely arise from vesicles that contain Sbr I.  Based on all these 
consistent findings, it is apparent that Sbr I can underlie this special type of exocytosis 
which would allow the released CGRP to activate its receptor on blood vessels in the 
vicinity (Edvinsson, 2004).  This also seems to apply to other sensory neurons because 
K+-evoked CGRP release from DRG neurons from mouse, but not rat, is blocked by 
BoNT/B. Furthermore, our proposal is supported by the lack of statistically significant 
inhibition of SP release by BoNT/B (unlike other serotypes) in cultured neurons from 
embryonic rat DRGs (Welch et al., 2000). In fact, the demonstrated involvement of Sbr 
I in peptide exocytosis from LDCVs in sensory neurons may contribute to the 
neurological defects found in mice with a Sbr I null mutation that die soon after birth 
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(Nystuen et al., 2007). Undoubtedly, identifying SNARE isoforms used preferentially 
in exocytosis from different vesicle types in other varieties of secretory cells, and 
pinpointing the inherent functional advantages, should shed light on subtle 
dissimilarities likely to exist in the exocytotic processes and/or their fine control in 
eukaryotic cells. 
Colletively, BoNTs and the newly developed chimeric toxins proved instrumental in 
dissecting the exocytosis pathway, providing evidence for the functionality of the 
SNAREs and, in one case, pinpointing Sbr I involvment in the pain-peptides release 
from sensory neurons. Also, the chimeric toxins may have distinctive pharmacological 
potential. Although BoNT/D served as a universal blocker of the release from sensory 
neurons, human neuromuscular junction has been demonstrated to be insensitive to 
BoNT/D due to lack of its receptor (Coffield et al., 1997), which excludes it as a 
therapeutic for humans. Another toxin, BoNT/A blocked K+- and bradykinin- evoked 
release, but hardly affected capsaicin-elicited release; the latter is a specific stimulant 
for C-fibres, indicating the requirement for an alternative (see Chapter 5), or a variant 
toxin. The information gained from this chapter provides new insights for designing 
novel recombinant chimeric BoNTs with improved anti-nociceptive function over 
natural BoNTs that should be effective on human sensory neurons (see Chapter 5).  
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5.0 Capsaicin-evoked CGRP release from nociceptive neurons is resistant to 
BoNT/A due to sustained increased [Ca2+]i but can be inhibited by a re-targeted   
E/A chimera 
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5.1 Overview  
Initial reports on the clinical applications of BoTOX for alleviating the symptoms of 
migraine indicated beneficial outcomes in just a certain group of sufferers (Mauskop, 
2002; Silberstein et al., 2000).  However, the impressive improvement in these 
responders, whose symptoms had proved resistant to other therapeutic regimes, 
highlights the importance of in-depth neurochemical examination of the inhibitory 
action of BoNT variants on the release of pain mediators from sensory neurons. Further 
justification is provided by the likelihood that an effective BoNT-based therapy will 
emerge for tension headache and other forms of chronic pain (Foran et al., 2003; Gupta, 
2005) because of the occurrence in various neuron types of the toxin’s target, SNAP-25.  
Such an important prospect is heightened by the remarkable success of BoTOX in 
treating numerous conditions arising from hyper-activity of nerves innervating muscles 
(Dolly, 2005) or secretory glands (Kim et al., 2006), due to cleavage of SNAP-25 by its 
LC protease (Dolly and Lawrence, 2007). Already, it is becoming apparent that the 
anti-nociceptive effects of BoTOX arise from peripheral inhibition of the release of 
transmitters/pain mediators (e.g. CGRP, SP and glutamate) which, in turn, minimise 
sensitisation of pain relay systems in the brain (Aoki, 2005). Nevertheless, though 
attenuation of nociception by this toxin has been demonstrated in animal pain models 
(Bach-Rojecky et al., 2005; Cui et al., 2004), other studies have found it to be 
ineffective (Schulte-Mattler and Martinez-Castrillo, 2006; Voller et al., 2003). 
TGNs, maintained in culture, provide a suitable model (Durham and Cady, 2004) for 
biochemical investigation of the inhibition by BoNTs of Ca2+-dependent CGRP 
exocytosis, a process known to involve SNAP-25, Sbr I and, probably, syntaxin I 
(Chapter 4). CGRP release can be triggered from TGNs by K+-depolarisation, 
bradykinin or capsaicin; bradykinin acts on its type 2 receptor and causes acute 
sensation of pain whereas capsaicin activates C-fibres by binding to VR1, opening its 
non-selective cation channel and, thereby, inducing pain (Caterina et al., 2000). Type A 
BoNT was found to inhibit CGRP exocytosis induced by elevated [K+] or bradykinin 
but to exert minimal effect on that evoked by capsaicin despite TGNs containing the 
toxin’s acceptor and target (Chapter 4). To gain insights into this enigma, BoNT/E was 
investigated because it shares the same intracellular SNARE target as /A but cleaves 26 
rather than 9 residues off the C-terminus of SNAP-25 (Binz et al., 1994). Furthermore, 
it could offer additional features attractive for future therapeutic purposes, namely, 
faster neuro-paralysis than /A (Lawrence et al., 2007; Simpson, 1980; Simpson and 
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DasGupta, 1983) indicating a more rapid translocation into neurons (Keller et al., 2004). 
Surprisingly, the present study found BoNT/E to be virtually ineffective in cleaving 
SNAP-25 and blocking CGRP release from TGNs. As this raised the suspicion of these 
lacking a high-affinity acceptor for /E (its identity remains unknown), the HC binding 
moiety of BoNT/E was replaced by its counterpart from /A (Wang et al., 2008). By 
availing of the toxin’s independent domains (Stevens et al., 1991), this EA chimera 
exploits the most active moieties of the two serotypes. It was shown that EA entered 
cultured rat CGNs faster than BoNT/A and potently cleaved SNAP-25 in TGNs, 
blocked the transfer of synaptic vesicle proteins to the cell surface and inhibited CGRP 
release elicited by all stimuli, including capsaicin.  
 
5.2 Results 
 
5.2.1 Capsaicin-evoked CGRP release from TGNs is only partially inhibited by 
BoNT/A and virtually resistant to /E 
Although BoNT/A entered TGNs and displayed a dose-dependent cleavage of SNAP-
25 (up to ~ 85% with 1 µM; Fig. 5.1 A) that correlates with its inhibition of  K+-evoked 
CGRP release (cf. Fig. 4.1), secretion elicited by bradykinin was blocked to a slightly 
lesser extent and the exocytotic response to capsaicin was only reduced by <20% even 
at 1 µM toxin (Fig. 5.1 B). As this suggests that the 9 residues removed from the C-
terminus of SNAP-25 by BoNT/A are not essential for inhibiting capsaicin-triggered 
CGRP release, the effects of deleting a total of 26 amino acids with type E were 
examined because it potently blocks exocytosis from central and peripheral neurons 
(Foran et al., 2003; Lawrence et al., 2007).  Surprisingly, TGNs proved virtually 
insensitive to BoNT/E, as reflected by the absence of SNAP-25 cleavage except for a 
trace at high concentations (Fig. 5.1 C) and the observation that neither K+- nor 
capsaicin-triggered CGRP release were reduced by more than 15% (Fig. 5.1 D). These 
findings suggest that TGNs lack a high-affinity acceptor for BoNT/E, unlike motor 
nerve terminals and cultures of other neuron types which internalise it more rapidly 
than /A (Keller et al., 2004; Wang et al., 2008). Alternatively, it is possible that 
capsaicin could stimulate release via a mechanism utilising an /E-insensitive 
homologue. Clearly, an alternative strategy was required to examine the role of SNAP-
25 in CGRP release elicited by capsaicin from these sensory neurons. Hence, a chimera 
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consisting of the acceptor-binding domain (HC) of /A together with SNAP-25 cleaving 
LC of /E and HN/E was utilised. 
 
 
Fig. 5.1 BoNT/A cleaves SNAP-25 in TGNs and inhibits CGRP release evoked by K+ 
>bradykinin>>capsaicin whereas BoNT/E is ineffective. Rat cultured TGNs at 7 DIV 
were exposed to BoNT/A (A, B) or /E (C, D) at 37°C in culture medium for 24 hours. 
Evoked release of CGRP (B, D) over 30 minutes at 37°C was measured by EIA (see 
Chapter 2). Cells were then solubilised in LDS-sample buffer and equal volumes 
subjected to SDS-PAGE and Western blotting (A, C), using an antibody that recognises 
intact and truncated SNAP-25. The proportions of intact substrate remaining (B, D) 
were calculated relative to the internal control, uncleaved syntaxin, by visualisation 
with its specific antibody and analysis of digital images of the gels. SNAP-25 was 
extensively cleaved by BoNT/A (A, B) but not /E (C, D, ?). BoNT/A inhibited CGRP 
exocytosis (B) triggered by K+ or bradykinin but gave a minimal reduction in that 
evoked by capsaicin; there was negligible inhibition by /E (D) of the release evoked by 
60 mM K+ (?) or 1 µM capsaicin (●). Data plotted are means ± S.E.M.; n ≥ 3. 
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5.2.2 Generation of chimera EA toxin: its design, production and characterisation 
As BoNT/A binds to cell surface acceptors via the C-terminal moiety of its HC, HC, 
delivery of the BoNT/E protease activity (i.e. its LC) into TGNs was attempted by 
swapping its HC domain with the corresponding region of /A. For this purpose, a 
synthetic DNA fragment encoding the LC and HN portions of BoNT/E had been ligated 
to that encoding BoNT/A HC, expressed as a single-chain (SC) in E. coli, purified and 
converted to the activated disulphide-linked dichain (DC) form (Wang et al., 2008).The 
schematic construction map is described in Fig. 5.2.  
 
5.2.3 Chimera EA toxin displays the desired properties  
EA was expressed and purified as a SC polypeptide whose major protein band 
migrated as Mr~145 k band upon SDS-PAGE in either the absence or presence of DTT; 
a minor amount of larger, aggregated material (that disappeared upon reduction) was 
detected by Coomassie staining and Western blotting (Fig. 5.3). Western blotting 
demonstrated the presence of BoNT/E LC and epitopes from BoNT/A (Fig. 5.3 B, C) 
in the SC and confirmed the absence of truncated forms. Controlled proteolytic nicking 
converted the SC to a disulphide-linked DC which, as expected, showed different 
behaviour in SDS-PAGE in either the absence or presence of DTT (Fig. 5.3 A). 
Incubation with Trypzean  achieved complete nicking of the chimera, as demonstrated 
by the appearance of Mr~97 k HC and Mr~47 k LC upon SDS-PAGE of the DC in the 
presence of DTT, whereas it appeared as a Mr~145 k band in the absence of reducing 
agent indicating that the inter-chain disulphide bond had been formed in the vast 
majority of the toxin (Fig. 5.3 A). The presence of the requisite moieties (LC/E and 
HC/A) in EA DC and the successful removal of the His6 tag were confirmed by 
Western blotting (Fig. 5.3). Therefore, the expected domains from each parental toxin 
were demonstrated to be incorporated into chimera EA (Fig. 5.3). 
 
 111
M1
Chimera EA
K871 L1296F844
DI
-S-S-
C412 C426
His6
LCE                         HNE                              HCA
Nde I                                       EcoRV Sal I
Lac I                                         KanR
pET29a-chimera EA-His6
Encode
KVDKLAAALE
His6
 
 
Fig. 5.2 Schematic representation of the novel EA chimeric construct generated. 
Chimera EA gene consists of synthetic LC-HNE (hatched box) and HCA (black box) 
gene fragments which were cloned into pET29a vector followed by C-ter His6 sequence 
(Wang et al., 2008). Numbers refer to residue positions in the amino acid sequences 
(GenBankTM accession numbers AF488749 and X62683) of corresponding parental 
BoNTs. S-S denotes the interchain disulphide bridge formed between LC and HC. 
Letters between bars specify amino acids in the single letter code that were chosen as 
linkers between domains.  
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Fig. 5.3 Properities of chimera EA: a highly purified and completely nicked 
recombinant protein. EA toxin was expressed in E.coli, purified by immobilized metal 
affinity and cation exchange chromatography  (Wang et al., 2008); the resultant SC 
toxin was converted to the DC form using trypzean (8 µg/mg BoNT incubated at room 
temperature for 1 hour). Aliquots were subjected to SDS-PAGE on 4-12% Bis-Tris gels 
in the absence or presence of 25 mM DTT (as indicated), followed by either Coomassie 
staining (A) or Western blotting (B-D) with antibodies against LC/E (B), BoNT/A (C) 
and His6(D). Arrows indicate the positions of SC/DC, HC and LC.  
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5.2.4 EA binds to the SV2C acceptor for /A and cleaves SNAP-25 like /E 
To examine if EA had acquired the binding selectivity of BoNT/A, its interaction with 
the fourth intra-lumenal loop of SV2C (SV2C-L4) (Fig. 5.4 A) was examined because 
this together with gangliosides act as acceptors for HC/A (Dong et al., 2006; Mahrhold 
et al., 2006). A SV2C fragment fused to GST (GST-SV2C-L4) and immobilised on 
glutathione-Sepharose was incubated with BoNT/A, /E or EA plus gangliosides before 
assessing toxin binding by Western blotting (see Chapter 2). As expected, BoNT/A was 
recovered with the glutathione-Sepharose when GST-SV2C-L4 was present (Fig. 5.4 
B); on omitting the fusion protein from control incubations no association with 
glutathione-Sepharose could be detected (data not shown). In contrast, BoNT/E failed 
to bind the fusion protein-beads, confirming that BoNT/A but not /E binds to SV2C 
(Mahrhold et al., 2006). Importantly, the DC form of EA was recovered with the 
affinity resin containing SV2C-L4, demonstrating that substitution of the HC of 
BoNT/E with the corresponding domain of /A conferred the acceptor specificity of the 
latter onto the chimera. As SC EA also bound the SV2C fusion protein (Fig. 5.4 B), 
nicking is not essential for interaction with the acceptor. EA also proved enzymically 
active towards a model substrate GFP-SNAP-25(134-206)-His6 (Wang et al., 2008) 
yielding a truncated fragment that co-migrated on SDS-PAGE with the product of 
BoNT/E but not /A (Fig. 5.4 C). This established the presence of /E-like protease 
activity in EA. 
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Fig. 5.4 Both SC and DC forms of EA bind to SV2C-L4 like BoNT/A but give /E-like 
cleavage products in vitro. (A) SV2C structure with the fourth loop highlighted in red 
circle, cited from (Mahrhold et al., 2006); SV2C has 12 transmembrane domains and 
one large intravesicular domain, named loop 4. Numbers specify amino acid positions 
of the isoform SV2C. (B) GST-SV2C-L4 immobilised on glutathione–Sepharose beads 
was incubated with EA (SC or DC), BoNT/A or /E (DC) at 4°C for 4 hours; after 
extensive washing, the bound proteins were eluted in LDS sample buffer; < 5% of the 
total protein or 40 ng of marker toxins were analyzed by SDS-PAGE (see Chapter 2). 
Toxins and the fusion protein were subsequently detected by Western blotting with the 
antibodies indicated. (C) A model substrate [GFP-SNAP-25(134-206)-His6; 13.5 µM] 
was incubated with 25 nM EA or its parental toxins for 30 minutes at 37°C (Wang et 
al., 2008); reactions were stopped by adding LDS-sample buffer and equal amounts of 
protein subjected to SDS-PAGE followed by Coomassie staining. 
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5.2.5 EA cleaves SNAP-25 in cultured CGNs as well as BoNT/E and shows a faster 
rate of uptake than BoNT/A 
5.2.5.1 EA efficiently binds, enters into rat cultured CGNs and cleaves SNAP-25 
Cultured CGNs 7 DIV were incubated with native BoNT/A, /E or chimera EA for ~24 
hours. These three toxins exhibited similar cleavage activity (Fig. 5.5 A) except /A 
reached saturation point at ~60% cleavage; this indicates EA is fully active (Fig. 5.5 B). 
5.2.5.2 EA enters cultured neurones more rapidly than /A 
The uptake of BoNT/A, /E or EA chimera was also studied in CGNs. Using conditions 
that stimulate synaptic vesicle recycling (Foran et al., 2003) in CGNs, which may 
promote the activity-dependent uptake of BoNTs as occurs at the neuromuscular 
junction (Dong et al., 2006), the potencies to BoNT/A, /E and EA chimera were 
increased but to different extents (Wang et al., 2008). However, the rates of cellular 
intoxication by BoNT/E and EA were clearly faster compared with BoNT/A (Fig. 5.6). 
Cleaved SNAP-25 was observed within 15 or 45 min of exposure to BoNT/E or 
chimera EA (Fig. 5.6 A); furthermore, in both cases, 50% of the total target had been 
cleaved within 160 min. In contrast, no product was detectable at 80 min in BoNT/A-
treated cells, and <20% SNAP-25 proteolysis occurred after 160 min (Fig. 5.6). These 
findings indicate that the apparent relatively rapid uptake of BoNT/E in these different 
neuronal populations can be attributed to its HN and/or LC. Moreover, the rate of 
uptake is not determined by acceptor binding domain, as  EA and /A both bind to 
acceptor SV2  (Fig. 5.4) that is not used by /E (Mahrhold et al., 2006). It was reported 
in previous study that the protease rate of chimera EA is similar to /A but faster than /E 
(Wang et al., 2008).  Thus, faster translocation to the cytosol seems to be the sole 
reason for the more rapid appearance of protease products.  
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Fig. 5.5 EA efficiently cleaves SNAP-25 with similar potency as BoNT/E or /A in 
CGNs. CGNs 7 DIV were incubated for 24 hours in culture medium with the specified 
concentrations of BoNT/A, /E or chimera EA. After removal of toxins by washing, cells 
were then solubilized in LDS-sample buffer and equal volumes of protein subjected to 
SDS-PAGE and Western blotting (A), with the specific antibodies indicated. (B) The 
extents of SNARE cleavage were quantified by densitometrically scanning and the 
proportion of substrate remaining calculated relative to an internal control, syntaxin I. 
Data plotted are means ± s.e.m.; n = 3. 
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Fig. 5.6 EA enters cultured neurones more rapidly than /A. CGNs 7 DIV were 
incubated with 500 pM toxins for 5 min in depolarization buffer (56 mM K+) followed 
by washing with medium and incubation under the indicated conditions in culture 
medium. After removal of medium, cells were then solubilized in SDS-sample buffer 
and equal amounts of protein subjected to SDS-PAGE and Western blotting, with the 
specific antibodies indicated (A). The extents of SNARE cleavage were quantified by 
densitometrically scanning and the proportion of substrate remaining calculated 
relative to an internal control (syntaxin I) (B). 
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5.2.6 EA, unlike /A, blocks synaptic vesicle fusion and CGRP release triggered by 
capsaicin in addition to K+ depolarisation 
The functional activity of EA relative to /A could be shown by monitoring its influence 
on the trafficking of exocytotic vesicles to the cell surface, using a proven immuno-
cytochemical technique (Matteoli et al., 1992). Binding of a mAb (Syt-Ecto), specific 
for the intra-lumenal domain of the synaptic vesicle protein synaptotagmin I, to TGNs 
was stimulated greatly by either K+-depolarisation (Fig. 5.7 A) or 1 µM capsaicin (Fig. 
5.7 B). This indicated increased exposure of the epitope due to fusion of vesicles 
containing synaptotagmin I with the plasmalemma. Although pre-exposing TGNs to 
100 nM BoNT/A blocked the enhancement of Syt-Ecto binding by K+-depolarisation 
(Fig. 5.7 A), this did not prevent the increase in binding elicited by 1 µM capsaicin (Fig. 
5.7 B), consistent with the toxin’s feeble inhibition of CGRP release elicited by this 
stimulus (Fig. 5.1 A). In contrast, EA prevented both capsaicin-triggered exposure of 
the Syt-Ecto epitope as well as that elicited by depolarisation, revealing blockade of 
vesicle fusion regardless of the stimulus (Fig. 5.7 B). 
The toxins’ potencies for blocking CGRP release from TGNs relative to cleavage of 
SNAP-25 were assessed by exposing primary cultures to a range of concentrations, as 
described in Fig. 5.1. The cells were > 1000-fold more susceptible to chimera EA (Fig. 
5.8) than BoNT/E (cf  Fig. 5.1 C, D), based on their EC50 values for SNAP-25 cleavage 
being ~ 1 nM and >> 1 µM, respectively. Moreover, CGRP release was inhibited dose-
dependently by EA (Fig. 5.8 B) whereas BoNT/E was impotent (cf. Fig. 5.1 D). 
Interestingly, after 12 hours incubation which proved to be optimal for SNAP-25 
cleavage and CGRP release inhibition (data not shown), the concentration-dependency 
of EA for inhibition of CGRP-release (Fig. 5.8 B) elicited by bradykinin (EC50 = 0.8 
nM) correlated very closely to the level of SNAP-25 cleavage, and K+-evoked release 
showed intermediate susceptibility. Although blockade of the capsaicin-triggered 
response was the least sensitive (EC50 ~ 10 nM), it showed far greater sensitivity to EA 
than BoNT/A (cf  Fig. 5.1 A).  
Clearly, recombination of the most desirable features of BoNT/E and /A to create 
chimera EA produced a more effective and broad-range inhibitor of CGRP release 
from sensory TGNs. As BoNT/A and EA bind to the same acceptor and, by 
extrapolation, the same population of cells, it seems probable that the greater versatility 
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of EA can be attributed to a more effective disabling of SNAP-25 than is caused by 
BoNT/A. 
 
 
Fig. 5.7 EA and BoNT/A both inhibit K+-evoked binding of synaptotagmin 1 
antibody to sensory neurons whereas only EA blocked the capsaicin-stimulated 
interaction. TGNs were grown on coverslips for 7 DIV, incubated with or without 100 
nM EA or BoNT/A for 24 hours before washing, and exposure to Syt-Ecto antibody for 
15 minutes in either basal or 60 mM K+ (A) or 1 µM capsaicin (B). Cells were then 
fixed (see Chapter 2) and images of the same field recorded in phase contrast (top 
panels) or fluorescent mode (bottom panels). The increased fluorescent signal induced 
by K+ stimulation was reduced to basal level by both toxins; in contrast, the elevated 
signal elicited by capsaicin remained unaffected by /A but significantly reduced by EA. 
In B, the vehicle (0.1% ethanol) for capsaicin was added to the basal medium. Scale 
bar = 20 µm. 
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Fig. 5.8 EA enters /E-resistant TGNs, cleaves SNAP-25 and inhibits CGRP release 
evoked by all stimuli. Cultured TGNs at 7 DIV were exposed to EA at 37°C in culture 
medium for 12 hours, and release of CGRP was assayed; Western blotting of the cells 
were performed and results calculated (as in Fig. 5.1) for  cleavage of SNAP-25 (?) 
by EA (A, B). (B) EA-induced inhibition of CGRP release evoked by 60 mM K+ (□), 0.1 
µM bradykinin (▲) or 1 µM capsaicin (●). Data plotted are means ± S.E.M.; n ≥ 4.  
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5.2.7 The inhibitory ineffectiveness of BoNT/A compared to EA in TGNs accords 
with a differential stability of SNARE complexes formed by their SNAP-25 
cleavage products 
It has been reported that the 17 amino acids between the cleavage sites for BoNT/A and 
/E at the C-terminal of SNAP-25 are required for its high affinity binding to syntaxin 
(Bajohrs et al., 2004), although previous studies had found that N-terminal residues 2-
82 are sufficient (Chapman et al., 1994; Hayashi et al., 1994). In view of these 
conflicting in vitro data, obtained with recombinant fusion proteins or tagged protein 
fragments, formation of SNARE complexes in sensory neurones in situ was examined 
for possible perturbations by BoNT/A or EA. For this purpose, neurones were 
solubilised with SDS and subjected to two-dimensional PAGE before detection of 
SNAREs by Western blotting (Lawrence and Dolly, 2002). This protocol exploits the 
stability of SNARE complexes, which resist dissociation in SDS at ambient 
temperature and can be electrophoretically separated from non-complexed SNAREs 
(Hayashi et al., 1994). Subsequent heating of the gel sections denatures the complexes 
and liberates their constituents, which can be resolved by a second electrophoresis step. 
In SDS extracts from non-intoxicated cells, the majority of each immunologically-
detected SNARE (syntaxin, SNAP-25 and Sbr I) was not associated with any SDS-
resistant complex (Fig. 5.9; note samples in lanes marked * were diluted before 
electrophoresis). This is shown by their migrations in PAGE being unchanged by 
boiling and matching the mobilities predicted by their molecular masses. However, 
some SNAP-25 was retarded in the primary gel, but not in the second gel of the boiled 
sample demonstrating that a minority of this protein is associated with SDS-resistant 
SNARE complexes. SNAP-25 was present in complexes of variable size from Mr = 
52k to over 288k and, particularly, in the 104-288k range. Likewise, syntaxin was 
detected in SNARE complexes with Mr values between 52 and >288k; the 146-205k 
range showed the strongest intensity. In contrast, only a weak Sbr I immuno-signal 
could be detected, restricted to the Mr = 104-205k range. These observations suggest 
that some of the SNAP-25 and syntaxin in sensory neurones are associated tightly 
enough to resist dissociation by SDS. Sbr I (Fig. 5.9 A) appear to be minor components, 
indicative of the majority being binary SNAP-25:syntaxin complexes. However, it is 
not possible to calculate the precise ratio of each SNARE with the semi-quantitative 
technique used here. Stimulation of the TGNs with capsaicin produced only a moderate 
increase in the amounts of SDS-resistant complexes detected (Fig. 5.9 A) compared to 
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resting samples (data not shown). In cells exposed for 24 hours to 100 nM BoNT/A, 
the bulk of SNAP-25 was truncated, as shown by its increased mobility on PAGE (Fig. 
5.9 A); notably, both cleaved and uncleaved SNAP-25 were detected in SDS-resistant 
complexes. Syntaxin was also found to be present together with a trace of Sbr I in these 
toxin-treated samples. The fraction of each SNARE associated with the complexes did 
not seem to be altered compared to non-intoxicated cells. Clearly, SNAP-25A retains 
the ability to form SDS-resistant complexes with its SNARE partners. In contrast, only 
traces of SNAP-25E were associated with complexes in the 74-146k range in TGNs 
treated with EA, despite most of the SNAP-25 having been cleaved (Fig. 5.9 A). In the 
EA- treated samples, the quantity of complexes was clearly reduced compared to toxin-
free cells or those exposed to BoNT/A; minute amounts of uncleaved SNAP-25 and 
syntaxin were found in those complexes but Sbr I was undetectable. The inability of 
SNAP-25E to form complexes in sensory TGNs, unlike SNAP-25A, seems a likely 
explaination for the more extensive inhibition of exocytosis by EA than BoNT/A. 
In separate series of experiments, the apparent scarcity of Sbr I in SDS-resistant 
SNARE complexes in TGNs was probed using BoNT/D because it cleaves Sbr I, II & 
III and inhibits evoked CGRP release (see Chapter 4). In cells exposed to this toxin, the 
amount of non-complexed Sbr I was reduced by 80% and Sbr I could not be detected in 
SDS-resistant complexes (Fig. 5.9 B). Nevertheless, the latter complexes containing 
syntaxin and SNAP-25 were not diminished compared to toxin-free controls, 
supporting the notion that such binary complexes lack Sbrs. In TGNs exposed 
simultaneously to both BoNT/A and /D, ~ 50% of the SNAP-25 and 80% of Sbr I were 
cleaved; notably, only intact SNAP-25 was found in complexes from these TGNs (only 
a trace of SNAP-25A was detected), a striking contrast to its distribution in cells 
exposed to BoNT/A alone (Fig. 5.9 A). This suggests that Sbr I is required for 
stabilisation of complexes containing SNAP-25A even though it cannot be detected in 
SDS-resistant complexes. One possible explanation is that Sbr I weakly associates with 
syntaxin:SNAP-25 (or SNAP-25A) but is dissociated by SDS during cell solubilisation. 
If stable binding with syntaxin underlies the ability of SNAP-25A to support CGRP 
release in TGNs, intact Sbr is essential for this to occur. 
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Fig. 5.9 The presence of BoNT/A-truncated SNAP-25 in SDS-resistant SNARE 
complexes requires intact Sbr. TGNs at 7 DIV were incubated with or without (A) 100 
nM BoNT/A or EA or (B) 100 nM BoNT/D or 100 nM BoNT/D plus BoNT/A in culture 
medium for 24 hours. After toxin removal, cells were stimulated with 1 µM capsaicin in 
the presence of 2.5 mM Ca2+ for 30 minutes, before lysis in 2xLDS sample buffer and 
SDS-PAGE (without boiling). Gel sections containing the separated proteins were 
excised according to migration distance and extracted by boiling in LDS sample buffer 
before re-electrophoresis and immunoblot analysis (see Chapter 2). Antibodies against 
syntaxin, SNAP-25 (recognizing intact and cleaved products) or Sbr I were used. 
Pictures shown are from a single experiment representative of results obtained on 3 
independent occasions; ∗ 20% of sample volume was loaded was used in the lanes (A, 
B). 
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 5.2.8 BoNT/A and EA reduce the sensitivity to external Ca2+ of CGRP exocytosis 
triggered by K+ from TGNs but only EA alters the Ca2+-dependency of the 
response to capsaicin  
SNAP-25 binds to synaptotagmin, a Ca2+-sensor thought to be the regulator of vesicle 
fusion, through Ca2+-independent and -stimulated interactions (Schiavo et al., 1997). 
The C-terminus of SNAP-25 has been implicated in the latter because its removal 
reduces the level of Ca2+-dependent binding (Gerona et al., 2000). However, in the case 
of SNAP-25A, the interaction is restored if [Ca2+]i is elevated, suggesting that BoNT/A 
reduces the sensitivity of the Ca2+-sensor. This finding has been used to explain the 
restoration of function to BoNT/A-intoxicated nerve terminals following treatments 
that open Ca2+-channels and/or increase membrane permeability to Ca2+. Applying this 
reasoning to the observed lack of blockade by BoNT/A of capsaicin-elicited responses 
from TGNs, stimulation with this agonist of VR1 may provoke greater elevation of 
[Ca2+]i than K+-depolarisation and, thereby, overcome the postulated reduction in Ca2+ 
sensitivity for triggering CGRP release. To test this hypothesis, the effects of BoNT/A 
or EA on the [Ca2+]-dependency and amounts of CGRP release from TGNs were 
quantified in the absence and presence of capsaicin or a Ca2+- ionophore, ionomycin. 
 Notably, dependencies on external [Ca2+] of the responses to K+ and capsaicin were 
similar in control cells (Fig. 5.10 A, B), although there was a higher level of basal 
release in the presence of capsaicin; the EC50 values for external [Ca2+] were 0.6 and 
0.9 mM, respectively, whilst ECMAX was ~5 mM in both cases. CGRP release elicited 
by either stimulus (Fig. 5.10 A, B) was effectively inhibited by 100 nM EA at [Ca2+] up 
to 5 mM, with some lessening at higher concentrations; the Ca2+-sensitivity was, 
apparently, reduced with respect to toxin-free control. In contrast, 100 nM BoNT/A 
poorly inhibited responses to capsaicin even at low external [Ca2+] but virtually 
abolished K+-evoked CGRP release in 1 mM [Ca2+] or less; however, further 
increments in external [Ca2+] supported increasing levels of K+-evoked CGRP release, 
with over 80 % of the maximal level seen at an extremely high [Ca2+] (Fig. 5.10 A). 
Assuming 100% recovery from inhibition could be achieved, the EC50 of Ca2+ for 
depolarisation-evoked release from BoNT/A-treated cells was ~15 mM, a ~30-fold 
reduction in sensitivity relative to that for toxin-free cells. On the other hand, BoNT/A 
did not alter the external Ca2+-dependency of capsaicin-evoked CGRP release (EC50 ~1 
mM) despite causing a partial decrement in the amount of exocytosis in response to 
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each [Ca2+] (Fig. 5.10 B). Notably, the latter findings are difficult to reconcile with 
BoNT/A directly lowering sensitivity of the Ca2+-sensing mechanism. To gain insights 
into this differential reversibility, the influence of altering [Ca2+]i on the restoration of 
CGRP release from inhibition by toxins was investigated. TGNs treated with 100 nM 
BoNT/A or EA for 24 hours resulted in ~70-80 % inhibition of K+-evoked CGRP 
release (Fig. 5.10 C).  Although  ionomycin (5 µM) gave a small (~10%) increase in 
CGRP release from toxin-free cells stimulated by K+, it caused ~70% and ~20% 
recovery of exocytosis from cells pre-treated with BoNT/A or EA, respectively (Fig. 
5.10 C). Notably, in Ca2+-free medium, ionomycin and K+ depolarisation failed to elicit 
any release from toxin-treated cells, indicating a requirement for extracellar Ca2+. In 
contrast to K+ depolarisation, ionomycin slightly decreased (~15%) the amount of 
CGRP release from toxin-free cells stimulated by capsaicin (Fig. 5.10 D); moreover, it 
did not rescue capsaicin-evoked CGRP release blocked by EA (Fig. 5.10 D; p > 0.05). 
When Ca2+ was omitted, neither capsaicin nor ionomycin could evoke release from 
TGNs pre-treated with BoNT/A or EA (Fig. 5.10 D). As differences in intracellular 
Ca2+ signalling could account for the observed discrepancy between the BoNT/A 
susceptibilities of responses to K+-depolarisation and capsaicin, this was examined 
using TGNs pre-loaded with the membrane permeable Ca2+-indicator dye, Fluo 4-AM. 
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Fig. 5.10 Raising extracellular [Ca2+] reveals differences in the effects of BoNT/A 
and EA on the Ca2+ dependency of release from capsaicin-stimulated cells whereas 
use of ionomycin showed that K+-depolarization alone does not elevate [Ca2+]i 
sufficiently to overcome inhibition by BoNT/A. TGNs at 7 DIV were exposed to 100 
nM BoNT/A (A, B ? or as indicated in C and D) or EA (A, B, ? or as indicated in C 
and D) at 37°C in culture medium for ~24 hours. CGRP release was evoked by 60 mM 
K+ (A, C) or 1 µM capsaicin (B, D) in BR-HBS containing various [Ca2+] (A, B), 2.5 
mM Ca2+ in the presence and absence of 5 µM ionomycin, or in Ca2+-free buffer with 2 
mM EGTA as indicated (C, D). Vehicle for ionomycin (0.05% DMSO) was included. 
Exocytosis was normalized to the maximal release (in 25 mM Ca2+) from toxin-free 
controls (A, B) and to the values from toxin- and ionomycin-free control cells (C, D). 
Data plotted are means ± S.E.M; n ≥ 3; Student’s unpaired t-test: ***, p<0.001; **, 
p<0.01; N.S., p>0.05. 
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5.2.9 Capsaicin elicits a more persistent increase in [Ca2+]i than K+ depolarisation 
Fluorescence signals in cell bodies of randomly-selected TGNs, preloaded with Fluo 4-
AM, was monitored before and during continuous exposure to 60 mM K+, or 1 µM 
capsaicin; increased intensity indicates an elevation in [Ca2+]i.  Notably, in toxin-free 
control cells, there was a sharp increase in [Ca2+]i immediately after superfusion of 60 
mM K+, followed by decay to 50% of the peak within ~10 minutes (Fig. 5.11 A, B). A 
similarly sharp initial increase in [Ca2+]i was elicited with 1 µM capsaicin in majority 
of the cells, presumably the VR1 positive neurons. Although the increment in intensity 
was lower than that evoked by K+-depolarisation, the elevated fluorescence persisted 
longer in capsaicin-treated cells, with > 60% of the peak signal retained after 30 
minutes (Fig. 5.11 A, B). Consistent with this, the level of  45Ca2+ accumulation elicited 
by capsaicin was > 2-fold higher than that for 60 mM K+ at each time point with a 
plateau not being reached even after 30 minutes; in contrast, nearly all the 45Ca2+ 
uptake evoked by 60 mM K+ occurred within 10 minutes (Fig. 5.11 E).  
  It is noteworthy that pre-treatment with 100 nM BoNT/A (Fig. 5.11 C) or EA (Fig. 
5.11 D) did not alter the capsaicin-induced elevation of [Ca2+]i which was more 
persistent than that caused by K+ depolarisation. To ascertain if the prolonged increase 
in [Ca2+]i by capsaicin influences exocytosis, the time course of CGRP release was 
monitored (Fig. 5.11 F). In toxin-free control cells, ~ 50% of the maximum response 
occurred within 2 minutes of capsaicin application, rising to ~90% at 8 minutes and 
reaching a plateau level within 15 minutes. Capsaicin-triggered CGRP release from 
BoNT/A-treated cells was notably lower at early time points (p = 0.02, t = 2 minutes; 
unpaired 2-tailed Student’s t-test), even though the maximum amount finally released 
was only slightly lower than in the control (p = 0.2, t = 32 minutes).  Calculation of the 
increments in release over time (Fig. 5.11 F inset) illustrated that exocytosis initially 
occurred more rapidly in the control than /A-treated TGNs but decelerated faster (p = 
0.02, t = 2 minutes). These findings indicate that BoNT/A does not reduce the total 
amount of CGRP-containing vesicles that fuse since the same maximum levels were 
reached eventually (Fig. 5.11 F) but, rather, lower the apparent initial rate (Fig. 5.11 F 
inset). Thus, persistence of the Ca2+ signalling seems to be more important than [Ca2+]i 
for alleviating inhibition by BoNT/A in these sensory neurons. EA decreased the level 
of exocytosis much further than BoNT/A, with only a fraction of the total release seen 
after 30 minutes (Fig. 5.11 F). Collectively, our results accord with the relative 
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stabilities of SNARE complexes containing Sbr I, syntaxin and full-length or BoNT-
truncated SNAP-25. Removal of 26 C-terminal amino acids by EA prevents adoption 
of a stable SDS-resistant conformation and severely blocks CGRP release.  In contrast, 
/A-truncated SNAP-25 is shortened  by only 9 C-terminal residues and retains ability to 
form SDS-resistant complexes with its SNARE partners, but their stability is lower 
than complexes formed with uncleaved SNAP-25.  Hence, BoNT/A inhibits release but, 
under certain circumstances, exocytosis can be recovered, albeit retarded relative to 
non-toxin controls; apparently, brief elevation of [Ca2+]i is insufficient to elicit CGRP 
exocytosis but prolonged Ca2+- signals can eventually elicit as much release as from 
toxin-free controls.  These results are consistent with the notion that BoNT/A 
compromises the stability of pre-fusion SNARE complexes required for optimal rates 
of CGRP exocytosis.  
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Fig. 5.11 Capsaicin induces a less acute, but more prolonged, increase in [Ca2+]i 
than  K+-depolarisation which negates the blockade by BoNT/A of its CGRP 
triggered release. (A) Ratios of the fluorescent readings relative to basal value (f/f0), 
taken every 10 sec over 30 minutes, are plotted for the control cells (A), BoNT/A- (C) 
or EA- treated (D) TGNs, recorded under continuous stimulation by 60 mM [K+] (red), 
or 1 µM capsaicin (green) in basal buffer. The data are also expressed as % of 
maximal signal (B) for the control cells. Individual cells were randomly selected for 
analysis from 2 independent preparations and the values were pooled to give the 
average ± S.E.M. at each time point; n = 45, 61 for control cells stimulated by 1 µM 
capsaicin or 60 mM K+; 67, 46, BoNT/A-; 28, 52 for EA-treated cells. (E) The rates of 
45Ca uptake were measured for control cells in 3.5 mM K+ (?) and those exposed to 1 
µM capsaicin (?) or 60 mM K+ (?) after incubation for the indicated periods at room 
temperature with 24 µCi/ml 45Ca. Following extensive washing, the cells were 
solubilized in 0.1% SDS buffer before counting in a β scintillation spectrometer. 
Capsaicin-induced 45Ca uptake over 32 minutes into TGNs was ~4 pmol/well from one 
representative experiment. (F) CGRP release over time was monitored from control 
cells (?) or those treated for 24 hours with 100 nM BoNT/A (?) or EA (?), as 
described in Fig. 5.1. The rate of CGRP release (∆CGRP/∆t) was calculated and 
plotted in the inset. All data plotted in (E) and (F) are means ± S.E.M., n ≥ 3. 
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Fig. 5.11 
 
 
 
 
 
 131
5.3 Discussion 
The usefulness of BoTOX for the treatment of pain symptoms was revealed by the 
reduced frequency and intensity of migraines seen in some sufferers who had received 
injections of BOTOX® (Binder et al., 2000).  This accords with the attenuation by the 
toxin of capsaicin-induced pain in certain patient groups (Bach-Rojecky et al., 2005) 
and not others (Schulte-Mattler and Martinez-Castrillo, 2006; Tugnoli et al., 2007). In 
this context, it is noteworthy that capsaicin, a stimulant of sensory C-fibres, but not K+-
depolarisation can trigger secretion of pain mediators from BoNT/A-intoxicated 
sensory neurones in vitro. Although the exact mechanism for pain relief by BoNT/A 
remains to be deciphered, there is mounting evidence from animal and human studies 
for a direct action of the toxin on sensory neurons to abrogate the release of pain 
mediators  [(Cui et al., 2004) and reviewed by (Aoki, 2005)]. Therefore, identifying 
features of other toxin forms with ability to completely block exocytosis from sensory 
neurones evoked by all stimuli is highly desirable because the resultant findings could 
help pinpoint the underlying mechanism; moreover, it would be advantageous to 
incorporate these into any new BoNT-derived analgesic. It was hoped that use of 
BoNT/E would achieve this objective due to its removal of 17 more residues than 
deleted by /A from the C-terminus of SNAP-25, and because of its higher potency and 
faster neuroparalytic action at motor terminals (Lawrence and Dolly, 2002; Simpson 
and DasGupta, 1983).  Furthermore, the shorter lifetime of /E protease compared to 
type /A (Foran et al., 2003) could be advantageous for treatment of transient pain 
episodes [e.g. typical duration of pain in migraine is 1 to 3 days (Durham, 2006)], 
particularly in patients for whom such attacks are infrequent and prolonged inhibition 
may not be necessary. Disappointingly, in TGNs __ a convenient model of sensory 
neurons __ BoNT/E cleaved little SNAP-25 and gave no significant inhibition of CGRP 
release triggered by K+ or capsaicin, highlighting a lack of its high-affinity acceptor 
(presently unknown) or a productive uptake system. Nevertheless, it is suggestive of 
HC/E being useful for targetting to other neuron types in conditions where sensory 
inhibition needs to be avoided (eg. normalization of occular muscles).  
Knowing that /A can access TGNs, it was predicted that HC/A could mediate cell 
binding of HNLC/E leading to intra-neuronal delivery of LC/E.  Indeed, chimera EA 
was shown to bind to the /A acceptor SV2 (loop 4), enter the rat cultured CGNs almost 
as rapid as BoNT/E and faster than /A. Further investigation into a structural basis for 
the faster transport of BoNT/E protease relative to /A is fully warranted, considering 
 132
that development of the full therapeutic response to BoNT/A takes days to a week after 
injection (Ward and Barnes, 2007) and faster onset of paralysis would be a highly 
desirable property. Notably, chimera EA produces a more-broadly effective block of 
evoked CGRP exocytosis than BoNT/A, an important functional attribute. Moreover, 
this established a requirement for SNAP-25 in capsaicin-elicited peptide release from 
TGNs, as well as a C-terminal region of SNAP-25, the 17 amino acids between the 
scissile bonds for each toxin (residues 181-197), being critical. Deciphering a 
molecular basis for this difference in inhibition by EA and BoNT/A could give insights 
into the fundamentally important and ubiquitous mechanism of SNARE-driven 
membrane fusion; also, the outcomes should aid the designing of improved treatments 
for pain. The greater effectiveness of EA in blocking capsaicin-evoked exocytosis from 
TGNs correlates with the observed inability of /E cleaved SNAP-25 to form SDS-
resistant complexes with syntaxin I. This constrasts with SNAP-25A which can stably 
associate with syntaxin I; importantly, this was found to only occur in the presence of 
intact Sbr, a requirement not applicable to intact SNAP-25. In accord with these 
findings, in vitro studies have shown that BoNT/E more effectively reduces the 
stability of ternary SNARE complexes compared to /A (Hayashi et al., 1994), an effect 
attributed to the fact that only 3 of the 9 residues removed by BoNT/A are involved in 
the formation of coiled-coil α helical domains in the tenary SNARE complex whereas 
all of the extra 17 residues removed by BoNT/E are required (Sutton et al., 1998). It is 
noteworthy that syntaxin: SNAP-25 complexes represent an important intermediate 
that binds Sbr to form a meta-stable ternary complex before Ca2+ triggers a rapid 
‘zippering-up’ that is thought to drive membrane fusion (Wojcik and Brose, 2007). One 
possible interpretation of the inhibitory effect seen with BoNT/A is that pre-fusion 
complexes are destabilised, as reflected by Sbr being needed for the complexes to 
acquire resistance to SDS. Such a perturbation could reduce the probability of vesicle 
fusion, leading to a reduced rate of CGRP release (Fig. 5.11 F). This deduction is fully 
consistent with the finding that, given sufficient time, almost as much CGRP was 
released from BoNT/A-treated cells as from controls (see later). However, the question 
remains as to why secretory responses to K+-depolarisation (or bradykinin) are 
effectively blocked by BoNT/A if SNAP-25A retains some functional capacity? 
It is well established that the potent inhibition of neuromuscular transmission by 
BoNT/A can be attenuated by raising extracellular [Ca2+] or by increasing the Ca2+ 
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permeability of the nerve terminal membrane (Cull-Candy et al., 1976). Herein, it was 
found that capsaicin-evoked CGRP release was insensitive to BoNT/A and inhibition 
of K+-evoked CGRP release was overcome by either increasing the external [Ca2+] or 
by including the Ca2+-ionophore, ionomycin. Likewise, BoNT/A abolishes K+-evoked 
transmitter release from synaptosomes or neuroendocrine cells, but such blockade is 
alleviated if the cell membrane is rendered permeable to Ca2+ with ionophores or pore-
forming detergents (Ashton and Dolly, 1991; Lawrence et al., 1996). Hence, it has been 
postulated that BoNT/A blocks exocytosis by reducing the Ca2+-affinity of the Ca2+-
sensor for exocytosis and, in support of this notion, it has been found that a higher 
[Ca2+] is required to stimulate the binding of synaptotagmin (the putative Ca2+-sensor) 
to SNAP-25A than to uncleaved SNAP-25 in vitro (Gerona et al., 2000), although the 
significance of this interesting observation is unclear because ~100-fold higher [Ca2+] 
was required in the binding than needed to trigger exocytosis (also see below). 
However, this latest study showed that BoNT/A causes little change in [Ca2+]-
sensitivity of capsaicin-evoked release from TGNs. Accordingly, BoNT/A is known to 
have minimal effect on the [Ca2+]i-dependency for catecholamine release from 
permeabilised neuroendocrine cells (Gerona et al., 2000; Lawrence and Dolly, 2002), 
wherein [Ca2+]i can be tightly buffered by injection into nerve endings, and only 
slightly increases the [Ca2+]i needed for vesicle fusion (Sakaba et al., 2005). Moreover, 
the Ca2+-sensitivity for catecholamine secretion from neuroendocrine cells closely 
correlates with the cation requirements for inducing conformational changes in 
synaptotagmin 1 and SNAREs in situ, and the Ca2+-sensitivities for all of these 
phenomena are unaffected by BoNT/A (Lawrence and Dolly, 2002). A reasonable 
conclusion from these arguments is that BoNT/A does not, in fact, reduce the [Ca2+]-
affinity of the exocytotic apparatus and, therefore, the success of capsaicin in triggering 
CGRP release from BoNT/A-intoxicated TGNs is unlikely to be due to higher levels of 
[Ca2+]i being elicited than by stimuli that are unable to overcome inhibition by this 
toxin. Furthermore, K+-depolarisation actually induced larger peak increases of 
fluorescence intensity in Fluo 4-AM loaded TGNs than exposure to capsaicin.  
It is necessary, therefore, to consider other aspects of Ca2+-signalling that may underlie 
differences in response to capsaicin and K+-depolarisation. The spatial and temporal 
patterns of [Ca2+]i signals are important factors that influence the amount and rate of 
exocytosis from secretory cells (Augustine and Neher, 1992). Fluo 4-AM revealed that 
capsaicin induced a more persistent increase in [Ca2+]i  than K+, despite the initial peak 
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signal being somewhat lower in toxin free cells. Accordingly, over a 30 minutes period 
capsaicin stimulated > 2-fold more uptake of 45Ca2+ than 60 mM [K+] did not reach a 
plateau. Thus, capsaicin induces more persistent Ca2+ signals than K+-depolarisation. 
Persistent elevation of [Ca2+]i signals was shown herein to be critical for capsaicin and 
ionomycin (Durham and Russo, 2003) to elicit CGRP release from BoNT/A-
intoxicated neurons, in accord with studies demonstrating that this toxin slows the rate 
of vesicle release and causes a delay before vesicles start fusing (Sakaba et al., 2005). 
Such functional data are consistent with the notion that BoNT/A may destabilise a pre-
fusion SNARE complex (Fig. 5.9) required for the initial fast exocytotic burst (Wojcik 
and Brose, 2007; Xu et al., 1998). Spatial localisation of Ca2+ needs to be considered 
and the spatial pattern of Ca2+ signals is also likely to differ because capsaicin and K+-
depolarisation activate distince channels, ionomycin is a Ca2+-selective ionophore that 
acts on both the plasma and intracellular membranes (Morgan and Jacob, 1994), and 
the high-concentration microdomains may be distant from secretory vesicles, especially 
large-dense core granules (Augustine and Neher, 1992) like those that contain CGRP. 
Thus, the successful insertion of a different binding domain into BoNT/E: (i) endowed 
an ability to target to /E-insensitive neurons; (ii) produced a novel chimera capable of 
abolishing capsaicin- or ionomycin-elicited exocytosis of a pain mediator unlike /A 
whose inhibition is precluded by sustained elevation of [Ca2+]i and (iii) revealed a basis 
for the ability of /EA, but not /A, to totally block capsaicin-induced CGRP release i.e. 
BoNT/A- but not /E-truncated SNAP-25 can participate in the formation of SDS-
resistant SNARE complexes. This accords with observations on intact and truncated 
recombinant SNAREs (Hayashi et al., 1994) and findings that /A retards rather than 
prevents vesicle fusion in neurons (Sakaba et al., 2005).  
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6.0 Summary and recommendations for future work 
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 6.1 The unique requirement of Sbr I for CGRP release from TGNs provides novel 
insights for designing new BoNT variants as anti-nociceptives  
In this thesis, Sbr I was found to be essential for evoked Ca2+-dependent CGRP release 
from TGNs (Chapter 4). For example, cleavage of Sbr II and III by BoNT/B and 
chimera BA in rat TGNs (I is resistant in this species) failed to block release of CGRP 
whereas it was inhibited in mouse neurons where Sbr I was also proteolysed. Knock-
down of Sbr I expression in mouse and rat TGNs led to a substantial reduction of 
CGRP release (Chapter 4). This demonstrated requirement of Sbr I in peptide release 
from LDCVs in sensory neurons contrasts with the ability of Sbr II / III to suffice for 
exocytosis of several neurotransmitters from SCSVs or, indeed, for secretion from 
granules in chromaffin cells and PC-12 cells (Foran et al., 2003; Lomneth et al., 1991). 
Such an unique feature of a dependence on Sbr I for CGRP exocytosis from TGNs may 
be related to this occurring at sites remote from the active zones (Bernardini et al., 
2004), enabling this pain mediator to reach blood vessels in the vicinity and activate its 
receptor thereon. In order to specifically target pain sensory neurons, novel BoNT 
forms which selectively cleave only Sbr I is fully warranted with the aid of insights 
gained from Sbr substrates, their recognition and cleavage (Chen et al., 2008; Sikorra et 
al., 2008). Modifications (mutations and/or deletions) of protease domains of Sbr-
cleaving BoNTs, which are responsible for individual isoform recognition and/or 
cleavage, might achieve a toxin only cleaving Sbr I. Such a toxin should not affect 
other neuron types because the latter seem to utilize Sbr II and/or III (see Chapter 4 
section 3). BoNT/D was demonstrated to be effective in blocking CGRP release 
elicited by all stimuli (Chapter 4), but the lack of its acceptor in human tissue makes it 
unsuitable for therapeutic purpose (Coffield et al., 1997). This could be resolved in 
future by engineering a new variant containing an acceptor binding domain shown to 
bind to TGNs with the protease of /D, known to cleave all the Sbr isoforms effectively 
blocking release of this pain peptide.  
 
6.2 Proof of principle was gained for desired toxin targeting from a novel BoNT 
EA chimera blocking capsaicin-evoked exocytosis of CGRP from TGNs much 
more effectively than /A or /E  
The ability of chimera EA to remove a further 17 residues from SNAP-25, in 
comparison to BoNT/A, yields a complete blockade of capsaicin-evoked CGRP release 
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rather than the negligible inhibition seen with /A (Chapter 5). EA is a more effective 
inhibitor of CGRP release from sensory neurones than either of its parents because it 
combines the superior /A property of cell binding via SV2 with the broader inhibitory 
capability of an /E protease that more effectively destabilises SNARE complexes. This 
demonstration of the successful substitution of the binding domain of /E with its 
counterpart from /A highlights the utility of protein engineering for retargetting 
BoNT/E to otherwise /E-insensitive cells. In a similar manner, the HC of tetanus toxin 
has been used to retarget diptheria toxin to neurones (Francis et al., 2000). As highly 
purified EA is easily prepared with good yield and, importantly, high potency, this 
technology represents a marked improvement over sensory targetting by chemical 
conjugation of Erythrina cristigalli lectin to the /A LC-HN fragment (Duggan et al., 
2002). The latter suffers from the drawbacks of inconsistent chemical conjugation, 
complex manufacturing procedure, product heterogeneity and low specific activity. 
However, as the BoNT/A acceptor SV2 is widely expressed in the nervous system, 
BoNT LC-HN fusions to polypeptide ligands for surface markers on specific neuronal 
system are now being developed for more specific targetting. A similar strategy has 
given encouraging results for targetting BoNT/C1 to lung epithilial cells with 
epidermal growth factor to inhibit mucus secretion (Foster et al., 2006). Further 
developments should incorporate the BoNT LC and translocation together with a 
specific acceptor binding moiety, a potential ligand for VR1, to selectively target 
nociceptive sensory neurons, the prime target of nociceptive C-fibres. The BoNT HN in 
this hybrid would form a channel allowing the attached LC protease to translocate to 
the cytosol, cleave its substrate and block neuro-exocytosis of the pain mediators 
(Koriazova and Montal, 2003).  
 
6.3 TGNs provide a natural BoNT/E acceptor null system for identify a putative 
/E acceptor 
Discovery of a protein acceptor for each serotype of BoNTs is another attractive and 
challenging project [reviewed in (Verderio et al., 2006)], especially for BoNT/E whose 
acceptor is known to be distinct from BoNT/A (Dolly et al., 1994; Mahrhold et al., 
2006). Lack of progress with investigations is in part due to a shortage of a suitable 
model system. The poor sensitivity of TGNs to BoNT/E (Chapter 5) is a novel feature, 
indicating a differential distribution of its unknown acceptor(s) in various neuronal 
systems. Thus, TGNs provide a natural null model for finding the specific /E acceptor, 
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in conjuncation with other highly susceptibable neurons i.e. CGNs (Chapter 5). With 
the aid of advanced substractive hybridization techniques, employing cDNA libraries 
encoding synaptic vesicle proteins derived from TGNs and CGNs might allow the 
putative protein acceptor for /E to be identified. 
 
6.4 The dependency of inhibition by BoNT of capsaicin-evoked CGRP release 
from nociceptive neurons on the persistence of intracellular [Ca2+]i warranted a 
more in-depth study 
Chimera EA, but not BoNT/A, blocks capsaicin-elicited CGRP release (Chapter 5). 
The existence of the /A- but not EA- truncated SNAP-25 in SNARE complex is a 
reasonable explaination for the more extensive inhibition of capsaicin-elicited 
exocytosis by EA than BoNT/A. Capsaicin stimulation elicites a greater and more 
persistent increase in [Ca2+]i than K+-depolarisation. Elevated [Ca2+]i was found to 
attenuate BoNT/A inhibition of CGRP release by slowing down the rate of vesicle 
release (Chapter 5); additionally, in moter nerve terminals, synaptosomes or 
neuroendocrine cell where [Ca2+]i was elevated upon addition of Ca2+ ionophore or 
pore-forming detergents, BoNT/A blockade was alleviated (Ashton and Dolly, 1991; 
Lawrence et al., 1996; Simpson, 1978). As capsaicin and K+-depolarisation activate 
distinct channels, and ionomycin is a Ca2+-selective ionophore that acts on both the 
plasma and intracellular membranes (Morgan and Jacob, 1994), the spatial Ca2+ 
localisation and pattern of Ca2+ signals are likely to differ. Future in-depth studies to 
address the relationship between Ca2+ entry events and transmitter release are 
warranted, perhaps, using a combination of patch-clamp, photo-sensitive Ca2+ chelators, 
Ca2+ reporter dyes and amperometry of loaded oxidisable ‘false transmitters’, similar to 
that described for chromaffin cells, DRGs and other neuron types (Chow et al., 1994; 
Sakaba et al., 2005; Zhang and Zhou, 2002), Tracking fluorescent-conjugated SNAREs 
upon vesicle fusion by intra- or inter- molecular fluorescence resonance energy transfer 
(An and Almers, 2004) might also shed light on the mechanisms governing CGRP 
release and its blockade by various BoNTs. 
  
In conclusion, this current study broadens the understanding of exocytosis of pain-
related peptides from nociceptive neurons, it contributes successful examples of proof 
of principle of the toxin targeting approach and opens a brand new scope for 
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controlling SNARE-dependent exocytosis in a wide variety of secretory disorder 
diseases. 
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 Company Country Web
A    
 Abcam Ltd. UK www.abcam.com
 
Amersham GE 
Healthcare UK http://www.amersham.com/
B      
 Biosciences  Ireland www.biosciences.ie
C       
 
Cayman 
Chemical (order 
through SPI-
BIO) France www.spibio.com
 
Chemicon 
Europe Ltd. UK www.chemicon.com
G       
 
Gibco (order 
through 
Biosciences) Ireland www.biosciences.ie
I       
 
Invitrogen 
(order through 
Biosciences) Ireland www.biosciences.ie
J       
 
Jackson 
Immunoresearch 
Europe UK http://www.jireurope.com/home.asp
M      
 
Millipore (order 
through AGB) Ireland www.agb.ie
 
Molecular 
Probes (order 
through 
Biosciences) Ireland www.biosciences.ie
N      
 Neuromics Inc USA www.neuromics.com
P      
 
Phoenix Europe 
GmbH Germany www.phoenixpeptide.com
 
Pierce (order 
through Medical 
Supply 
Company Ltd.) Ireland www.medical-supply.ie
S       
 
Santa Cruz 
(order through 
Fannin) Ireland http://www.fanninhealthcare.com/
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 Sigma-Aldrich Ireland www.sigmaaldrich.com/ireland
 SPI-BIO France www.spibio.com
 
Sternberger 
Monoclonals 
Inc. USA www.sternbergermonoclonals.com
 
Synaptic 
Systems GmbH Germany www.sysy.com
T      
 
Tecan (order 
through Alpha 
Technologies) Ireland www.alphatech.ie
 
Trinity College 
Dublin, 
Bioresources 
Dept. Ireland www.tcd.ie/BioResources
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